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                                               Abstract 
 
Ageing is accompanied by impairments in immune responses. In this thesis, an age 
associated numerical and functional deficit in a novel subset of immunosuppressive CD19
+ve
 
CD24
hi
 CD38
hi
 B cells is reported, which might be an additional factor contributing towards 
increased risk of systemic autoimmunity with advancing age. The immune system is 
profoundly affected by environmental factors such as stress. This thesis also examined the 
synergistic effect of the physical stress of a hip fracture and the psychological stress of 
depressive symptoms on immune function of older adults.  It was observed that 37% of our 
hip fracture patients had developed depressive symptoms 6 weeks post-surgery. A 
significant decline in neutrophil, monocyte and NK cell functioning was reported in hip 
fracture patients with depressive symptoms, but not in those with hip fracture alone. 
Additionally, an increased cortisol: DHEAS ratio was also only found in hip fracture 
patients with depressive symptoms. An elevated level of pro-inflammatory (IL6, TNFα) and 
anti-inflammatory (IL10) cytokines were observed in hip fracture patients with depressive 
symptoms. In the adaptive immune system, a reduction in circulating T cells and an 
accumulation of senescent and activated T cells was also found in the hip fracture patients 
who developed depressive symptoms. Finally, the age associated numerical and functional 
deficit in IL10 production by CD19
+ve
 CD24
hi
 CD38
hi
 B cells was further suppressed on 
exposure to chronic stress in hip fracture patients with depressive symptoms. In conclusion, 
depressive symptoms in hip fracture patients have been associated with immune 
dysregulation. 
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Chapter 1 
General Introduction 
  
1 | P a g e  
 
1.0 Population ageing  
We are an ageing population, with a falling birth rate and an increase in the number of 
people reaching older age. Advances in the field of medicine and improvement in public 
health, socio-economic developments and scientific advances have led to an increase in 
human life-span in developed countries. According to the UK national statistics in 2010, 
17% percent of the total population were over the age of 65, and if current demographic 
trends continue it is predicted that by 2035, the population aged 65 and over will account 
for 23 percent of the total population; resulting in a twenty percent increase in people aged 
65 and over [Figure1.1]. The number of people aged 85 and over has been predicted to 
double over the period1985-2010 (UK National Statistics website).   
                              
Figure 1.1 The proportion of individuals aged over 65  is predicted to increase over 
the time period 2010-2035.  
Over the period 1985-2010 a twenty percent increase was observed in the number of 
individuals aged 65 and above. The number of people aged 85 and above more than 
doubled. By 2035, the numbers of individuals aged 85 and above are predicted to be 
almost 2.5 times larger than in 2010. Individuals aged 65 and over are predicted to account 
for 23 percent of the total population by 2035. Figure taken from the  UK National 
Statistics website (e(http://www.statistics.gov.uk/hub/population/ageing/older-people)  
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This increase in life expectancy will have a potential benefit only if the ‘added years’ are 
years of relative good health. But, advancing age is accompanied by an increase in 
susceptibility towards infections (pneumonia, urinary tract infections), cancer and 
development of chronic illnesses 
[1, 2]
 that have a negative impact on an individual’s quality 
of life 
[3]
. Additionally, older adults account for a large proportion of health-care resources 
[4]
. Suggesting, that healthy life expectancy is not keeping pace with the increase in life 
expectancy [Figure 1.2] , which is a matter of concern for individuals and health care 
providers. Development of strategies to delay or reverse the negative impact of ageing will 
have a beneficial effect on health in older adults and are now urgently needed.  
 
Figure 1.2 The life expectancy and healthy life expectancy proportion of individuals 
aged over 65 .  
For males in the UK , life expectancy has inceased from 70.8 years in 1981 to 75.9 in 
2002, for females an increase in life expectancy from 76.8 years in 1981 to 80.5 years in 
2002 occurred. At the current rate, an increase in life expectancy of about two years has 
been reported for each decade. However, healthy life expectancy based on the self-assessed 
general health questionnaire is not keeping pace with the increase in life expectancy. 
Figure taken from the House of Lords Science and Technology Committee Report, 
Ageing: Scientific Aspects, July 2005. 
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1.1 Immunesenescence 
Healthy ageing has been associated with a significant decline in immune competence and 
ability to mount a robust immune response, termed Immunesenescence 
[5]
. A Swedish 
longitudinal study reported an association between reduced immune function and individual 
longevity 
[6]
. The lifelong exposure to pathogenic agents for a longer period than previously 
encountered during human evolution (chronic antigen load), reduced production of new T 
lymphocytes from the thymus, increased proliferation of peripheral T and B lymphocytes 
(homeostatic proliferation) in response to thymic atrophy and an age-related increase in 
systemic inflammation (inflammaging) are thought to act as major driving forces of immune 
system ageing 
[7]
. The clinical consequences of this impairment in immune responses imply 
that immunesenescence might be responsible for an increase in the incidence and severity of 
infections 
[8]
 , impaired vaccine responses 
[3] 
and possibly increased risk of cancers and 
chronic inflammatory disorders with advancing age 
[9]
. 
All cells of the immune system (myeloid and lymphoid lineage) are formed from the 
differentiation of the multipotent haematopoietic stem cell (HSC). Hematopoietic stem cells 
differentiate into multipotent progenitor cells, which can produce cells of either myeloid 
(neutrophils, monocytes, macrophages, dendritic cells and eosinophils) or lymphoid (T cells, 
B cells and NK cells) lineage. HSCs in older donors have a reduced ability for self-renewal 
and a myeloid skewing of their differential potential 
[10, 11]
. Molecular factors contributing to 
HSC ageing include ; accumulation of DNA damage, altered gene expression patterns and 
epigenetic dysregulation 
[12]
. Skewing of the HSCs with age is thought to be an additonal 
factor contributing towards declining immuno-competence 
[12]
.                                                                                                    
Several innate and adaptive immunological parameters are altered with age, and they can be 
used as biomarkers of likely mortality in older adults and have been defined as the ‘Immune 
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Risk Phenotype’. The IRP is characterised by an inverted CD4/CD8 ratio, highly 
differentiated circulating CD8 T cells, CMV seroposititvity and high levels of 
proinflammatory cytokines, specifically IL6 
 [6, 13, 14]
 . 
1.2 Inflammaging 
A universal feature of physiological ageing is an increase in circulating levels of pro-
inflammatory cytokines (IL-1β, IL-6, IL8, TNFα, IFNγ, and CRP) termed “Inflammaging” 
[15-17]
. A strong association has been reported between elevated pro-inflammatory cytokine 
levels in older adults and an age-associated increase in mortality 
[18, 19]
, frailty 
[20, 21] 
prevalence of age related chronic diseases 
[17, 21] 
and cognitive impairment 
[22, 23]
. Studies in 
centenarians 
[24]
 and extremely long-lived mice 
[25]
 show that long lived individuals maintain 
the cytokine profile of younger adults.  
The various factors driving inflammaging include; increase in adipose tissue (a major source 
of inflammatory cytokines and adipokines) 
[26]
, decreased production of sex steroids many of 
which are anti-inflammatory 
[27]
, sub-clinical infections 
[28]
, sedentary lifestyle 
[29]
 and a low 
grade activation of cytokine producing cells such as macrophages 
[17]
. Interestingly, CMV 
infection was previously proposed as a major driver of  inflammaging 
[30]
, however this 
theory has been recently challenged as inflammaging still occurred in a longitudinal study of 
CMV negative adults 
[31]
. Anti-inflammatory cytokines (such as IL10) that might help to 
counteract the age associated elevated inflammatory state are known to decline with age 
[32]
, 
resulting in disturbed immune homeostasis. However, this finding has been contradicted 
with another report of elevated circulating levels of IL10 with age 
[33]
 . Interestingly, 
possession of genetic variations associated with high IL10 production has been associated 
with successful ageing 
[32]
. 
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1.3 Ageing of the innate immune system 
The innate immune system acts as the first barrier encountered by pathogens and is 
responsible for immediate and robust immune responses towards micro-organisms. In aged 
subjects, a breakdown in the integrity of innate physical barriers such as the skin, 
gastrointestinal tract and lung occurs, resulting in increased susceptibility to invasion by 
pathogens and an increased burden on the cells of the innate immune system.  
1.3.1 Neutrophils 
Neutrophils are the most abundant leukocyte and are one of the first cells to migrate into 
the site of infection. They are responsible for recognising, ingesting and destroying 
pathogens, most importantly rapidly dividing bacteria, yeast and fungi. The increased 
incidence of bacterial infections in older adults suggests 
[2, 34]
 that neutrophil numbers 
and/or function might be compromised with age.  
Neutrophils have a very short life span (8-12 hr) in peripheral blood and are lost due to 
spontaneous apoptosis and as a consequence they are produced in large numbers (1-2 x 10
11
 
per day) 
[35]
. The bone marrow content of precursors for the neutrophil lineage as well as 
their number in blood remains unchanged in healthy older adults 
[36, 37]
. During infection, an 
increase in neutrophil production is observed (neutrophilia) in order to combat infection. 
Studies have shown that older adults are able to mount a normal neutrophilia in response to 
an infection 
[38]
. Neutrophil life span is controlled by pro-inflammatory cytokines (IFNγ)  
and chemokines, including granulocyte-colony stimulating factor (G-CSF) and granulocyte- 
macrophage colony stimulating factor (GM-CSF)
 [36]
 that are able to delay apoptosis and 
extend neutrophil functional efficiency during infections. Neutrophils from older donors 
have a diminished ability to respond to anti-apoptotic mediators such as GM-CSF 
[39]
.   
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During an infection; neutrophils leave the circulation (extravasation), roll along and then 
adhere to vascular endothelial cells, followed by migration to the site of infection along a 
gradient of chemotactic factors. Once neutrophils have reached the site of infection via 
chemotaxis they engulf the invading microbes by phagocytosis. Pathogen phagocytosis by 
neutrophils is followed by microbial killing by several mechanisms, including generation of 
reactive oxygen and nitrogen species 
[40]
, release of proteolytic enzymes from intracellular 
granules 
[41]
. Adherence of neutrophils to endothelium, which is essential for neutrophil 
extravasation, remains unaltered with age 
[42]
. The expression of adhesion markers CD11a 
and CD11b, necessary for neutrophil extravasation is stable with age
 [43]
, but an increase in 
the expression of CD15 has been reported in older adults  
[44, 45]
.  
Chemotactic molecules (IL-8, fMLP, complement C5a) are responsible for attracting 
neutrophils to the site of infection. There is a significant degree of discordance in the 
literature regarding chemotaxis (directional movement) of neutrophils from older adults; a 
few studies have reported that chemotaxis remains unchanged with age 
[42, 46]
, whilst others 
have reported reduced chemotaxis of neutrophils in response to fMLP and GM-CSF in older 
adults. Neutrophil chemokinesis (non-directional movement) remains unaltered with age 
[47-
49]
. A study taking place in our own group has shown a reduction in neutrophil chemotaxis 
with age 
[50]
. This decrease in neutrophil directional control may compromise the efficiency 
of recruitment of neutrophils to the infection focus and neutrophils might take a longer route 
to the infection site, resulting in an increased exposure of tissue to proteases causing damage 
to healthy tissue.  
An age related decline has also been reported in the percentage of phagocytosing neutrophils 
and the ability of neutrophils to ingest opsonised bacteria and yeast 
[45, 49]
. However, 
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neutrophil ability to phagocytose unopsonised bacteria remains unaltered with age 
[51]
, 
suggesting that it is the response via opsonin receptors (Fc and C3b complement receptors) 
that is affected by ageing. A number of intracellular defects might contribute to this reduced 
neutrophil phagocytic ability including; impaired calcium mobilisation, reduced hexose 
transport, reduced CD16 expression, impaired downstream signalling events and impaired 
ligand induced actin polymerisation 
[35, 45, 52]
. In addition to these intrinsic factors; extrinsic 
factors such as altered circulating cytokine levels may also contribute towards reduced 
neutrophil functioning efficiency with age.  
Ingested microbes are destroyed by two different microbicidal mechanisms; production of 
reactive oxygen species and degranulation, which both lead to the release of cytotoxic 
proteases. Regarding the first mechanism, studies of neutrophil respiratory burst have 
reported unaltered superoxide production in response to PMA with age 
[44, 53, 54]
. However, 
neutrophil superoxide production in response to gram-positive bacteria such as S.aureus has 
been shown to be reduced in older adults 
[49]
. A few studies have reported an unaltered 
superoxide production in response to E.coli with age 
[35, 55]
 , but these findings have been 
contradicted by another study reporting reduced superoxide production
 [56]
. The consensus 
thus appears to be that superoxide generation is impaired to gram positive bacteria, but may 
be less affected in response to gram negative infections. Also,  a decline in degranulation in 
response to microbial products occurs with age 
[57]
. 
In addition to phagocytosing pathogens and destroying them by generation of reactive 
oxygen species, neutrophils are also capable of engulfing and destroying pathogens via 
extrusion of neutrophil extracellular traps (NETs) 
[58]
. However, so far, the effect of 
advancing age on NET generation remains unexplored. 
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1.3.1.(a) Mechanisms of reduced neutrophil function 
Impaired neutrophil functioning detected in older adults might be a result of modifications in 
signalling pathways and receptor distribution with age. Alterations in physiochemical 
properties of neutrophil membranes, such as reduced membrane fluidity due to altered 
cholesterol/phospholipid content and changes in actin cytoskeleton occur with age in 
rodents, though the situation in humans has not been examined 
[59]
. Altered membrane 
fluidity could explain the reduced signalling through PI-3 kinase, MAP kinase, protein 
kinase B, Jak-STAT, and SHP-1 signalling observed in neutrophils with increasing age 
[60]
. 
Ca
2+ 
ion mobilisation plays a central role in intracellular signal transduction, resting 
neutrophils of older adults have an increased level of Ca
2+
 
[49]
 and are unable to mount a 
proper Ca
2+
 mobilisation response 
[61]
. TREM-1 is a recently identified receptor responsible 
for initiating neutrophil responses, and impairment in TREM-1 engagement has also been 
observed in neutrophils of aged donors 
[62]
.  
1.3.2. Monocytes / Macrophages 
Circulating monocytes play a critical role in defense against invading pathogens by 
migrating to sites of infection, engulfing and killing microorganisms and cytokine release 
[63]
.  The differential expression of CD14 and CD16 has been used to define the three 
peripheral subsets of monocytes; classical monocytes (CD14
+ve 
CD16
-ve
) represent about 90 
% of peripheral monocytes; intermediate monocytes (CD14
+ve
 CD16
+ve
) and non-classical 
monocytes (CD14
+ve 
CD16
++ve
) comprise the remaining fraction of  peripheral monocytes
 
[64]
.  Classical monocytes are more efficient phagocytes and are major producers of reactive 
oxygen species, whereas CD16
+ve
 monocytes are major producers of pro-inflammatory 
cytokines on stimulation 
[65]
 . 
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The percentage and absolute number of peripheral monocytes remains unaltered with age 
[37, 
66]
. However, monocyte subsets considerably change and an increase in non-classical 
monocytes occurs with age, resulting in an overall shift from classical to non-classical 
monocytes 
[67, 68]
. The bone marrow of older adults has lower numbers of CD68
+ve 
macrophage precursors 
[69, 70]
. A decline in haematopoietic cell proliferation due to 
replicative senescence and increased apoptosis could explain the reduction in macrophage 
precursors. However, the number, size, DNA content and cell surface markers expressed 
during macrophage maturation (e.g. Mac 1) are similar in macrophages from aged and 
young mice 
[71]
. 
Ageing is accompanied by reduced surface expression of adhesion molecules such as 
CD62L, CX3CR1 in older adults which might have an effect on monocyte adherence and 
migration to inflammation site 
[72, 73]
; resulting in impairments in chemotactic responses 
[74]
. 
Further, a reduction in monocyte phagocytic ability 
[73]
 and a decline in production of 
reactive oxygen species and nitrogen intermediates has also been reported with age; 
resulting in delayed pathogen clearance 
[75, 76]
. Studies done in mice and humans have also 
reported a decline in macrophage migration and phagocytic ability with age 
[77-80]
. On the 
contrary, studies done in aged rats have reported an increase in the phagocytic ability of 
specialised liver macrophages (Kupffer cells) and alveolar macrophages 
[81, 82]
 . Impairments 
in production of reactive oxygen intermediates in response to IFNγ, PMA or opsonised 
zymosan stimulation have been reported by macrophages in aged rats 
[83, 84]
. Similarly, 
reductions in reactive nitrogen intermediate production by macrophages have also been 
reported in aged rodents 
[84-86]
. 
Monocytes and macrophages activate other inflammatory cells via secretion of a range of 
cytokines (TNFα, IL-6), chemokines (IL-8), growth factors (GM-CSF, M-CSF), coagulation 
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factors and prostaglandin E2. As discussed previously, ageing is accompanied by an increase 
in levels of serum pro-inflammatory cytokines. Monocytes from aged individuals exhibit 
increased production of cytokines such as IL6, IL1β in basal conditions [87]. A study of 
monocytes from 154 young and old individuals found an age-associated reduction in TNF-α 
and IL-6 secretion after stimulation via TLR1/2 heterodimer 
[88]
, these findings have also 
been confirmed by another study 
[68]
. Similarly, macrophage production of pro-inflammatory 
cytokines (IL-6, TNFα, IL12, and IL-1β) upon LPS stimulation is also reduced in both aged 
mice and humans 
[89-92]
. This impairment in cytokine production has been related to 
decreased cell surface expression of TLR1, TLR2 and TLR4
 
on aged monocytes
 [88, 93]
 and 
macrophages 
[89, 92, 94, 95]
.  Additionally, defects in downstream signal transduction pathways 
have also been reported in LPS activated aged monocytes including ; impaired  protein 
kinase C (PKC) activation , reduced expression of c-Fos , c-Jun and deficient mitogen 
activated protein kinase (MAPK) activation 
[68, 96]
. Studies have also reported lower 
expression of MAP kinases p38 and Jun kinases in macrophages with age 
[91, 92]
. However, a 
recent study reported an increase in IL8 production by aged monocytes on stimulation via 
TLR5 pathway, and have correlated this elevated cytokine production with increased levels 
of expression of TLR5 and increased levels of TLR5 mediated phosphorylation of MAPK 
p38 and ERK on monocytes with age 
[93]
. 
Monocytes and macrophages are also involved in T cell mediated immunity. A decline in  
antigen presentation has been  reported with advancing age 
[97]
, possibly due to reduced 
expression of MHC class II molecules on human monocytes 
[98, 99] 
and murine macrophages 
[100]
. Co-stimulatory molecules CD80 and CD86 are also involved in mediating T cell 
response to infectious agents 
[101, 102]
. Ageing is accompanied by diminished monocyte co-
stimulatory activity due to reduced CD80 expression 
[98]
. Additionally, an age associated 
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defect in upregulation of co-stimulatory molecules CD80 and CD86 by monocytes on 
stimulation via TLR agonists has also been observed, which contributes towards diminished 
vaccination responses in older adults 
[101]
.  
1.3.3 Dendritic cells  
Dendritic cells (DC) represent a rare population of circulating cells that form about 1% of 
total peripheral blood cells and play a key role in initiating and regulating pathogen-
specific adaptive immune responses 
[103]
. DCs in human peripheral blood have been 
divided into two subsets - myeloid lineage marker (CD11c) expressing DCs, termed 
myeloid DC (mDC) and lymphoid marker (CD123) expressing DCs , termed plasmacytoid 
DCs (pDC) 
[104]
. pDCs are characterised by low phagocytic ability and production of type I 
interferon that plays an essential role in providing protection against viral infections 
[105, 
106]
. On the other hand, mDCs control immune responses by presenting antigens to activate 
naïve CD4 T cells
[107]
.  
A decline in circulating levels of DC precursors has been shown in older adults 
[108]
. 
Further, a reduction in frequency and absolute numbers of pDCs has also been reported in 
older adults, which might contribute towards increased susceptibility towards infections 
[109-112]
. However, percentage and absolute numbers of mDCs in peripheral blood of aged 
donors remain unaltered compared to young donors 
[111-113]
 , but one study so far has 
reported contradictory findings 
[108]
.  On examining DC phenotype, a decline in surface 
expression of MHC class II and unaltered expression of CD80 and CD40 has been reported 
with advancing age 
[108, 113, 114]
. However, there is a slight contradiction regarding the effect 
of age on CD86 expression on DC, a few studies reported no effect of age on CD86 
expression 
[113, 114]
 whilst another study reported an increase in CD86 expression on aged 
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DC 
[108]
. Further, DCs in older adults show a more mature phenotype (express high levels 
of maturation marker CD83) 
[108]
.  
Ageing is accompanied by a decline in DC ability to uptake foreign antigen and 
phagocytose apoptotic cells 
[114]
. This impaired removal of apoptotic cells by DCs might be 
a contributing factor towards age associated increase in inflammation and may be 
responsible for higher risk of autoimmunity 
[115, 116]
. Further impaired DC migratory 
responses towards chemokines (MIP-3β, SDF-1) also occurs with advancing age, which 
might have a negative effect on DC ability to migrate to lymph nodes and induce immune 
responses 
[114]
.      
Studies examining constitutive cytokine production by DCs with age showed similar 
expression of IL12 and IL10 in young and aged donors 
[108]
. However, on stimulation of 
DCs with a pathogen derived stimulus (such as LPS) a decline in IL12, TNFα and IL6 
production occurs with age 
[117]
. DCs play a critical role in generating immune responses 
against viral infections by secretion of interferons. An age associated decline has been 
reported in DC production and secretion of IFNγ [110, 111, 118], which might be a result of 
reduction in TLR7 and TLR9 expression 
[111, 113]
. Interestingly, there is recent evidence 
suggesting that age associated defects in cytokine production by DCs correlates with poor 
vaccination responses reported in older adults 
[117]
.  
DCs are involved in stimulation of T cell responses upon encounter of viral pathogens 
[119]
. 
There is disagreement regarding capacity of aged DCs to stimulate T cells, a few studies 
have shown an age associated decline in DC capacity to induce proliferation and IFNγ 
secretion in T cells 
[120, 121]
 , but another study has shown that aged DC were effective in 
stimulation of clonal expansion of antigen-specific T cells 
[122]
. Further,  an age associated 
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decline in p DC capacity to induce perforin and granzyme B expression has also been 
reported; resulting in impaired ability to prime cytotoxic responses of CD8 T cells 
[120]
.  
1.3.4 Natural Killer cells   
Natural killer (NK) cells are cytotoxic lymphoid cells capable of destroying tumour and 
virus infected cells 
[123]
. NK cells have been divided into two subsets on the basis of 
relative expression of CD56 and the Fcγ receptor CD16, namely CD16+ve CD56dim and the 
CD16
-ve/dim
 CD56
bright  [124, 125]
. Majority of NK cells are CD56
dim
 and these cells have high 
cytotoxic potential. CD56
bright 
cells have immunomodulatory properties and are capable of 
initiating adaptive immune responses including; activation of DCs and production of 
immunoregulatory cytokines (IL-10, IL-13, TNFα, IFNγ) [124, 126].  
Granule exocytosis and engagement of death receptors are the two main mechanisms used 
by NK cells to induce MHC class I-deficient target cell lysis 
[127, 128]
. NK cell killing via 
granule exocytosis pathways is initiated by target cell recognition, followed by 
immunological synapse formation between target cell and NK cell
[129]
. NK cells have lytic 
granules containing cytotoxic proteins; perforin and granzyme 
[130]
. Post conjugate 
formation, lytic granules polarise towards the immunological synapse and the cytotoxic 
content is released into the synapse
[131]
. Perforin is a ‘key shaped’ molecule that 
oligomerises to form pores that disrupt the target cell membrane 
[132]
, facilitating delivery of 
granzymes into target cells and induction of caspase dependent and independent cell 
apoptosis 
[130, 133]
 [Figure 1.3].  The second NK cell killing pathway involves engagement of 
death receptor with their ligands, for instance TNF –related apoptosis inducing ligand 
(TRAIL) is capable of inducing apoptosis of TRAIL sensitive target cells 
[134]
. NK cells also 
express Fas Ligand (Fas L) that can induce caspase- dependent apoptosis by binding to Fas 
expressed on target tumor cells 
[127, 135]
. 
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An increased in frequency and absolute numbers of circulating NK cells has been observed 
in older adults 
[136-138]. 
This increase in the number of NK cells, results from an expansion of 
the CD56
dim
 subset, however a decline in the number of CD56
bright
 NK cells 
[139, 140] 
 occurs 
with age 
[139, 141]
. Further, the increase in CD56
dim 
NK cell subset suggests a phenotypic shift 
towards a more mature phenotype in NK cells with age.  Additionally, an accumulation of 
mature CD57
+ve
 NK cells has also been associated with ageing of human immune system 
[142]
. 
A decline in NK cell cytotoxic potential on a per cell basis has been observed in older adults 
[143-146]
. The increase in proportion of CD56
dim 
NK cells with age might be a compensatory 
mechanism to overcome reduced per cell cytotoxicity. Importantly, this decline in NK cell 
activity has been associated with a higher incidence of infections in older adults 
[147]
. 
Preserved NK cell activity in older adults has been associated with better response to 
influenza vaccines and protection against respiratory tract infections 
[148]
. Interestingly, 
studies in centenarians have shown preserved NK cell cytotoxicity, suggesting that intact 
NK cell activity can act as a marker for healthy aging 
[138, 149]
. 
Studies examining the mechanism responsible for reduced NK cell activity with age have 
shown that the ability of NK cells to form conjugates with target cells is preserved with age 
[150]
. Further, the ability of cytotoxic granules to fuse with NK cell membrane, examined by 
expression of CD107a on NK cell surface post stimulation also remains unaltered with age 
[150, 151]
. Another study has suggested that defective NK cell signal transduction following 
stimulation with target cells due to reduced release of IP3 with age might be contributing 
towards impaired NK cell cytotoxicity due to defective granule exocytosis 
[152]
. However, a 
recent study has proposed that even though perforin levels are preserved with age
[153]
, a 
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reduction in perforin binding to target cell surface due to reduced release of perforin is the 
underlying mechanism for reduced NK cell cytotoxicity in older adults 
[150]
.  
NK cells can also eliminate antibody coated target cells via ligation of the Fc receptor 
CD16, termed antibody-dependent cellular cytotoxicity (ADCC). CD16 expression on NK 
cells has been reported to remain unaltered in older adults 
[150, 154, 155]
 and CD16 induced 
cytotoxicity is also preserved with age 
[156]
 .  
NK cell activation is regulated by a balance of signals from specific activatory and 
inhibitory receptors 
[157]
. Ageing is accompanied by a decline in the expression of natural 
cytotoxicity receptors (NCR) ; NKp46 
[150] 
and NKp30 
[136]
. In young individuals, most of 
the NK cells express high levels of NKp30 and NKp46 (NCR
bright
 phenotype) and very few 
NK cells express low levels of these receptors (NCR
dull
 phenotype), but in older adults a 
higher proportion of NK cells exhibit NCR
dull
 phenotype 
[141]
.  Since both these receptors 
play an essential role in target cell killing by NK cells, reduced expression of these 
receptors might be a contributing factor towards reduced NK cell cytotoxicity with age 
[141]
. Further, NKG2D expression has been shown to be preserved on NK cells in older 
adults 
[136, 150, 154]
. There is discrepancy in the data regarding the effect of age on killer 
immunoglobulin like receptors (KIR), one study has reported an increase in KIR 
expression 
[136]
, whilst another study failed to report an alteration in KIR expression on NK 
cells of older adults 
[154]
. Further, a decline in KLRG-1 and CD94 expression has been 
reported on NK cells with age 
[151]
. 
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Figure 1.3 The two main mechanisms used by NK cells to induce MHC class I-
deficient target cell lysis - Granule exocytosis and engagement of death receptors .  
The granule exocytosis pathway begins with immunological synapse formation between 
target cells and NK cell, followed by polarisation and release of cytotoxic granule contents 
(Perforin and granzyme B). Perforin form pores in a target cell membrane facilitating 
Granzyme up take by target cells. Grz trigger apoptosis via activation of caspase pathway 
or caspase independent pathways that still remain uncharacterised. The second pathway 
involving ligation of Fas and TRAIL with their ligands induces caspase dependant cell 
apoptosis. Image taken from Smyth et al 2005 
[127]
.  
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NK cell functional capabilities also include secretion of cytokines and chemokines. 
According to a study done in older adults, IFNγ production by NK cells remains intact with 
age 
[154]
, but these findings were contradicted by another study showing IFNγ production by 
CD56
bright
 NK cells increased post stimulation in old donors 
[151]
.  Further, an increase in IL-
4 and IL-10 production by NK cells and unaltered TNFα production has also been reported 
with age 
[158, 159]
. A decline in chemokine production (IL8, RANTES, and MIP-1alpha) 
occurs in aged NK cells on IL2 stimulation 
[160, 161]
.  
1.3.4 (a) NKT cells  
NKT cells are ‘innate immune lymphocytes’ that in addition to T-cell receptor (TCR) also 
express certain NK cell receptors 
[162]
. The origin and function of NKT cells are poorly 
understood, but these cells have been suggested to play an important role in defense against 
viral infections mainly via cytokine production (especially IFNγ) or via direct killing of 
target cells 
[163]
. Studies done in rodents have reported an increase in the number of NKT 
cells with age 
[164, 165]
. Additionally, a decline in NKT cell cytotoxicity and impaired IFNγ 
production has been reported in aged mice and humans
 [166]
. Studies in centenarians and very 
old mice have reported increased numbers of NKT cells 
[167]
, preserved IFNγ production [167, 
168]
 and cytotoxic potential 
[168]
. Although only limited data on age associated changes in 
NKT cells are available, so far the age-related changes in NKT cells are similar to those 
observed in NK cells.  
The current literature regarding the effects of ageing on innate immune cells and their 
function are summarised in Figure 1.4. 
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Figure 1.4 Summary of age associated changes in innate immune cells; Neutrophils, 
Monocytes, Dendritic cells and NK cells.  
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1.4 Ageing of the adaptive immune system 
Ageing results in extensive remodelling of the adaptive immune system contributing 
towards inefficient control of infectious diseases, increased autoimmunity and reduced 
immune surveillance against cancers and ultimately towards increased  mortality.  
1.4.1 Thymus and T cells  
The thymus is devoted to thymocyte differentiation and maturation and is the first organ to 
age in the human body. In 1985, Steinman et al reported that the thymus reaches its peak 
size within first year of life after which thymic involution occurs 
[169]
. Further, a decline in 
recent thymic emigrants also occurs in aged mice 
[170]
. Thymic atrophy and decline in 
thymopoiesis result from a number of alterations in the thymus including; loss of thymic 
epithelial cells, replacement of lymphoid with fat tissue, loss of cytokines and hormones 
essential for thymopoiesis (e.g. IL-7, KGF and Ghrelin) and upregulation of 
thymosupressive cytokines (e.g. IL-6, TNFα) with age [171-173] . Recently, novel molecular 
strategies have been developed to measure T cell generation by quantification of T-cell 
receptor excision circles (TREC) 
[174, 175]
, revealing an exponential drop of around 95% in 
frequency of TRECs between 25 and 60 years of age 
[176]
.  
Mature T lymphocytes are divided into two distinct subsets on the basis of expression of cell 
surface markers CD4 and CD8. CD8
+ve 
T cells are cytotoxic cells, whilst CD4
+ve
 T cells are 
predominantly helper T cells. A few studies have reported a decline in peripheral T cell 
numbers with age 
[138, 177-179]
. Further, ageing is also accompanied by an increase in CD8
+ve
 
T cells, resulting in a slight decline in CD4:CD8 ratio 
[14, 178]
 . It has been suggested  that the 
CD4:CD8 ratio can be used as a biomarker of ageing to predict longevity and it is part of the 
IRP 
[180]
. 
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Antigen exposure results in clonal expansion of naïve T cells and generation of effector 
cells. On resolution of infection only a few memory T cells survive to provide protection in 
case of future encounter with the antigen. A decline in the proportion of naïve T cells and an 
increase in memory T cells have been widely observed with advancing age 
[177, 178, 181]
. This 
is likely a result of repeated exposure to antigens over the lifetime, homeostatic proliferation 
of the peripheral pool and reduced thymic output of naïve T cells 
[182]
. Memory T cells have 
been classified into three distinct subsets on the basis of expression of CCR7 and CD45RA; 
central memory (CM), effector memory (EM) and effector memory RA (EMRA) 
[183, 184].
 
Studies examining the effect of ageing on CD8 memory T cells have reported, that 
frequency of CM T cells remains unaltered , but an increase in the frequency of EM and 
EMRA CD8
+ve
 T cells is seen in older adults 
[185, 186]
 . In the case of memory CD4
+ve
 T cells, 
an increase in CM cells occurs with age 
[186, 187]
. Further , ageing is also accompanied by a 
skewing of memory CD8
+ve
 T cells towards clones of latent viruses, specifically CMV 
[188, 
189]
, resulting in filling of valuable ‘immunological space’ and  reduced ability of CD8+ve T 
cells in older adults to respond to novel  pathogens 
[190]
. T cell ability to provide effective 
immune response against new antigens depends on naïve T cell receptor diversity 
[191]
. T cell 
diversity has been reported to be maintained up to the age of 65, after which a drop in T cell 
diversity occurs ; resulting in contraction of naïve T cell repertoire and poor responses to 
neoantigens 
[176, 182]
. 
T cell activation requires two distinct signals. Firstly, an antigen specific signal involving T 
cell receptor (TCR) followed by a co-stimulatory signal provided by antigen presenting cells 
via CD28 pathway 
[192]
. Ageing is accompanied by the accumulation of CD28
-ve
 T cells 
[193-
195]
 with impaired proliferation capacity due to shortened telomeres 
[196] 
. This loss seems to 
be more apparent in CD8
+ve
 T cells, such that by the age of 80 more than 50% of CD8 T 
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cells are CD28
-ve
 and about 10-15% of CD4
+ve 
T cells 
[197]
. Furthermore, accumulation of 
CD28
-ve
 T cells has been associated with CMV seroposititvity 
[198]
 and correlates with poor 
vaccine responses in older adults 
[199]
. Expression of NK cell receptors, such as CD57 occurs 
in these senescent T cells and has been suggested as a marker for T cell senescence 
[200]
.  
The majority of CD28
-ve 
T cells are CD57
+ve
 and an increase in CD28
-ve
 CD57
+ve
 T cells 
occurs in older adults 
[200, 201]
, which has also been associated with CMV seroposititvity 
[201]
. 
An increase in expression of another NK cell receptor, NKG2D has also been reported in 
CD4
+ve 
T cells with advancing age; representing a subset of highly differentiated senescent T 
cells
[202]
. Further, on examining the activation status of circulating lymphocytes an increase 
in frequency of HLADR
+ve
 T cells 
[138, 179, 203]
 and CD25
+ve
 T cells occurs with age 
[203]
 , but 
frequency of CD69
+ve
 T cells remains unaltered 
[203, 204]
. 
Ageing is accompanied by a decline in T cell helper activity, resulting in impairment in 
antigen specific B cell responses 
[182, 205]
. Naive CD4
+ve
 T cells from aged mice exhibit 
reduced expansion and IL2 production upon stimulation 
[205, 206]
. CD40L (CD154) 
expression by CD4
+ve
 T cells also plays an essential role in mediating B cell responses. An 
age associated decline occurs in CD40L expression on CD4
+ve
 T cells 
[205, 207]
, which can be 
overcome by addition of IL2 to in-vitro cultures of T cells 
[206]
. Furthermore, ageing is 
accompanied by incomplete differentiation of naïve CD4 T cells into Th1 and Th2 cells 
[208]
 
and a shift of T helper cells from Th1 (IFNγ, IL2) to Th2 ( IL10, IL4, IL5) has also been 
reported 
[209-211]
.  
An age associated reduction occurs in CD8
+ve
 T cell effector function including, cytokine 
production (IFNγ) and target cell lysis ; contributing towards delayed pathogen clearance[212, 
213]
. Several factors such as impairments in dendritic cells 
[214, 215]
, age-associated alterations 
in Tregs and CD4 helper T cells contributes towards decreased CD8 T cell responses 
[216, 217]
. 
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Further, intrinsic defects, for instance a reduction in CD8 T cell expansion in response to an 
infection have also been reported with age 
[213]
.  
1.4.1 (a) Regulatory T cells  
Tregs play a central role in immune regulation via cell-contact, secretion of 
immunosuppressive cytokines (IL10 and TGFβ) or deprivation of cytokines (IL2) essential 
for expansion and survival of T cells 
[218, 219]
. An age associated increase in the frequency of 
CD4
+ve
CD25
+ve
Foxp3
+ve
 Tregs has been reported in aged mice 
[220-222]
 and older adults 
[223, 
224]
, which might contribute towards increased incidence of infections, poor tumor killing 
and reduced vaccine responses with age 
[220, 225]
. Factors that might be responsible for 
accumulation of Tregs with age include; alterations in expression of trafficking receptors 
(CD69, CD62L, CCR7) resulting in impaired T cell migration through lymphoid tissue 
[221]
 
and impaired ability of aged Treg cells to undergo apoptosis
[224]
. Further, a shift in peripheral 
Tregs from naïve to memory phenotype has also been reported in aged mice 
[222] 
and humans 
[226]
. 
Although, CD4
+ve
CD25
+ve
Foxp3
+ve
 Treg numbers increase with age, a decline in the 
suppressive capacity of Tregs has been reported by a few studies 
[222, 224]
. But, these results are 
not widely confirmed, a few studies have reported intact suppressor function of aged Tregs 
[223, 227]
. Interestingly, a recent study reporting an intact ability of aged Tregs to suppress 
effector T cell function has observed defects in Treg capacity to constrain IL17 producing T 
cells, which might be a contributing factor towards age associated inflammation 
[228]
.  
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1.4.2 B cells 
It is well accepted that B cell lymphopoiesis declines with age 
[229-231]
. Multiple mechanisms 
have been suggested which might contribute towards reduced B cell production including ; 
decline in the numbers of precursor B cells 
[232] 
due to increased apoptosis of precursor B 
cells in aged mice 
[233, 234] 
, reduced expression of transcription factors crucial for B cell 
generation (e.g. E47) 
[235]
 and reduced expression of  genes essential for B cell development 
(e.g. recombination activating gene (RAG)) 
[229, 236]
. In addition to cell intrinsic changes, 
altered bone marrow microenvironment including ; decline in the sites of naïve B cell 
production,  decline in growth factors and reduced IL7 production by bone marrow stromal 
cells might also contribute towards impaired B cell lymphopoiesis 
[232, 237]
. Interestingly, B 
cell depletion results in expansion of B cell precursors in old mice, suggesting a “negative-
feedback” from mature B cells in aged mice on B cell lymphopoiesis [238]. It has been 
recently reported in mice that ageing is accompanied by an accumulation of a CD23
-
ve
/CD21
-ve 
mature B cell subset termed age associated B cells (ABC), that are capable of 
inducing apoptosis of pro-B cells via TNFα secretion [239].  However a human equivalent of 
ABC cells is yet to be reported. Taken together it is clear that there is a decline in both 
frequency and absolute numbers of circulating B cells with age 
[240-244]
 .  
In addition to a decline in frequency of B cells, an age associated decline in naïve B cells 
(CD27
-ve
 IgD
+ve
) 
[245, 246]
 and an increase in memory B cells has also been reported 
[246-248]
. 
Memory B cells have been divided into different subsets; unswitched memory B cells 
(CD27
+ve 
IgD
+ve
), IgM memory B cells (CD27
+ve 
IgD
+ve
 IgM
+ve
) and switched memory B 
cells (CD27
+ve 
IgD
-ve
) 
[249]
.  Ageing is accompanied by a decline in IgM memory B cells, 
predisposing older adults to pneumococcal infections 
[250]
.  Late memory/exhausted memory 
B cells (CD27
-ve
 IgD
-ve
) have also been reported to increase with age 
[251]
.  
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Ageing is accompanied by poor vaccination responses, likely due to reduced antibody 
response on immunisation and impaired T cell activity 
[245, 252]
. Older adults have been 
reported to generate tenfold fewer antibody secreting cells relative to young individuals on 
antigenic stimulation 
[253]
, suggesting that the increase in the number of memory B cells is 
not paralleled by an increase in number of plasma cells 
[253]
. Surprisingly, even though the 
actual amount of antibody secreted by plasma cells remains unaltered with age 
[254, 255]
, the 
antibodies produced by aged B cells have lower affinity and fewer antibodies are pathogen 
specific 
[255, 256]
. Antigen encounter induces B cells to form germinal centres which require 
help of T cells and follicular dendritic cells to provide survival signals and display antigens 
to B cells. A decline in CD4 T cell and dendritic cell functioning , along with intrinsic 
changes in B cells might be responsible for the age-associated reduction in number and size 
of germinal centres 
[257]
  and might contribute towards the decline in antibody production by 
older individuals with age 
[169]
.  
Additionally, a reduction in B cell diversity has also been reported with advancing age; 
resulting in impaired ability of B cells to respond to new pathogens 
[229]
. This age associated 
decline in BCR diversity has an important implication on health status of older individuals 
and has been linked to frailty 
[258]
. 
The literature concerning the age-related changes in T and B lymphocytes is summarised in 
Figure 1.5. 
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Figure 1.5 Summary of age-associated changes in adaptive immune cells, T cells, 
Regulatory T cells and B cells.  
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1.5 Ageing and risk of autoimmunity   
As previously discussed, ageing is characterised by remodelling and decline in immune 
responses; leading to older adults who are more susceptible to chronic diseases and 
infections. Interestingly, age is also an important risk factor for development of rheumatoid 
arthritis (RA) 
[259, 260]
.  RA is a chronic immune mediated disease involving, infiltration of T 
cells, B cells and macrophages into the synovium; resulting in synovial inflammation and 
joint destruction 
[261]
. The synovial joint also accumulates large numbers of neutrophils 
which contribute to joint destruction. There is evidence suggesting that patients suffering 
from RA are immunocompromised 
[262]
. Interestingly, immune-ageing emerges at 
approximately the same age when susceptibility to develop RA peaks 
[260]
; leading to the 
suggestion that premature immune ageing and reduced immune tolerance might be 
contributing factors towards development of RA [Figure 1.6] 
[263]
. 
1.5.1 T cell immunesenescence in rheumatoid arthritis 
RA has been associated with premature T cell immunesenescence 
[264, 265]
. As previously 
discussed, advancing age is accompanied by thymic involution and a subsequent decline in 
TREC numbers (section 1.4.1). Interestingly, an inverse relationship occurs between thymic 
capacity and incidence of RA 
[266]
. Also, a reduction in number of TREC expressing T cells 
has been observed in RA patients 
[267, 268] 
, such that a 45 year old patient has the TREC 
levels normally seen in a healthy 70 year old. Further, ageing is accompanied by 
accumulation of CD4
+ve 
CD28
-ve 
T cells 
[269]
 , which produce pro-inflammatory cytokines 
(IFNγ), have cytotoxic abilities and also react with auto antigens and are thus capable of 
triggering development of RA 
[266]
. An elevated frequency of CD4
+ve
CD28
-ve 
T cells has also 
been reported in RA patients 
[267, 270]
. Additionally, an age associated increase in 
differentiation towards Th17 cells has been reported 
[271-273]
. Th17 cells are involved in 
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mediating RA 
[274] 
and this skewing towards Th17 in older adults might be an additional 
factor contributing towards autoimmunity associated with age 
[271]
.  
Breakdown in immunological self-tolerance also contributes towards the development of 
autoimmunity. Functional deficiencies in Tregs occur in autoimmune disorders, including RA 
[275, 276]
. Studies of animal models of autoimmunity have shown that defects in Tregs cell 
numbers or immune suppressive functions can contribute towards disease development 
[277]
. 
Even though older adults are characterised by higher numbers of Tregs, a decline in per cell 
immune suppression activity of these cells has been reported 
[278, 279]
. Thus, increased 
incidence of autoimmune disorders, such as RA might also be a result of failing ability of 
Tregs to suppress autoimmunity 
[225, 280]
. 
 1.5.2 B cell immunosenescence and autoimmunity 
B cells are known to play a pathogenic role in autoimmune disorders 
[281]
. Profound changes 
have been reported in B cells with advancing age , such as a shift in antibody specificity 
from non-self to self-antigens 
[282]
. Ageing is accompanied by an increase in B cells with 
autoreactive properties and higher levels of autoantibody levels such as rheumatoid factor 
(RF) and anti-nuclear antibodies 
[283, 284]
. It has been hypothesised that accumulation of self-
reactive memory B cells with age that may become reactivated later in life due to deficiency 
in immune tolerance in aged individuals might be responsible for elevated autoantibody 
levels in older adults 
[285]
.  
Additionally, as detailed above (section 1.4.2) novel peripheral subset of B cells known as 
ABCs have been reported to accumulate in aged mice
 [286]
. ABCs contribute towards age 
associated tendencies towards autoimmunity by producing autoantibodies, presenting 
antigens to T cells and enhancing polarisation towards Th17 phenotype 
[286, 287]
.   
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1.5.3 Innate immunosenescence and autoimmunity 
 
In addition to the adaptive arm of the immune system, innate immune cells are also involved 
in development of autoimmunity. Dendritic cells are responsible for  presenting antigens to 
autoreactive T cells and  promote B cell activation and differentiation into plasma cells and 
increase autoantibody production 
[288]
.  Aged DCs react more strongly than DCs from young 
individuals to self-antigen 
[289]
. Moreover, presentation of arthritogenic self-antigens by DCs 
to auto reactive CD4
+ve
 CD28
-ve 
T cells might be an additional contributing factor towards 
the development of RA in older adults 
[263]
 . 
1.5.4 Inflammaging and autoimmunity  
TNFα and IL-6 have pleiotropic functions and are known to promote processes involved in 
pathogenesis of RA including ; release of leukocytes driving tissue destruction and 
promoting infiltration of inflammatory cells into the synovium 
[290]
. Ageing has been 
associated with chronic inflammation and elevated serum levels of proinflammatory 
cytokines 
[291]
 (discussed in detail in section 1.2) and such elevated levels of pro-
inflammatory cytokines in older adults might promote processes involved in pathogenesis of 
RA.  
1.6 B cells with immunosuppressive properties  
B cells are known to play a pathogenic role in human autoimmune diseases due to their 
ability to secrete autoantibodies, serve as antigen presenting cells to T cells and induce T 
cell expansion and cytokine secretion 
[281]
.
  
Janeway and colleagues provided the first 
evidence that B cells could be involved in suppression of inflammation, reporting that the 
absence of B cells exacerbated T cell mediated autoimmune reactions 
[292]
, which has also 
been confirmed by other groups 
[293]
. Over the last decade, evidence has emerged for an  
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Figure 1.6 Ageing of immune system increases susceptibility to autoimmune disorders 
especially rheumatoid arthritis. 
 The arrow indicates a progressive decline in integrity of the immune system, involving a 
decline in T cell diversity, accumulation of CD28
-ve
 senescent T cells and increase in levels 
of pro-inflammatory cytokines and autoantibodies. Immunesenescence is accompanied by 
an increase in incidence of several diseases, including infectious disease, cancer and 
rheumatoid arthritis. The line graph of RA incidence is a schematic approximation of the 
general trend in incidence with age. Image taken from Lindstrom et al 2010 
[263]
. 
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immunoregulatory role of B cells, analogous to the suppressive activity of regulatory T cells.  
B cells may therefore play both protective and pathogenic roles in the same pathological 
setting. Since then a subset of B cells with immunosuppressive properties, have been shown 
to suppress inflammation in a number of murine models of chronic inflammation, including 
collagen induced arthritis (CIA), experimental autoimmune encephalitis (EAE) , 
inflammatory bowel disease (IBD) as well as skin inflammation 
[294-297]
.  
Mauri et al were the first to assess the role of B cells at different stages of development in 
the pathogenesis of autoimmunity. They isolated splenocytes from mice during the 
remission phase of CIA and sorted B cells into different subsets; transitional 2 marginal 
zone precursor B cells (T2MZP), follicular B cells (FO) and marginal zone B cells (MZ). 
These B cells were transferred into syngeneic mice on the same day as experimental 
induction of arthritis, after which the disease incidence and severity was monitored.  
The mice in which T2-MZP B cells were transferred were the only mice that were protected 
from arthritis, by rendering T cells hyporesponsive to collagen re-stimulation. This data lead 
to the hypothesis that transitional B cells (recent emigrants from the bone marrow) have 
immunosuppressive properties 
[298]
.  
Three major populations of circulating B cells have been identified in human peripheral 
blood discriminated on the basis of relative distribution of developmentally regulated 
markers CD24 and CD38; memory B cells (CD24
hi
 CD38
-ve
) form about 20-40 % of 
peripheral B cells, 60-70 % of B cells are mature B cells (CD24
int 
CD38
int
) and transitional B 
cells (CD24
hi
 CD38
hi
) form about 2-7 % of the peripheral B cell population 
[299, 300]
. 
Interestingly, CD19
+ve
 CD24
hi
 CD38
hi 
immature transitional B cells have been shown to 
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exhibit immunosuppressive properties and were the main IL10 producers amongst B cells 
[301, 302]
 .  
Tedder and colleagues have suggested that CD19
+ve
CD5
+ve
CD1d
hi
 B cells referred to as 
‘B10 cells’ possess immunoregulatory properties and are capable of producing IL10 in mice 
[303, 304]
 . Adoptive transfer of CD5
+ve
CD1d
hi 
B
 
cells into CD19
-/-
 mice inhibits inflammatory 
responses during EAE 
[297]
 and contact hypersensitivity 
[303]
. However, this IL10 producing 
B10 subset still remains largely unexplored in humans. Phenotypic identification has 
confirmed that the majority of CD19
+ve
 CD1d
hi
 CD5
+ve
 B cells are contained within the 
CD24
hi
 CD38
hi
 B cell subset
 [305]
.Similarly, Tedder and colleagues have also reported a high 
CD24 expression  in CD5
+ve
CD1d
hi 
B cell subset 
[303]
 and  the same group have reported 
CD24
hi
CD27
+ve
 B cells , with 60% of these cells CD38
+ve
  are main IL10 producers in 
humans and parallel mouse B10 cells 
[306]
. Since, a number of cell surface markers are 
shared by both subsets of Bregs (transitional B cells and B10 cells), it might be possible that 
both these subsets are derived from a common Breg cell precursor and the phenotypic 
differences between these subsets is a result of activation of a common Breg precursor in 
different microenvironments 
[283, 305]
.  
1.6.1 Mechanism of immune regulation by Breg cells  
Immunosuppressive B cells are known to exert their effect via two main modes of action: 
cytokine production (IL10 and TGFβ) and direct cell-cell contact. B cells are capable of 
producing IL10 was reported over twenty years ago 
[307]
, but over the past decade literature 
highlighting the protective role of IL10 producing transitional B cells and B10 cells has 
accumulated in both mice and humans 
[294, 301, 308]
 . IL10 plays an essential role in 
maintaining immune homeostasis 
[309]
 via down regulation of antigen presentation by 
macrophages and DCs, suppressing production of pro-inflammatory cytokines by CD4 T 
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cells, monocytes and macrophages and inhibition of antigen specific T cell proliferation 
[310-
312]
. Exacerbated inflammatory responses and an increased incidence and severity of 
autoimmune disorders have been reported in IL10 deficient mice 
[313-315] 
and IL10 
administration can have a beneficial effect on autoimmune responses 
[316, 317]
. Interestingly, 
the mRNA expression of IL10 in central nervous system (CNS) correlates with remission in 
EAE 
[318]
. Studies using a bone marrow chimeric system in which IL10 deficiency was 
restricted to B cells have highlighted the importance of B cell IL10 production in recovery 
from autoimmune disorders 
[293]
. Further, adoptive transfer studies in mice have shown that 
IL10 producing B cells are capable of ameliorating established inflammatory responses 
[304, 
319]
. It has been recently reported that IL10 producing CD19
+ve
CD24
hi
 CD38
hi
 B cells are 
capable of suppressing  T cell proliferation , cytokine production by CD4 T cells ( IFNγ, 
TNFα) and impairing differentiation of naïve T cells to Th17 cells [301, 302] [Figure 1.7]. 
Interestingly, Bregs are also capable of regulating innate immune responses. For instance, 
reductions in TNFα production has been reported in monocytes when cultured with activated 
human B10 cells 
[306]
. 
Even though IL10 production is the main mechanism of immune suppression by Breg cells, 
not all of these cells produce IL10 post-stimulation, suggesting the presence of alternative 
immune suppressive mechanisms. For instance, production of transforming growth factor 
(TGF-β1) by B cells upon LPS stimulation plays an essential role in preventing 
inflammation and autoimmune disorders 
[320]
. Studies have shown that transfer of  in-vitro 
generated TGF-β1 producing B cells into non-obese diabetic (NOD) mice, can suppress the 
development of diabetes in recipient mice and down regulate pathogenic responses by 
inducing apoptosis of effector T cells and/or inhibition of APC activity 
[321]
.  
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The B7 family of co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) are capable of 
regulating T cell growth, survival and differentiation via ligation to CD28 and cytotoxic T 
lymphocyte protein 4 (CTLA4) receptor on CD4
+ve
T cells 
[322, 323]
.  In addition to cytokine 
secretion, contact between CD4
+ve
 T cells and Bregs cells via CD80 and CD86 ligation to 
CTLA4/CD28 plays an important role in suppression of activated CD4
+ve
 T cells 
[298]
. 
Interestingly, mice with B7- deficient B cells were unable to recover from EAE , a result of  
delayed upregulation of IL10 expression and mobilisation of Treg cells into site of 
inflammation 
[324]
. In humans, blocking antibodies against CD80 and CD86, inhibit CD19
+ve 
CD24
hi
 CD38
hi
 cells from suppressing TNFα and IFNγ production by CD4 T cells [301, 325]. 
Bregs are also capable of mediating immunosuppressive effects via induction of Foxp3 
expression in CD4
+ve
CD25
+ve 
Tcells. Interestingly, CD40 activated B cells have a higher 
capacity to induce Tregs generation than DC’s 
[326]
. Additionally, B cells have also been 
reported to play a role in recruitment of Tregs to the site of inflammation [Figure 1.7] and B 
cell deficiency results in delayed emergence of Tregs, which might prevent recovery from 
inflammation 
[324]
. However, depletion of Tregs does not alter the capacity of Bregs to regulate 
immune responses, suggesting that Tregs are unlikely to play a role in B cell mediated 
immune regulation 
[327]
. 
1.6.2 Induction of transitional B cells and B10 cells  
Development, maturation and expansion of immunosuppressive B cell subsets require 
specific external signals that inform B cells of their extracellular environment. According to 
current data BCR, CD40, LPS and CpG generated signals are involved in Bregs development 
[308, 328]
  [Figure 1.7].  
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CD40 signalling mediates B cell survival, stimulates B cell proliferation and up regulation 
of cytokines (IL10, TNFα, IL6) and co-stimulatory molecules (CD80 and CD86) [329]. 
Interestingly, T cell mediated B cell activation is capable of inducing immunosuppressive 
function in B cells 
[325, 330]
. CD40 engagement halts B cell differentiation into antibody 
producing plasma cells and maintains the undifferentiated state of B cells to facilitate 
differentiation into cells with immunosuppressive properties 
[331]
. The importance of CD40 
stimulation in immune regulation was highlighted in a murine model of autoimmunity, in 
which transfer of splenocytes stimulated with agonistic anti-CD40 results in amelioration of 
arthritis due to an increase in IL10 producing B cells 
[294]
. Similarly, chimeric mice 
reconstituted with CD40 deficient B cells were unable to recover from EAE compared with 
wild type mice due to impairment in IL10 production by B cells 
[293]
. BCR ligation 
combined with CD40 signalling results in the production of pro-inflammatory cytokines 
(TNFα, Lymphotoxin) and promotes B cell development and plasma cell differentiation [332].  
A range of studies have used CD40 stimulation to induce IL10 production in Bregs in both 
mice
 [293, 294] 
and humans 
[301]
 
 
[Figure 1.7]. CD40 signalling results in the activation of 
multiple signalling cascades, including nuclear factor kappa B (NFkB), mitogen activated 
protein kinase (MAPK) and signal transducer and activator of transcription-3 (STAT3) 
[333]
. 
CD40 receptor binding with its ligand results in auto phosphorylation of Janus kinase (Jak) 
which in turn induces phosphorylation of tyrosine residue of STAT3, resulting in its 
dimerisation and nuclear translocation, where it binds to promoter region of target genes and 
regulates their expression 
[334]
 .  
Toll-like receptors (TLRs) are pattern-recognition receptors that can activate immune 
responses in the presence of pathogen associated molecules such as lipopolysaccharides 
(LPS), viral ribonucleic acid, viral and bacterial DNA, lipoteichoic acids and flagellin 
[335]
. 
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Recently expression of TLR1, TLR2, TLR4, TLR7 and TLR9 transcripts has been reported 
in B cells, suggesting that B cells are capable of recognising a range of pathogenic antigens 
through TLRs 
[336, 337]
. Stimulation via agonists of TLR2, TLR4 and TLR9 has been shown 
to stimulate IL10 production in murine B cells 
[337, 338]
. Further, LPS and CpG stimulations 
also induce clonal expansion and IL10 production by B10 cells in mice
 [308, 339]
 and humans 
[306] 
[Figure 1.7]. TLR agonists can also induce IL10 production in transitional B cells in 
mice 
[319]
.  
TLR-induced IL10 producing B cells suppress differentiation of Th1 and Th17 cells, 
limiting T cell mediated inflammation from driving autoimmunity 
[338]
. TLR agonists can 
also suppress autoimmunity in mice models 
[340, 341]
. Defective IL10 production by B cells 
on TLR stimulation has been reported during autoimmunity 
[342]
 and mice with B cell 
restricted deficiencies in TLR4
 
develop an aggravated EAE 
[338]
 . TLR9 gene polymorphisms 
resulting in reduced expression have been associated with an increased predisposition 
towards systemic lupus erythematosus (SLE) in a Japanese population 
[343]
.  Interestingly, 
early life exposure to LPS in mice results in delayed onset and diminished severity of EAE, 
an increased spinal cord transcript level of IL10 has been reported in LPS exposed mice 
[344]
.  
Thus, B cell activation for IL10 production can occur via two different modes; T-cell 
dependant (via CD40 pathway) or T-cell independent (via TLR), which has led to 
development of a two-step model for B cell mediated regulation of immune responses by 
Lampropoulou et al. According to which, TLRs initiate IL10 mediated suppression by B 
cells, but it is possible that TLR stimulation induces IL10 production in only a few B cells. 
Suggesting that a second phase involving signalling via CD40 pathway might amplify the 
IL10 producing B cell population and re-stimulate B cells activated via TLRs to maintain the 
suppressive program resulting in effective immune suppression 
[338, 345]
. 
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In addition to CD40 and TLR stimulation, IL10 production by B cells can be triggered by a 
range of other stimuli. For instance, B cell activating factor (BAFF), a member of TNF 
family cytokines that acts as a key regulator of B cell maturation and survival has been 
identified as an additional stimulus for induction of IL10 production in CD5
+ve 
CD1d
hi
 B 
cells
[346]
.  Stimulation of B cells with GM-CSF and IL15 fusion protein known as GIFT15, 
has also been shown to convert naive B cells into B cells with immunosuppressive 
properties and may serve as a novel treatment for autoimmunity
 [347]
. Interestingly, apoptotic 
cells have also been shown to exert a protective effect on CIA development, via induction of 
IL10 secretion by B cells 
[348]
. 
 
1.7 Ageing, stress and immunity   
Stress has been defined as a state of reduced homeostasis, following exposure to extrinsic or 
intrinsic adverse forces (stressors), resulting in precipitation of a spectrum of adaptive 
physiological and behavioural reactions to re-establish homeostasis 
[349]
. Healthy older 
individuals have been reported to experience greater levels of stress, anxiousness and 
depression than young adults
 [350, 351]
. Meta-analysis of literature over the past few decades 
has led to the development of the hypothesis according to which chronic stressful life events 
are suppressors of immune function 
[352, 353]
. Immune dysregulation associated with chronic 
distress has clinical implications, for example individuals who report relationship conflict 
lasting a month or more are at increased risk of developing illness when exposed to an 
infectious agent 
[354]
 and relationship stress has also been associated with slower wound 
healing
 [355]
 . 
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Figure 1.7 Generation and mechanism of action of regulatory B cells.  
The primary mechanism of immune tolerance mediated by transitional B cells and B10 cells 
involves IL10 production which supress unwanted immune responses. Activation of B cells 
by CD154
+ve
 CD4
+ve
 T cells via CD40 pathway or via T cell independent TLR stimulation 
(LPS) induces IL10 production in Bregs. IL10 produced by these Bregs has 
immunosuppressive effects; including limiting differentiation of Th1 and TH17 cells, 
modulating differentiation and migration of Tregs and inhibiting pro-inflammatory cytokine 
production by monocytes and macrophages.  
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Immunesenescence has already been discussed (section 1.1) and there is now accumulating 
evidence suggesting that the effects of stress and age are interactive; chronic stress 
exacerbating the effects of ageing on immune function 
[4, 356]
. For example, a study 
examining the effect of the chronic stress of caregiving on vaccine responses reported that 
even though there was a deficit in the vaccine response of young caregivers when compared 
with young controls, this defect was magnified in older adults who were caregivers 
[357]
. 
Additionally, a negative association between exposure to stressful life events such as 
bereavement and marital dissatisfaction and a significant positive effect of marital 
satisfaction on vaccination responses has been reported in older adults 
[358]
. A previous study 
done in our own group has also shown that innate immunity is susceptible to the effects of 
physical stress, specifically a reduction in neutrophil superoxide production is seen on 
exposure to the trauma of a hip fracture 
[359]
 or the psychological distress of bereavement in 
older adults 
[360]
. These interactive effects of stress and ageing on the immune system in 
older adults are particularly troubling, as older adults are already at a higher risk of health 
complications due to immunesenescence. In addition, older adults have an increased risk of 
exposure to life events such as hip fracture, care-giving, bereavement and social isolation. 
1.8 The Hypothalamus-Pituitary-Adrenal axis  
The nervous, endocrine and immune systems are closely integrated and play an essential role 
in enabling organisms to adapt to stressful situations 
[349]
. The hypothalamus-pituitary-
adrenal (HPA) axis acts as a pivotal regulator of the stress responses by mobilising energy 
reserves and modulating immune responses, enabling individual to adapt to environmental 
changes 
[361]
. The central control point of this system is in the hypothalamus. Corticotrophin 
releasing hormone (CRH) secreted by the hypophysiotropic neurons localised in the para 
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ventricular nucleus (PVN) of the hypothalamus is the principal regulator of the HPA axis 
[362]
. CRH  binds to its receptor on pituitary corticotropes stimulating the secretion of 
adrenocorticotrophic hormone (ACTH) 
[363]
. The adrenal cortex is the principal target for 
circulating ACTH, where it stimulates secretion of glucocorticoids (GC) from zona 
fasciculata [Figure 1.8]. GCs are the final effectors of the HPA axis and act as principal 
hormone mediators of the stress system. Additionally, ACTH also stimulates secretion of 
another steroid, Dehydroepiandrosterone (DHEA) by the zona reticularis of the adrenal 
gland 
[364]
.  
 
GCs play a prominent role in regulating the magnitude and duration of the HPA axis 
activation 
[362]
 and are responsible for terminating stress responses through negative 
feedback. They exert a negative effect on secretion of ACTH, limiting the total exposure of 
organism to glucocorticoids, thus minimising the catabolic and immune suppressive effects 
of these hormones 
[361, 365]
. A dual glucocorticoid receptor system exists in the CNS, 
glucocorticoid receptor type I responds to low concentrations of GCs, glucocorticoid 
receptor II responds to both basal and stress concentrations of GCs and is responsible for 
mediating negative feedback control
 [363]
.  
 
The HPA axis exhibits a diurnal rhythm of secretion. In non-stressful events, CRH is 
secreted in portal system in a circadian fashion, the increased amplitude of CRH in the early 
morning results in ACTH and cortisol secretory bursts 
[361, 366]
. Cortisol secretion rises 
during sleep and reaches its peak 30-45 minutes after awakening, cortisol levels steadily 
decline throughout the day 
[367]
. Although DHEA levels are elevated post awakening, the 
diurnal rhythm of DHEAS (the sulphated and major form of DHEA in the circulation) does 
not display an awakening secretory activity. Post awakening DHEAS levels displays a flat 
secretion pattern and a decline in DHEAS levels has been reported 3 hr post-awakening 
[368]
. 
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Thus DHEAS levels do not display significant diurnal fluctuations and are relatively 
stable
[369]
.  
 
1.8.1 Glucocorticoids in humans 
  
Cortisol is a major glucocorticoid, synthesised from cholesterol by adrenocortical cells in 
response to ACTH in humans
 [370]
. Upon secretion, only 5-10% of cortisol circulates 
unbound and is biologically active, the remaining cortisol is bound to corticosteroid binding 
globulin (CBG)
[371]
.  Cortisol is a pleiotropic hormone that influences gene expression of up 
to 20% of human genes 
[349]
.  GCs are responsible for  controlling whole body homeostasis 
by mediating a range of metabolic processes including; mobilisation of energy, glucose 
utilisation, enhancing cardiovascular output and respiration, redistributing blood flow, 
increasing energy and substrate delivery to brain and muscle , increasing cerebral perfusion 
rates and modulating immune functioning 
[372, 373]
. 
GCs exert their effects via interaction with glucocorticoid receptors (GR). In the absence of 
GCs, the non-activated glucocorticoid receptor resides in the cytoplasm as a multiprotein 
complex consisting of two molecules of hsp90 and several other proteins 
[374]
. Upon ligand 
binding, GR undergoes a conformational change and dissociates from the multiprotein 
complex and translocates to the nucleus, where it binds to glucocorticoid response elements 
(GREs) located in promoter region of target genes and regulates expression of 
glucocorticoid responsive genes 
[363]
. 
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Figure 1.8 The Hypothalamus-Adrenal-Pituitary Axis.  
 
During stressful situations, the parvocellular neurons of the hypothalamus release 
neuropeptide CRH into portal blood vessels that stimulate ACTH secretion by anterior 
pituitary which in turn stimulates secretion of glucocorticoids by adrenal glands. 
Glucocorticoids secreted regulate HPA axis activation by negative feedback mechanism. 
Image taken from Murgatroyd et al 2011
[375]
. 
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1.8.2 DHEAS/DHEAS  
Dehydroepiandrosterone (DHEA) together with its sulphated precursor DHEAS are the most 
abundant steroids in the human circulation 
[364]
. A small fraction (< 1%) circulates in 
unsulphated form, as DHEA.  Large quantities of DHEAS (3.5 to 20 mg) are produced on a 
daily basis in both sexes 
[376]
. DHEA is predominantly synthesised in the human adrenal 
cortex from cholesterol, and serves as a precursor to sex hormones estradiol and 
testosterone. The human adrenal cortex is divided into three histologically distinct zones, 
which produce different classes of steroid hormones. The inner zone (zona reticularis) 
produces DHEA and its sulphate ester DHEAS 
[364, 377]
. Even though the physiological role 
of DHEAS is poorly understood, it has been reported to have memory-enhancing, cardio 
protective, anti-diabetic, anti-obesity, anti-depressive, anti-glucocorticoids and immune-
enhancing properties 
[364, 378]
. 
1.8.3 Alterations in HPA axis in older adults 
Healthy ageing is accompanied by relative activation of the HPA axis, due to a decline in 
production of DHEA/S and maintained or slightly increased production of cortisol 
[379]
. 
Studies examining the effects of ageing on diurnal cortisol secretion have yielded conflicting 
results. A few studies have reported flattening of the diurnal pattern of secretion in older 
adults 
[379-381]
, which might be due to hippocampal atrophy 
[381]
. Whilst other studies have 
reported either normal diurnal rhythm of cortisol 
[382, 383]
 or decreased diurnal rhythm 
[384, 385]
 
with age . An overall elevated basal cortisol levels has been reported with age 
[386, 387]
. 
However, a high variability has been reported in plasma cortisol levels with age, according 
to  a longitudinal study about 40% of older adults exhibit an increase in cortisol levels and a 
similar proportion showed only moderate increase in cortisol levels whilst the remaining 
showed a decline in basal cortisol levels 
[387]
.Genetic factors are likely to be responsible for 
this high degree of variability in cortisol levels with age 
[388]
. Further, there have also been a 
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few reports of unchanged cortisol levels with age 
[389, 390]
, with a trend towards elevated 
cortisol levels during evening in older subjects 
[391]
.  
 
 A major regulatory switch controlling tissue-specific activation of glucocorticoids is the 
enzyme 11β-hydrosteroid dehydrogenase type I (11 β- HSD1), which converts inactive 
cortisol to active cortisol 
[392]
. Inflammatory cytokines can upregulate expression of 11β-
HSD1 
[393]
. As ageing results in increased levels of pro-inflammatory cytokines (discussed in 
section 1.2), this might result in increased activity of 11 β-HSD1, leading to increased tissue 
exposure to the damaging effects of glucocorticoid 
[394, 395]
.  
 
Sapolsky et al  proposed the ‘glucocorticoid cascade hypothesis’ in 1986, according to 
which  the ability to switch off the HPA axis declines with age 
[396]
 . During stressful events, 
impairments in feedback regulation of the HPA axis occur in older adults resulting in hyper 
secretion of glucocorticoids. Further, an age-related decline in levels of glucocorticoid 
receptors and their binding capacity, resulting in impaired feedback inhibition, might be the 
underlying cause for HPA axis hyperactivation 
[397]
.  
 
DHEAS secretion follows a specific age associated secretion pattern [Figure 1.9]. High 
circulating DHEAS levels have been reported on birth, which rapidly drop and only rise 
again between the ages of 6-10 years, termed adrenarche 
[398, 399]
. DHEAS levels reach peak 
concentrations during third decade of life. Once peak levels have been reached a steady 
decline occurs with age (1-2 % per year), such that by the age of 80 DHEA/S levels are only 
10-20% of that seen in young adulthood 
[400-402]
. This fall in DHEA/S levels, termed 
adrenopause, occurs in both sexes 
[403, 404]
. Reduction in the size of the zona reticularis and 
reduced sensitivity towards ACTH are thought to contribute to diminished DHEA 
production with age 
[378, 405]
. 
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DHEA and DHEAS have been shown to act as immune enhancers, thus it can be 
hypothesised that age associated decline in DHEAS levels might contribute towards 
deterioration in immune functioning in older adults 
[406]
.  For instance, ageing is 
accompanied by dysregulated IL6 production, resulting in elevated serum IL6 levels with 
age, DHEAS supplementation in old mice has been shown to restore regulation of IL6 
production 
[407]
. Also, studies in animal models have reported success in using DHEA as a 
vaccine adjuvant to improve vaccine responses with age 
[408, 409]
. In-vitro studies have 
reported that pre-treatment of human T cells with DHEA increased IL2 production and 
enhanced cytotoxic potential of T cells 
[410]
 and in vitro treatment of human neutrophils with 
DHEAS increased superoxide generation and was able to overcome inhibition of neutrophil 
function by cortisol 
[411]
. 
Importantly, the elevated cortisol/DHEA(S) ratio that occurs with age might have a negative 
impact on the health of older adults 
[412]
. 
 
1.9 Hip Fracture in older adults 
Hip fracture is defined as any fracture of the femur between the articular cartilage of the hip 
joint to 5 cm below the distal point of the lesser trochanter 
[413]
 . Age is an important risk 
factor for hip fracture 
[414]
 and the majority of hip fractures are reported in older adults 
[413]
. 
370,000 older adults fall every year, 67000 of these resulted in a hip fracture in 2010 and 
this is predicted to rise to 117,000 by 2016 
[415, 416]
. Additionally, an estimated cost of about 
£12,000 was reported per hip fracture to the National Health Services in 1996 
[417]
 which 
continue to increase, highlighting the burden of hip fractures on health care costs.  
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Figure 1.9 Schematic representations of serum DHEAS levels in men and women 
lifespan.  
Immediately after birth, high circulating levels of DHEAS were reported, after which serum 
DHEAS levels rapidly decline and only begin to rise around the age of 10 years, termed 
‘adrenarche’. DHEAS levels reach maximum levels during the third decade of lifespan, after 
which a drop has been reported. DHEAS levels decline to 10-20% of its maximum levels by 
the age of 70. Image taken from Arlt et al, 2004
[402]
. 
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Increased incidence of hip fracture with age might be a result of increased risk of falling in 
older adults due to neuromuscular deterioration and osteoporotic changes 
[418]
. Even though 
hip fracture is treatable, it has a devastating effect on the life of older individuals and has 
been associated with poor outcomes including:  increased mortality 
[419]
, reduced life 
expectancy 
[420, 421]
 and physical disability 
[422, 423]
 . Magaziner et al reported that only one-
third  of patients return to their pre-fracture level of physical functioning one year after a hip 
fracture 
[424]
 .  
In a previous study by our group we have reported that about 37% of the older hip fracture 
patients that were in good health prior to the fracture succumbed to serious infections (the 
majority were bacterial infections) within 5 weeks of sustaining the fracture and were 
readmitted to hospital 
[359]
. Diminished neutrophil superoxide production was reported in 
older hip fracture patients compared with younger individuals suffering from a similar 
injury, which might contribute towards the increased risk  of infection in these individuals 
[359]
.  Further, older hip fracture patients had an increased serum cortisol: DHEAS ratio 
compared with young trauma patients and healthy older adults, which could mediate the 
suppressed neutrophil bactericidal function 
[411]
.   
1.10 Depressive symptoms in hip fracture patients  
Depression is the most common mood disorder reported in older adults 
[425]
, characterised by 
cognitive, behavioural, somatic and affective impairments that have a negative effect on 
functional activity, quality of life and social participation of an individual 
[426]
. Stressful life 
events such as bereavement or a disabling medical event (e.g. heart attack, rheumatoid 
arthritis, cancer, lung disease) are frequent precipitants of depressive symptoms 
[427, 428]
. 
Depressive symptoms have been associated with poor outcomes and an increased mortality 
in medical inpatients 
[429, 430]
.The development of depressive symptoms in medical 
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conditions rather than being a physiological reaction to the incapacitation and pain caused 
by the physical disease might also be in part a result of immune activation and cytokine 
secretion induced by the illness as many pro-inflammatory cytokines can lower mood 
[431, 
432]
.  
A high incidence of depression (9 - 47%) has been reported in UK and USA based studies of 
older adults with hip fracture 
[433-435]
 compared with the general population. Hip fracture is 
thus a risk factor for depression 
[426]
. Depression is a highly disabling condition and has been 
identified as a predictor for health outcomes and recovery after hip fracture 
[436, 437]
. Mossey 
et al reported that hip fracture patients with few depressive symptoms were nine times more 
likely to return to their pre-fracture level of physical functioning than those hip fracture 
patients with more depressive symptoms  
[438]
.  Interestingly, a two year  follow up study has 
shown that diagnosis of depressive symptoms in older adults soon after hip fracture 
substantially elevates the risk of mortality 
[435]
.  
1.11 Aims of this thesis   
A novel subset of B cells with immunosuppressive properties has been recently identified in 
humans. Although most aspects of immunity have been studied with respect to ageing, the 
effect of ageing on this subset of CD19
+ve
CD24
hi
CD38
hi
 B cells is unknown. Thus the first 
aim of this thesis was to examine the effect of age on peripheral count and IL10 production 
by CD19
+ve
CD24
hi
CD38
hi
 B cells. 
Ageing, physical stress and psychological stress are key interacting factors that have a 
detrimental effect on immune function.  A previous study done in our group had reported 
suppressed neutrophil superoxide production 
[359]
 and an elevated serum cortisol:DHEAS 
ratio in older individuals post hip fracture 
[411]
. Additionally, a high incidence of 
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development of depressive symptoms has been previously reported in hip fracture patients, 
even in those with no previously known psychiatric history 
[439]
. However the potential 
combined effect of hip fracture and depressive symptoms on immune and endocrine 
variables in older adults has not been examined. The second aim of this thesis was to 
examine the effects of hip fracture and depressive symptoms on innate immune function 
(neutrophils, monocytes, and NK cells), adaptive immune function (T cells, B cells and 
regulatory cells), serum stress hormone levels (cortisol, DHEAS) and serum cytokine levels 
in older adults.  
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                        Chapter 2 
The effect of ageing on immunosuppressive  
properties of Transitional B cells  
 
 
 
 
 
 
 
 
 
 
 
  
50 | P a g e  
 
2.1 Introduction 
2.1.1 Background 
It is well accepted that ageing is accompanied by immune dysregulation and an increase in 
the incidence of autoimmunity, for example RA, has been reported with advancing age 
[260]
. 
Age associated accumulation of senescent T cells, skewing towards Th17 phenotype, 
reduced immunosuppressive properties of Tregs , increased B cell autoreactive properties, an 
elevated circulating level of pro-inflammatory cytokines have all been previously discussed 
as factors that might be contributing towards increased risk of RA in older adults
 [263, 265]
.  
B cells are known to play a pathogenic role and exacerbate autoimmune diseases 
[281]
. In 
recent years, evidence has emerged for the presence of a subset of B cells with 
immunoregulatory properties in a number of murine models of inflammation 
[294, 304]
. Two 
phenotypically distinct subsets of B cells: transitional CD19
+ve
CD24
hi
CD38
hi 
B cells 
[301] 
and 
CD19
+ve
CD5
+ve
CD1d
hi “
B10” cells [306] have been reported to possess immunosuppressive 
properties, mainly via IL10 production. CD40 pathway stimulation induces expansion and 
IL10 production in both transitional B cells and B10 cells 
[301, 308, 319]
 . Interestingly, 
stimulation via TLRs has also been shown to induce IL10 production in B10 cells 
[306, 308]
 , 
whereas transitional B cells are capable of producing IL10 on stimulation via the CD40 
pathway 
[301]
 . In addition to IL10 production, murine Bregs have been shown to secrete 
TGFβ, but the inhibitory effect of human CD19+veCD24hiCD38hi B cells is TGFβ 
independent 
[440]
. Additionally, the suppressive effect of CD19
+
CD24
hi
CD38
hi
 B cells is also 
mediated via engagement of CD80 and CD86 
[301, 328]
. 
In this chapter, the effect of age on peripheral numbers of Breg cells and their IL10 
production capacity was investigated to examine if defects in Breg cells might be an 
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additional factor contributing towards the age-associated increase in incidence of 
autoimmunity, especially RA. 
2.1.2 Aims 
The aims of this chapter were: 
(a)  To confirm that it was possible to stimulate human B10 cells and transitional B cells via 
CD40 and TLR stimulations;  
(b) To determine if ageing is accompanied by numerical alterations in transitional B cells 
and B10 cells;  
(c) To examine if advancing age has an effect on IL10 production by both subsets of Bregs on 
stimulation via TLR and CD40 pathway and if so to determine the mechanisms involved; 
(d) To determine if there is an association between IL10 production by 
CD19
+ve
CD24
hi
CD38
hi
 and levels of serum autoantibodies (Rheumatoid Factor) with age.  
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2.2 Materials and Methods 
2.2.1. Media, solutions and antibodies 
Complete RPMI medium consisted of RPMI 1640 (Sigma Aldrich, UK) containing 1% GPS 
(2 mM glutamine, 100U/ml penicillin, and 100μg/ml Streptomycin; Sigma Aldrich, UK) and 
10% Heat inactivated fetal calf serum (HiFCS). Fetal calf serum (FCS; Sera Laboratories, 
UK) was incubated for 30 minutes in water bath at 56C to heat-inactivate it and prepare 
HiFCS. Phosphate buffer saline (PBS) was NaCl (137 mM), KCl (2.7 mM), NA2HPO4 (10 
mM) and KH2PO4 (2 mM) in double distilled H2O. PBS was prepared by dissolving one 
PBS tablet (Sigma Aldrich, UK) in 200 ml of distilled H2O. The PBS solution prepared was 
autoclaved prior to use. MACS buffer was PBS containing 2mM ethylenediamine tetra-
acetric acid (EDTA; Sigma Aldrich, UK) and 0.5% bovine serum albumin (BSA; Sigma 
Aldrich, UK). The antibodies used in the thesis, their working dilution and source are shown 
in Table 2.1. 
2.2.2. Subjects and blood sample collection  
56 young (mean age 26.81, range 20 - 36 years, 29 females) and 65 older (mean age 70.12, 
range 60 – 84 years, 32 females) subjects participated in this study. A venous sample was 
taken from each subject between the hours of 0900-1100 am after obtaining informed 
consent. At the time of blood sampling, none of the subjects had infections, and fulfilled a 
health criterion that was implemented to exclude subjects on steroid medication and those 
suffering from co-morbidities including; autoimmune diseases, infectious diseases, 
malignancy, diabetes and asthma. The study was approved by the North Staffordshire 
Research Ethics Committee. 
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2.2.3 Peripheral Blood Mononuclear (PBMC) Isolation 
Peripheral blood was collected in vacutainers and transferred into a 50 ml falcon tube 
(Becton Dickinson, UK). The blood was diluted 1:1 with RPMI medium (Sigma Aldrich, 
UK). The diluted blood was gently layered on top of 6mls of Ficoll-Paque
TM 
PLUS (GE 
Healthcare, Sweden) in a 25 ml universal tube (Starsted, UK). The tube was centrifuged at 
420 x g for 30 minutes with no break using a centrifuge (Jouan CR3i, DJB Labcare Ltd, 
UK). Post centrifugation, the mononuclear cell layer containing PBMC, which resided at the 
interface between plasma and Ficoll-Plaque was removed using a plastic pasteur pipette 
(Starsted, UK) and was added to a new universal tube and the tube was topped up with PBS. 
The cells were centrifuged at 300 x g for 10 minutes. This wash step was repeated and the 
cells were resuspended in PBS and were counted using a haemocytometer (Sigma Aldrich, 
UK). 
2.2.4 Freezing and thawing PBMCs 
PBMCs were frozen down by re-suspending cells in freezing medium consisting of 10% 
DMSO (Sigma Aldrich, UK) in heat inactived fetal calf serum (Biosera, UK) and 
transferring them in small aliquots into cryovials. The cryovials were transferred into a 
freezing container (Mr Frosty, Sigma Aldrich, UK) containing isopropanol (VWR 
International, UK). This allowed the samples to freeze gradually at the rate of 1C per 
minute. Cells were then stored at -80C. When thawing out frozen samples, they were put in 
a water bath at 37C. Once the cells had been thawed out they were washed in 10 ml of 
RPMI 1640 (Sigma-Aldrich, UK) to remove DMSO and cells were pelleted by 
centrifugation at 300 x g for 10 minutes.  
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2.2.5 Surface immunostaining for phenotypic analysis of B cells and T cells 
Isolated PBMCs resuspended in PBS (1 x 10
6
/ml) were transferred into polypropylene tubes 
(Becton Dickinson, UK) for immunostaining with a combination of fluorochrome 
conjugated antibodies including; anti-human CD19-PE (eBiosciences, UK), anti-human 
CD24-FITC (eBiosciences, UK), anti-human CD38-PEcy7(eBiosciences, UK), anti-human 
CD19-FITC (eBiosciences, UK), anti-human CD5-PEcy7 (eBiosciences, UK), anti-human 
CD1d-PE (eBiosciences, UK), anti-human CD40-APC (eBiosciences, UK), anti-human 
TLR4 (CD284)-APC (eBiosciences, UK), anti-human CD80-APC (Biolegend, UK), anti-
human CD86- APC (Biolegend, UK), anti-human CD3-FITC (Dako, UK), anti-human CD4-
PE (eBiosciences, UK), anti-human CD154-APC (eBiosciences, UK), anti-human CTLA4- 
APC (Biolegend, UK) and anti-human CD28-APC (BD Biosciences, UK) antibodies at the 
dilutions shown in Table 2.1. Staining for cell surface markers took place for 20 minutes in 
dark at 4C.  Following incubation, cells were washed twice with 300 μl of PBS and 
centrifuged at 250 x g for 5 minutes. Post washing, cells were resuspended in 300 μl of PBS 
for flow cytometric analysis on a Cyan 
TM
 ADP (Dako Ltd, UK) 
[441]
.  
2.2.6 B cell functional assays – CD3 stimulation of PBMCs 
Human cell cultures were performed in complete RPMI1640 medium (described in section 
2.2.1) which was pre-warmed to 37C. For CD3 stimulation, a 2μg/ml solution of anti-CD3 
mAb (BD biosciences, UK) was prepared, 50μl of this solution was added into each well of 
a 96 well round bottom microtitre plates (Becton Dickinson, UK). The plate was incubated 
at 37C for 1 hr prior to addition of 150μl of PBMCs in culture medium (at 1x 106/ml) to 
each well. The cells were cultured for 72 hr at 37C in a humidified atmosphere of 5% CO2 
[441]
. Brefeldin A (10μg/ml; Sigma Aldrich, UK) was added for the last 6 hr of the 
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stimulation along with PMA (50ng/ml; Sigma Aldrich, UK) and Ionomycin (500ng/ml; 
Sigma Aldrich, UK).  
Antibody  Dilution  Company 
Anti-human CD19 PE  (clone ׃ H1B19 ) 1/50 eBiosciences 
Anti-human CD19 FITC (clone ׃  H1B19) 1/50 eBiosciences 
Anti-human CD24 FITC (clone ׃ eBioSN3 ) 1/20 eBiosciences 
Anti-human CD 38 PEcy7 (clone ׃  HIT2) 1/100 eBiosciences 
Anti humanCD5 PE cy7 (clone  ׃UCHT2 ) 1/50 eBiosciences 
Anti-human CD 1d PE (clone  51.1 ) 1/50 eBiosciences 
Anti-human CD40 APC (clone ׃ 5C3 ) 1/20 eBiosciences 
Anti-human CD3 FITC ( clone ׃ UCHTI) 1/100 Dako 
Anti-human CD4 PE ( clone  ׃ RPA-T4) 1/100 eBiosciences 
Anti-human CD154 APC ( clone ׃ 24-31) 1/100 eBiosciences 
 Anti-human TLR4 APC ( clone ׃ HTA125) 1/20 eBiosciences 
Anti-human CD80- APC (clone ׃2D10) 1/20 Biolegend 
Anti -human CD86 - APC (clone ׃ IT2.2) 1/20 Biolegend 
Anti-human CTLA4-APC ( clone ׃ L3D10)    1/20 Biolegend 
Anti-human CD28-APC ( clone ׃ CD28.2)    1/1000 BD biosciences 
Anti-human  Stat3 (p Y705) Alexa fluor 647 1/10 BD biosciences 
Anti-human  IL10 Alexa fluor 647(clone׃ JES3-9D7) 1/40 eBiosciences 
BD biosciences Isotype controls   
APC mouse IgG2b ( clone: MPC-11) 1/100 Biolegend 
FITC mouse IgG1 ( clone : DAK-GO1 ) 1/100 Dako 
RPE mouse IgG2b ( clone :  DAK-GO9) 1/100 Dako 
PEcy7 mouse IgG2a (clone : P 3.6.2.81) 1/100 eBiosciences 
Alexafluor 647 mouse IgG2b (clone : MOPC-173) 1/100 BD biosciences 
 
 Table 2.1.Primary and isotype control antibodies used for flow cytometry. 
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2.2.7 Measuring CD154 expression on CD4 T cells post CD3 stimulation  
PBMCs were stimulated with plate bound CD3 for 72 hr (described in 2.2.6), but Brefeldin 
A was not added during the last 6 hr of stimulation. Post stimulation, cells were transferred 
into polypropylene tubes (Becton Dickinson, UK) and were pelleted by centrifugation at 250 
x g for 5 minutes and washed twice with 300 μl of PBS. Post washing, cells were re-
suspended in 100 μl of PBS and stained using cell surface marker antibodies anti-CD3-FITC 
(Dako, UK), CD4-PE (eBiosciences, UK) and CD154-APC (eBiosciences, UK) for 20 
minutes in the dark at 4C. Post immunostaining, cells were washed with 300 μl of PBS and 
were centrifuged at 250 x g for 5 minutes. The cells were re-suspended in 300 μl of PBS for 
flow cytometric analysis of immunofluorescence using a Cyan 
TM
 ADP (Dako Ltd, UK) and 
the percentage of CD154
+ve
 CD4 T cells and CD154 expression (MFI) levels were recorded 
[441]
. 
2.2.8 Flow cytometric detection of intracellular IL10 
Post CD3 stimulation (described in 2.2.6), cells were transferred into polypropylene FACS 
tubes (Becton Dickinson, UK) and washed with 300 μl of PBS and centrifuged at 250 x g for 
5 minutes. Post washing, cells were suspended in 100 μl of PBS and were stained with a 
combination of extracellular surface markers to identify transitional B cells using anti-
human CD19 PE (eBiosciences, UK), anti-human CD24 FITC (eBiosciences, UK) and anti-
human CD38 PEcy7 (eBiosciences, UK) antibodies or B10 cells using anti-human CD19 
FITC (eBiosciences, UK), anti-human CD5 PEcy7 (eBiosciences, UK)  and anti-human 
CD1d PE antibodies (eBiosciences, UK) for 20 minutes in dark at 4C. Post 
immunostaining, cells were washed with 300 μl of PBS and were centrifuged at 250 x g for 
5 minutes. The supernatant was removed and the cells were re-suspended in 50 μl of 
Reagent A (Fix and Perm kit, Invitrogen, UK) and were incubated for 30 minutes in the dark 
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at room temp. Post fixing, the cells were washed with 300 μl PBS and centrifuged at 250 x g 
for 5 minutes. Pelleted cells were resuspended in 50 μl of Reagent B (Fix and Perm kit, 
Invitrogen, UK) and anti-human IL10 Alexa fluor 647 antibody (eBiosciences, UK) was 
added to the cells and they were incubated for 30 minutes in the dark at room temperature. 
Post incubation, the cells were washed with 300 μl of PBS and centrifuged at 250 x g for 5 
minutes. Cells were resuspended in 300 μl of PBS for flow cytometric analysis using a Cyan 
TM
 ADP (Dako Ltd, UK) and the percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 cells and 
IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 cells as well as IL10 expression (MFI) levels were recorded 
[441]
.  
2.2.9 Isolation of B cells  
B cells were isolated from PBMCs by negative selection using magnetic activated cell 
sorting (MACS) technology (Human B cell isolation kit; Miltenyi Biotech, Germany). 
Freshly isolated PBMCs were counted and washed in 10 ml of MACS buffer (Miltenyi 
Biotech, Germany) at 300 x g for 10 minutes at 4C. The cell pellet obtained was re-
suspended in 40 μl of MACS buffer (per 107 cells; Miltenyi Biotech, Germany). To this 
suspension, 10 μl of B cell Biotin- antibody cocktail (per 107 cells; Miltenyi Biotech, 
Germany) was added and the sample was incubated for 10 min at 4C with occasional 
vortexing. Post incubation, 30 μl MACS buffer (per 107 cells; Miltenyi Biotech, Germany) 
and 20 μl B cell microbead cocktail (per 107 cells; Miltenyi Biotech, Germany) was added to 
the cells and they were incubated for 15 min at 4C. Post incubation, cells were washed in 
2ml of MACS buffer (per 10
7
 cells) and were centrifuged at 300 x g for 10 minutes at 4C. 
The sample was resuspended in 500 μl of MACS buffer.  
For magnetic isolation of B cells an LS column (Miltenyi Biotech, Germany) was placed in 
the magnetic field of a Quadra MACS separator (Miltenyi Biotech, Germany). The column 
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was prepared by washing with 3ml of ice cold MACS buffer .The PBMC suspension in 
MACS buffer was then applied to the column, followed by 9 ml (1ml at a time) of MACS 
buffer. The elute containing purified B cells was collected in a universal tube (Starsted, UK). 
Cells were pelleted by centrifugation at 300 x g for 10 minutes at 4C and the cells were 
resuspended in complete RPMI 1640 medium (described in 2.2.1) at 2.5 x 10
4
 cells/ml.  
To determine the purity of isolated B cells, 100 μl of the isolated B cells were taken up in a 
FACS tube (Becton Dickinson, UK) and were stained with anti-human CD3 FITC (Dako , 
UK) and anti-human CD19 PE (eBiosciences , UK) for 20 minutes at 4C in the dark. Post 
incubation, cells were washed with 300 μl of PBS and centrifuged at 250 x g for 5 minutes 
and taken up in 300 μl of PBS and purity was assessed using Cyan TM ADP (Dako Ltd, UK). 
B cells were defined as CD3
-ve
 CD19
+ve 
cells and purity obtained on a routine basis was > 
92%. 
2.2.10 Stimulation of isolated B cells – CD40L and LPS  
Purified B cells were taken up in 200μl of complete RPMI medium (described in section 
2.2.1) which was pre-warmed to 37C and cultured in a 96 well U bottom plate (Becton 
Dickinson, UK) at 2 x 10
5
 cells per well for 48 hr at 37C at 5% CO2 with recombinant 
human CD40L (1μg/ml; Peprotech, UK) or LPS isolated from Escherichia coli serotype 
0111:B4 (1μg/ml; Sigma-Aldrich, UK). Brefeldin A (10 μg/ml; Sigma Aldrich, UK) was 
added during the last 6hr of the stimulation. Post incubation, B cells were transferred into 
polypropylene FACS tubes (Becton Dickinson, UK) washed with 300 μl PBS and were 
centrifuged at 300 x g for 10 minutes 
[441]
. Cells were stained to measure intracellular IL-10 
levels (described in section 2.2.8). Cells were resuspended in 300 μl of PBS for flow 
cytometric analysis using a Cyan 
TM
 ADP (Dako Ltd, UK) and the percentage of 
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IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 cells and IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 cells as well as IL10 
expression (MFI) levels were recorded.  
2.2.11 Quantification of IL10 levels in supernatant  
Isolated B cells (1 x 10
6
) were taken up in 200μl of pre-warmed complete RPMI medium 
(described in section 2.2.1). B cells were stimulated in a 96 well U bottom plate (BD 
biosciences, UK) with either recombinant human CD40L (1μg/ml; Peprotech, UK) or LPS 
isolated from Escherichia coli serotype 0111:B4 (1μg/ml; Sigma Aldrich, UK) for 48 hr at 
37C at 5%CO2. Brefeldin A was not added during the last 6 hr of stimulation. Post 
stimulation, cells were pelleted by centrifugation at 300 x g for 10 minutes and supernatants 
were transferred into cryovials and snap frozen in liquid nitrogen and stored at -80C, until 
future analysis.  
IL10 levels in supernatants were quantified using commercially available Human IL-10 
ELISA (Abcam, UK), as per manufacturer’s instructions. Firstly, frozen supernatants were 
thawed on ice and 100 μl of cell culture supernatants were added to 96 well plate coated 
with anti-mouse IL10. 50μl of secondary biotinylated anti-IL10 was added to each well and 
the plate was incubated at room temperature for 2hr. Post incubation, liquid was aspirated 
and the plate was washed three times with 300 μl of washing solution. Post washing, 100μl 
of Streptavidin –HRP was added to each well and incubated for 30 minutes at room temp. 
The liquid was aspirated and the plate was washed again three times with 300 μl of washing 
solution. Post washing, 100μl of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution 
was added into each well and incubated in dark for 12-15 minutes at room temp. The 
enzyme substrate reaction was stopped by adding 100μl of stop reaction (H2SO4) into each 
well. The plate was read on a spectrophotometer (BioTek® Synergy HT, UK) using 450 nm 
as the primary wavelength within 5 minutes of adding stop solution. The OD values for 
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individual samples were calculated using a standard curve created by GraphPad Prism® 
software (GraphPad Software Limited, USA). 
2.2.12 Measuring phosphorylation state of STAT3  
PBMCs isolated from healthy young and old donors (described in section 2.2.3) were rested 
for 1 hr in 150 μl of complete pre warmed RPMI medium (described in section 2.2.1) in a 96 
well U bottom plate (Becton Dickinson, UK) at 37C at 5% CO2 . After 1 hr, cells were 
stimulated with 0.5μg of purified mouse-anti-human CD40 mAb (per 106 cells; BD 
biosciences, UK for 0, 5, 15 or 30 minutes in the dark at 4C.  Post stimulation, cells were 
transferred into polypropylene FACS tubes (Becton Dickinson, UK) and were washed with 
300 μl of ice cold PBS and centrifuged at 250 x g for 5 min. Cells were resuspended in 
100μl of PBS and stained with cell surface markers antibodies anti-human CD19-PE 
(eBiosciences, UK), anti-human CD24-FITC (eBiosciences, UK) and anti-human CD38-
PEcy7 antibodies (eBiosciences, UK) for 20 minutes in the dark at 4C. Post 
immunostaining, cells were washed in 300 μl PBS and centrifuged at 250 x g for 5 minutes 
and were resuspended in 100μl of warm PBS and rested for 30 minutes at 37C at 5% CO2. 
Post incubation, cells were fixed immediately to maintain phosphorylation state by adding 
100μl of 1.6% paraformaldehyde (Sigma Aldrich, UK) for 30 minutes at room temperature 
in the dark. Post fixation, cells were washed with 300 μl ice-cold PBS and centrifuged at 250 
x g for 5 min. 2 ml of ice-cold methanol (VWR International, UK) was added to and the 
cells were incubated for 30 min in the dark at room temperature. Post permeabilisation, 
samples were washed with 300 μl of PBS and centrifuged at 250 x g for 5 minutes and pellet 
was taken up in 100 μl of cold PBS and stained with anti-STAT3 (pY705) phosphospecific 
antibody (BD biosciences, UK) or appropriate phosphoflow Alexa fluor 647 isotype mouse 
IgG2b control (BD biosciences, UK) for 30 minutes in the dark at 4C. Cells were 
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resuspended in 300 μl of PBS for flow cytometric analysis using a Cyan TM ADP (Dako, 
UK) and the percentage of pSTAT3
+ve
CD19
+ve
CD24
hi
CD38
hi
 cells as well as pSTAT3 
expression (MFI) levels were recorded 
[441]
. 
2.2.13 Flow cytometry analysis 
During flow cytometric analysis using a Cyan 
TM
 ADP (Dako Ltd, UK) 50,000 live 
lymphocytes were gated; dead cells were excluded on the basis of forward and side scatter. 
Appropriate isotype controls were used for setting gates. During multicolour 
immunostaining compensation was performed to ensure that spectral of different 
fluorochrome conjugated-antibody did not overlap by staining cells individually with each 
antibody. Flow cytometry data was analysed using Summit v 4.3 software (Dako, USA).  
2.2.14 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism
®
 (Graph Pad, La Jolla, USA) 
software. Data distribution was checked using the Kolmogorov-Smirnov test. For normally 
distributed data, a Student’s t test analysis was performed to assess differences between two 
groups. P values of <0.05 were considered significant. To assess the relationship between 
two variable linear regressions was used.  
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 2.3. Results 
2.3.1 Identification of IL10 producing B cells in peripheral blood.   
Transitional B cells have been identified previously on the basis of differential expression of 
CD24 and CD38 
[300]
 and the gating strategy used to identify the different peripheral B cell 
subsets is shown in Figure 2.1a. Functionally immature CD19
+ve
CD24
hi
CD38
hi
 B cells have 
been reported to comprise the highest percentage of IL10 producing B cells upon CD40 
stimulation 
[301, 305]
. These findings were confirmed here as demonstrated by an enrichment 
of IL10
+ve
 B cells within the CD19
+ve
CD24
hi
CD38
hi 
subset in peripheral blood upon CD40 
stimulation [Figure 2.1b] 
[441]
. Additionally, studies done on B10 cells have reported an 
increase in IL10
+ve
 B cells on stimulation via TLR signals 
[308]
. Here for the first time I have 
shown that LPS stimulation also upregulated the percentage of IL10 producing 
CD19
+ve
CD24
hi
CD38
hi 
cells in humans [Figure 2.1c] 
[441]
. B cells were also cultured in the 
absence of stimulus and in the presence of BrefeldinA to block IL10 secretion and serve as 
negative control.  
Tedder et al reported that CD19
+ve
 CD5
+ve
 CD1d
hi
 B cells have immunoregulatory properties 
and referred to them as “B10” cells [303]. I have confirmed their presence in the peripheral 
circulation in humans [gating strategy shown in Figure 2.2a] and shown that B10 cells 
respond to stimulation via CD40 pathway [Figure 2.2b] and TLR4 ligation to induce IL10 
expression [Figure 2.2c]. 
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Figure 2.1. CD19
+ve
CD24
hi
CD38
hi
 B cells are the main producers of IL10 in B cells.  
PBMCs were isolated from peripheral blood, stimulated using anti-CD3 antibody for 72 hr 
and immunostained for expression of CD19, CD24, and CD38 and intracellularly stained to 
measure IL10 levels. (a) Representative flow cytometric plot showing the gating strategy 
used to identify transitional B cells in the B cell pool via expression of CD24 and CD38; (b) 
IL10 expression in B cell subsets following T cell dependent stimulation via CD3,(c) or T 
cell independent stimulation via LPS. 
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Figure 2.2. IL10 production by CD19
+ve
CD5
+ve
CD1d
hi
 B cells.  
PBMCs isolated from peripheral blood were stimulated using anti-CD3 antibody  or LPS for 
72 hr and immunostained for expression of CD19, CD5, and CD1d and intracellularly 
stained to measure IL10. (a) Representative flow cytometric plot showing the gating strategy 
used to identify B10 cells in the B cell pool via expression of CD5 and CD1d, (b) IL10 
expression in B cell subsets following T cell dependent stimulation via CD3 (c) or T cell 
independent stimulation via LPS. 
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2.3.2 Effect of age on the frequency of circulating transitional B cells and B10 cells 
 
On examining the percentage and absolute numbers of B cells in peripheral blood of healthy 
young and old donors, a significant decline in both percentages, p < .001, [Figure 2.3a] and 
absolute numbers of total B cells, p = .03, [Figure 2.3b] was found in older donors. These 
findings are in broad agreement with previous studies reporting a decline in circulating B 
cells with age 
[241, 243, 244]
. 
Previous studies have used two separate set of phenotypic markers to identify Bregs. In this 
chapter, the effect of age on both transitional B cells (CD19
+ve
CD24
hi
CD38
hi
) and B10 
(CD19
+ve
CD5
+ve
CD1d
hi
) subsets of Bregs was assessed. A significant decline in the 
percentage, p < .001 [Figure 2.4a] and absolute number of CD19
+ve
CD24
hi
CD38
hi
 B cells in 
peripheral blood was seen with age, p < .001 [Figure 2.4b] 
[441]
. Aditionally, a significant 
decline in the percentage, p < .001 [Figure 2.4c] and total number of B10 cells, p < .001 was 
also found in older adults [Figure 2.4d] 
[441]
.  
Interestingly, a significant negative correlation,  β = -.68, p <.001, ΔR2 = .47 was found 
between age and frequency of CD24
hi
CD38
hi
 cells in B cell pool [Figure 2.5], such that with 
increasing age the frequency of CD24
hi
CD38
hi
 B cells declines.  
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Figure 2.3 B cells in peripheral blood of young and old donors.  
 
(a) Representation of percentage of B cells in peripheral blood of healthy young (n = 34) and 
old donors (n = 35) .The mean value is indicated by the bar. (b) Representation of the mean 
absolute number of B cells in peripheral blood of healthy young (n = 15) and old donors (n = 
15). Data is expressed as mean ± SEM. * p <.05, ** p <.005. 
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 Figure 2.4 Transitional (CD19+veCD24hiCD38hi) B cells and B10 
(CD19
+ve
CD5
+ve
CD1d
hi
) cell frequency in peripheral blood with age.  
(a) The percentage of CD19
+ve
CD24
hi
CD38
hi
 B cells in the peripheral B cell pool of young 
donors (n= 24) and old donors (n = 22) in the basal state. The mean value is indicated by the 
bar. (b) The absolute number of CD19+veCD24hiCD38hi B cells in peripheral blood of 
healthy young (n=15) and old donors (n=15). Data is expressed as mean ± SEM. (c) The 
percentage of CD19
+ve
CD5
+ve
CD1d
hi
 B cells in the peripheral B cell pool of young donors 
(n= 18) and old donors (n = 18) in the basal state. The mean value is indicated by the bar. (d) 
The absolute number of B10 cells in peripheral blood of healthy young donors (n=15) and 
old donors (n=15). Data is expressed as mean ± SEM.  * p <.05, ** p <.005 , *** p <.001 .  
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Figure 2.5 Correlation between age and frequency of CD19
+ve
CD24
hi
CD38
hi
 B cells.  
Representation of the correlation between percentage of circulating CD24
hi
CD38
hi
 B cells 
and age in healthy individuals (n = 58). 
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Further , on examining CD19
+ve
CD24
int
CD38
int
 (mature) B cells in peripheral blood of 
healthy young and old donors, a significant decline in their frequency was seen with age, p = 
.002 [Figure 2.6a] although the absolute number of mature B cells in peripheral blood 
remained unaltered, p = .12 [Figure 2.6b].  An increase in the frequency of 
CD19
+ve
CD24
neg
CD38
+ve 
(memory) B cells
 
was also detected in old donors, p = .03 [Figure 
2.6c], but the absolute number of memory B cell subsets in peripheral blood did not differ 
between the two groups, p = .89 [Figure 2.6d]. 
2.3.3 Impaired IL10 induction by transitional B cells and B10 cells in older adults – T 
cell dependent stimulation  
The hallmark of suppressive function of transitional B cells and B10 cells is their ability to 
produce IL10 
[294, 308, 319]
. Contact dependent delivery of activating signals by CD4 T cells to 
the Bregs induces IL10 production. To mimic T-B cell interaction, PBMCs were stimulated in 
the presence of plate bound CD3 monoclonal antibody, a physiologically relevant stimulus 
capable of upregulation of CD154 expression on CD4 T cells, which in turn induces IL10 
production by CD19
+ve
CD24
hi
CD38
hi 
B cells 
[301]
.  
A time course experiment was performed to determine the optimal time point for IL10 
expression by CD19
+ve
CD24
hi
CD38
hi 
B cells on CD3 stimulation. PBMCs were stimulated 
in a CD3 coated plate for 24, 48 and 72 hrs. Very few CD19
+ve
CD24
hi
CD38
hi 
B cells 
expressed IL10 without stimulation (control) and on CD3 stimulation an increase in IL10 
expression by transitional B cells at 24 hr, p < .01; 48 hr, p = .01 and 72 hr, p = .001 was 
seen, with the highest IL10 expression after 72 hr stimulation [Figure 2.7]. Thus, hereafter 
CD19
+ve
CD24
hi
CD38
hi 
B cells were stimulated with plate bound CD3 for 72 hr to measure 
IL10 induction.  
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Figure 2.6 Mature (CD19
+ve
CD24
int
CD38
int
) and memory (CD19
+ve
CD24
-ve
CD38
+ve
) B 
cells in peripheral blood with age.  
(a) The percentage of CD19
+ve
CD24
int
CD38
int
 B cells in the peripheral B cell pool in young 
donors (n= 30) and old donors (n = 27) in the basal state. The mean value is indicated by the 
bar. (b) The absolute number of CD19+veCD24intCD38int B cells in peripheral blood of 
healthy young (n=15) and old donors (n=15) in the basal state. Data is expressed as mean ± 
SEM (c) The percentage of CD19
+ve
CD24
-ve
CD38
+ve
 B cells in the peripheral B cell pool of  
young donors  (n= 30) and  old donors  (n = 27). The mean value is indicated by the bar. (d) 
The absolute number of CD19
+ve
CD24
-ve
CD38
+ve
 B cells in peripheral blood of healthy 
young (n= 15) and old donors (n = 15). Data is expressed as mean ± SEM * p <.05, ** p 
<.005. 
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Figure 2.7 Time course experiment showing the frequency of IL10 producing 
CD19
+ve
CD24
+ve
CD38
+ve
 B cells upon CD3 stimulation of whole PBMCs.  
The mean frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral blood of healthy 
young donors on CD3 stimulation of whole PBMCs (n =3). Data is expressed as mean ± 
SEM. * p <.05 and ** p <.005. 
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To examine the effect of ageing on immunosuppressive properties of B cells, the percentage 
of IL10 expressing CD19
+ve
CD24
hi
CD38
hi
 B cells and CD19
+ve
CD5
+ve
CD1d
hi
 B cells was 
assessed post-stimulation of PBMCs with plate bound CD3 for 72 hr. A significant decline 
was observed in the percentage of IL10 expressing CD19
+ve
CD24
hi
CD38
hi
, p < .001 [Figure 
2.8a] and CD19
+ve
CD5
+ve
CD1d
hi
 B cells, p < .001 [Figure 2.8c] in old compared to young 
donors
[441]
. This decline in IL10 induction by CD19
+ve
CD24
hi
CD38
hi
 B cells with age was 
not affected by gender (data not shown). On comparing the level of IL10 expressed on a per 
cell basis no significant differences  were observed between young and aged donor 
CD19
+ve
CD24
hi
CD38
hi
 B cells, p = .46 [Figure 2.8b] or B10 cells, p = .84 [Figure 2.8d]
[441]
.  
Further, on examining IL10 induction by B cells as a whole or CD19
+ve
CD24
neg
CD38
+ve 
and 
CD19
+ve
CD24
int
CD38
int
 B cells no differences were observed with age [Table 2.2]. The 
decrease in IL10 expressing B cell subsets is thus restricted to the transitional B cells and 
B10 cells. 
Variable        Young        Old    p 
                 
Mean (SD) 
(SD)  
IL10
+ve
 B cells (%) 1.37 (1.22) 1.16 (.96) .54 
IL10 production (MFI value)                           31.15 (12.99)             30.05 (7.85)                 .75
IL10
+ve
 CD19
+ve
CD24
neg
CD38
+ve 
(%)                  1.61 (1.14)                 1.44  (1.23)              .70 
IL10 production (MFI value)                           20.29 (5.63)               21.09 (6.38)                 .61
IL10
+ve
 CD19
+ve
CD24
int
CD38
int 
(%)                   .95 (.75)                 .93  (.63)               .94 
IL10 production (MFI value)                           21.12 (9.73)                21.62 (7.66)                 .88
             
           Table 2.2 IL10 expression by B cell subsets on CD3 stimulation with age. 
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Interestingly, a significant negative correlation , β = -.62, p <.001, ΔR2 = .38 between age 
and percentage of IL10
+ve
CD24
hi
CD38
hi
 B cells on CD3 stimulation was observed [Figure 
2.9] such that with increasing age the frequency of IL10
+ve
CD24
hi
CD38
hi
 B cells declines.  
Previous studies on CD19
+ve
CD24
hi
CD38
hi
 B cells have routinely included 6h stimulation 
with PMA and Ionomycin at the end of the 72h anti-CD3 treatment
 [301]
. To test if the defect 
in IL10 induction by CD19
+ve
CD24
hi
CD38
hi
 B cells with age could be overcome by short re-
stimulation (6 hr), cells were also similarly treated with PMA and Ionomycin. However, a 
significant decline in the percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
, p < .001 [Figure 
2.10a] and IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 B cells, p < .001 [Figure 2.10c] remained in older 
individuals. Further, on comparing the levels of IL10 expressed by the Bregs, no significant 
differences were observed in IL10 expression by CD19
+ve
CD24
hi
CD38
hi
 cells, p = .17 
[Figure 2.10b] or CD19
+ve
CD5
+ve
CD1d
hi
 B cells, p = .54 [Figure 2.10d] with age after PMA 
and Ionomycin treatment.  
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Figure 2.8 IL10 expression by transitional
 
B cells and B10 cells post stimulation with 
plate bound CD3 in young and old adults. 
(a) Percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cells on CD3 stimulation for 72 hr in the 
peripheral B cell pool of young (n= 15) and old donors (n = 15). The mean value is indicated 
by the bar. (b) Mean amount of IL10 expressed (MFI values) by 
IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cells on CD3 stimulation of PBMCs isolated from young (n 
= 15) and old donors (n=15). Data is expressed as mean ± SEM (c) Percentage of 
IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 cells on CD3 stimulation in the peripheral B cell pool of 
young (n=13) and old donors (n=13). The mean value is indicated by the bar. (d) Mean 
amount of IL10 (MFI values) expressed by individual IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 cells 
on CD3 stimulation of PBMCs isolated from young (n=13) and old donors (n=13). Data is 
expressed as mean ± SEM. *** p <.001. 
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Figure 2.9 Correlation between age and frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B 
cells.  
Representation of the correlation between percentage of IL10
+ve
CD24
hi
CD38
hi
 B cells and 
age healthy individuals (n = 50). 
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Figure 2.10 IL10 inductions with age by transitional B cells and B10 cells on CD3 
stimulation along with short term stimulation with PMA and Ionomycin.  
 (a) The percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 on CD3 stimulation along with short 
term stimulation with PMA and Ionomycin (last 6 hr) in the peripheral B cell pool of young 
(n=14) and old donors (n=16). The mean value is indicated by the bar. (b) Mean amount of 
IL10 expressed by CD19
+ve
CD24
hi
CD38
hi
 B cells on CD3 stimulation plus PMA and 
Ionomycin stimulation in young (n=14) and old donors (n=16). Data is expressed as mean ± 
SEM (c) Percentage of IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 B cells on CD3 stimulation along with 
short term stimulation with PMA and Ionomycin (last 6 hr) in peripheral B cells of young 
(n=13) and old donors (n=13). The mean value is indicated by the bar. (d) Mean amount of 
IL10 expressed by CD19
+ve
CD5
+ve
CD1d
hi
 B cells on CD3 stimulation plus PMA and 
Ionomycin in young (n=13) and old donors (n =13). Data is expressed as mean ± SEM. *** 
p <.001. 
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2.3.4 CD40 expression on aged and young B cell subsets   
CD40 is an integral membrane protein expressed during all stages of B cell differentiation 
and development 
[329, 442]
. The proportion of CD40
+ve
 cells in the B cell pool and the 
proportion of CD40
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cells in peripheral blood remained stable 
with age (p = .52 and p = .77 respectively) 
[441]
. In addition, CD40 expression on total B 
cells and on CD19
+ve
CD24
hi
CD38
hi
 B cells also did not differ between young and aged 
donors (p = .56 and p = .51 respectively) [Table 2.3]. Thus, the impaired ability of IL10 
production by CD19
+ve
CD24
hi
CD38
hi
 cells in healthy older adults on CD3 stimulation was 
not simply a result of reduced CD40 expression on these cells with age.  
Variable        Young        Old    p 
                      Mean (SD)  
CD40
+ve
 B cells (%)                                        95.48 (2.08)             94.61 (4.58) .52 
CD40 expression (MFI value)                        40.53 (19.50)               43.80 (12.59) .56 
CD40
+ve
 CD19
+ve
CD24
hi
CD38
hi 
(%)                 94.18 (6.55)               94.86 (7.78) .77 
CD40 expression (MFI value)                        41.52 (20.03)               45.83 (16.79) .51 
           
          Table 2.3 CD40 expression by B cell subsets with age in resting state. 
 
2.3.5 Expression of CD40L (CD154) on CD4
+ve
 T cells with age  
 T cells activated via the TCR/CD3 pathway are capable of providing a co-stimulatory signal 
for induction of IL10 production by CD19
+ve
CD24
hi
CD38
hi
 B cells via upregulation of 
CD40 ligand (CD154) expression 
[443, 444]
. It was observed that resting CD4 T cells 
expressed very low levels of CD154 (0.2-1.5 %), which has been reported previously 
[445]
. 
On examining the percentage of CD154
+ve
 CD4 T cells it was observed that levels were 
lower in old donors compared to young donors , p = .02 in resting state [Figure 2.11a], 
  
78 | P a g e  
 
though expression levels of CD40L (CD154) on resting CD4 T cells on a per cell basis 
showed no significant differences with age, p = .67 [Figure 2.11b]. 
CD3 activation results in transient upregulation of CD154 expression. A 5-10 fold increase 
in percentage of CD4 T cells expressing CD40L post-CD3 stimulation (72 hr) was observed, 
which is similar to previous reports
 [445]
. Activation of T cells revealed an age related decline 
in CD3-induction of CD40L
 
expressing CD4 T cells, p = .003 [Figure 2.11 c], though the 
mean expression levels of CD40L on CD3 stimulated CD4 T cells did not significantly 
differ between young and aged donors, p = .31 [Figure 2.11d]. Thus, suggesting the 
possibility that age related decline in CD4 T cell ability to provide an activating stimulus to 
B cells might be one of the factors contributing towards impaired induction of IL10 
production by CD19
+ve
CD24
hi
CD38
hi
 B cells with age 
[441]
.  
2.3.6 Intrinsic defects in CD19
+ve
CD24
hi
CD38
hi
 B cells with age  
To further examine the mechanisms responsible for low induction of IL10 producing cells 
with age, whether CD19
+ve
CD24
hi
CD38
hi
 B cells also exhibited any cell-intrinsic defects in 
response to CD40 stimulation was determined. Recombinant CD40 ligand protein 
(Peprotech, UK) was used to stimulate isolated B cells as used in another study 
[306]
 . A time 
course experiment was performed to determine the optimal time point for IL10 production 
by CD19
+ve
CD24
hi
CD38
hi 
B cells on stimulation of isolated B cells with recombinant 
CD40L for 24 and 48 hrs. Very few CD19
+ve
CD24
hi
CD38
hi 
B cells produced IL10 in 
absence of stimulation (control). There was a significant upregulation in IL10 producing 
CD19
+ve
CD24
hi
CD38
hi 
B  cells on 24 hr stimulation with recombinant CD40L, p = .02 and a 
further increase in the percentage of IL10 producing CD19
+ve
CD24
hi
CD38
hi 
 B cells after 48 
hr stimulation, p = .004 , [Figure 2.12]. Hereafter CD19
+ve
CD24
hi
CD38
hi 
B cells were 
stimulated for 48 hr via CD40 pathway to induce IL10 production, which has been reported 
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previously 
[319, 446]
. CD40 stimulation also induces IL10 production in B10 cells 
[308]
. Similar 
time course experiments done on isolated B cells revealed maximum IL10 production by 
CD19
+ve
CD5
+ve
CD1d
hi
 B cells on 48 hr stimulations with recombinant CD40L protein (data 
not shown). 
An age associated decline in the percentage of IL10 expressing CD19
+ve
CD24
hi
CD38
hi
,   p = 
.002 [Figure 2.13a] and CD19
+ve
CD5
+
CD1d
hi
 B cells. p = .003 [Figure 2.13c] was seen in 
healthy older individuals on stimulation with recombinant CD40L. However, no significant 
differences were observed in the mean intracellular expression of IL10 by 
CD19
+ve
CD24
hi
CD38
hi
 B cells, p = .76 [Figure 2.13b] and CD19
+ve
CD5
+
CD1d
hi
 B cells, p = 
.61 [Figure 2.13d] post stimulation with CD40L 
[441]
. 
2.3.7 IL10 secretion by B cells from older adults is impaired on stimulation via CD40  
CD40 generated signals in addition to promotion of IL10 production also induces IL10 
secretion by B cells 
[294, 319]
. IL10 secretion by isolated B cells on prolonged stimulation (48 
hr) with recombinant CD40L was determined by performing an ELISA to measure IL10 
levels in supernatants of cell cultures. A significant decline in IL10 levels in supernatant of 
CD40 stimulated aged donor B cells on comparison with young donor B cells, p = .04 was 
found [Figure 2.14] 
[441]
. These data suggest that IL10 secretion by B cells on CD40 
stimulation is impaired with age.  
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Figure2.11 CD40L expression on CD4 T cells in the resting and activated state with 
age.  
(a) Percentage of CD40L
+ve
CD4 T cells in young (n=14) and old donors (n=15) in the 
resting state. The mean value is indicated by the bar. (b) Mean per cell expression of CD40L 
(MFI value) on CD40L
+ve
 CD4
 
T cells in young (n=14) and old donors (n=15) in the resting 
state. Data is expressed as mean ± SEM (c) Percentage of CD40L
+ve
 CD4 T cells post CD3 
stimulation  in young (n=14) and old donors  (n=15). The mean value is indicated by the bar. 
(c) Mean expression of CD40L (MFI value) on CD40L
+ve
 CD4T cells in young (n=14) and 
old donors (n=15) post stimulation. Data is expressed as mean ± SEM * p < .05, ** p < .005. 
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Figure 2.12 Time course of induction of IL10 producing CD19
+ve
CD24
+ve
CD38
+ve
 B 
cells on CD40L stimulation of isolated B cells.  
Representation of the mean frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral 
blood of healthy young donors on stimulation of isolated B cells with recombinant CD40L 
(n=3). Data is expressed as mean ± SEM. * p <.05, ** p <.005. 
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Figure 2.13 CD19
+ve
CD24
hi
CD38
hi
 B cells and CD19
+ve
CD5
+
CD1d
hi
B cells from old 
donors display impaired IL10 induction on CD40 (T cell dependent) stimulation.  
(a) Percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells on stimulation of isolated B cells for 
48 hr with CD40L in peripheral B cell pool of young (n=15) and old (n=15). The mean 
value is indicated by the bar. (b) Mean expression of IL10 in CD19
+ve
CD24
hi
CD38
hi
 B cells 
on 48 hr with CD40L in young (n=15) and old donors (n=15). Data is expressed as mean ± 
SEM. (c) Percentage of IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 cells on stimulation of isolated B 
cells for 48 hr with CD40L in peripheral B cell pool with age in young (n=15) and old 
donors (n=15).  The mean value is indicated by the bar. (d) Mean expression of IL10 in 
CD19
+ve
CD5
+ve
CD1d
hi
 on 48 hr with CD40L in young (n=15) and old donors (n=15). Data 
is expressed as mean ± SEM.  * p <.05, ** p <.005. 
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Figure 2.14 IL10 secretion by B cells on CD40 (T cell dependent) stimulation with age. 
Representation of the mean IL10 concentration in cell culture supernatants post 48 hr  
stimulations with CD40L in B cells isolated from young (n=16) and old donors (n=15). Data 
is expressed as mean ± SEM * p <.05. 
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2.3.8 Impaired STAT3 signalling after CD40 stimulation in CD19
+ve
CD24
hi
CD38
hi
 B 
cells with age.  
 
CD40 signalling results in the activation of multiple signalling cascades , including nuclear 
factor kappa B (NFkB), mitogen activated protein kinase (MAPK) and signal transducers 
and activators of transcription factor 3 (STAT3) 
[334]
. CD40- mediated STAT3 activation is 
known to induce IL10 gene expression. Due to the very low numbers of 
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral blood , STAT3 phosphorylation at tyrosine 
residue Y705 was assessed on a single cell basis using phosphoflow cytometry rather than 
western blotting, immunoprecipitation or immunofluorescence microscopy that have been 
used previously 
[301, 447]
. PBMCs isolated from young and old donors were stimulated using 
an agonistic anti-CD40 antibody for 0, 5, 15 or 30 minutes. A significant lower percentage 
of CD19
+ve
CD24
hi
CD38
hi
 cells expressing phosphorylated STAT3 was seen in old donors 
compared with young subjects cells at 5 min , p = .004; 15 min  , p = .03; and 30 minutes , 
p= .04 post-stimulation [Figure 2.15] 
[441]
.  Protein levels (MFI value) of phosphorylated 
STAT3 between young and aged donor cells after CD40 stimulation showed no significant 
differences at any time point [Table 2.4]. 
 
Variable        Young        Old    p 
                      Mean (SD)  
p STAT3 expression (0 min)                     52.35 (19.18)                            48.31 (18.98)                            .74
p STAT3 expression (5 min)                     98.83 (21.50)                          87.44 (19.80)                        .53                          
p STAT3 expression (15 min)                     136.76 (26.14)                            102.19 (22.81)                         .40
p STAT3 expression (30 min)                     84.79 (26.99)                             68.89 (24.64)                          .74                    
 
Table 2.4 The expression levels phosphorylated STAT3 (MFI) by transitional B cells 
in young and aged donors post CD40 stimulation. 
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Figure 2.15 Reduced STAT3 phosphorylation in transitional B cells in response to 
CD40 stimulation with age. 
 
PBMCs were isolated from young (n = 5) and old donors (n = 5) and stimulated with an 
agonistic anti-CD40 antibody after which cells were fixed and stained for phosphorylated 
STAT3 (pY705) at the time points shown. Data are represented as percentage of 
CD19
+ve
CD24
hi
CD38
hi 
B cells expressing pSTAT3. Data is expressed as mean ± SEM * p 
<.05, ** p <.005. 
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2.3.9 Age associated alteration in IL10 production by B cells – T cell independent 
stimulation 
Activation of B cells via TLR agonists, including LPS (TLR4) and CpG oligonucleotides 
(TLR9) induces IL10 production 
[338, 448]
. Therefore, whether age associated defects in IL10 
production upon stimulation also extended to T cell-independent (LPS) stimulation was 
assessed.   
Time course experiments showed a significant upregulation in IL10 producing 
CD19
+ve
CD24
hi
CD38
hi
 B cells upon 24 hour stimulation with  LPS compared to B cells in 
culture without stimulus, p = .003, with a further increase after 48 hr stimulation, p < .001 , 
[Figure 2.16]. Thus, 48 hr stimulation with LPS was chosen to induce IL10 production, 
which has been reported previously 
[319, 446]
. Similar time course experiments done on 
isolated B cells revealed maximum IL10 production by CD19
+ve
CD5
+ve
CD1d
hi
 B cells on 48 
hr stimulation with LPS (data not shown). 
A comparison of B cell responses by cells isolated from young and old donors showed an 
age associated decline in the percentage of IL10 producing CD19
+ve
CD24
hi
CD38
hi
 cells, 
p<.001 [Figure 2.17a] and CD19
+ve
CD5
+ve
CD1d
hi
 B cells, p <.001 [Figure 2.17c] on LPS 
stimulation. However, no significant differences were observed in the mean values of IL10 
produced by CD19
+ve
CD24
hi
CD38
hi
 B cells, p = .48 [Figure 2.17b] and 
CD19
+ve
CD5
+ve
CD1d
hi
 B cells, p = .52 [Figure 2.17d] on stimulation with LPS [441]. 
 Thus, Bregs show impaired IL10 production on stimulation via CD40 pathway as well as 
TLR pathway with advancing age. 
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Figure 2.16 Time course experiment showing the frequency of IL10 producing 
CD19
+ve
CD24
+ve
CD38
+ve
 B cells frequency on LPS stimulation of isolated B cells.  
Representation of the mean frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral 
blood of healthy young donors on stimulation of isolated B cells with recombinant LPS (n 
=3). Data is expressed as mean ± SEM * p <.05, ** p <.005 and *** p <.001. 
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Figure 2.17 CD19
+ve
CD24
hi
CD38
hi
 B cells and CD19
+ve
CD5
+ve
CD1d
hi
B cells from old 
donors display impaired IL10 expression upon LPS stimulation  
(a) Percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells on stimulation of isolated B cells for 
48 hr with LPS in peripheral B cell pool of young (n=15) and old donors (n=15). The mean 
value is indicated by the bar. (b) Mean amount of IL10 expressed by CD19
+ve
CD24
hi
CD38
hi
 
B cells on stimulation with LPS in peripheral blood of young (n=15) and old donors (n=15). 
Data is expressed as mean ± SEM .(c) Percentage of IL10
+ve
CD19
+ve
CD5
+ve
CD1d
hi
 B cells 
on stimulation of isolated B cells with LPS in peripheral B cell pool of young (n=15) and old 
(n =15). The mean value is indicated by the bar. (d) Mean amount of IL10 expressed by 
CD19
+ve
CD5
+ve
CD1d
hi
 B cells on LPS stimulation in peripheral blood of young (n=15) and 
old donors (n=15). Data is expressed as mean ± SEM.  *** p <.001. 
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Further, on examining IL10 production after LPS stimulation by B cells as a whole, 
CD19
+ve
CD24
neg
CD38
+ve
, or CD19
+ve
CD24
int
CD38
int
 B cells no differences were found with 
age [Table 2.5]. 
Variable        Young        Old    p 
                 Mean 
(SD) 
(SD)  
IL10
+ve
 B cells (%) .59 (.26) .43 (.18)                .51 
IL10 production (MFI value)                           34.25 (12.56)               32.05 (14.67)               .75
IL10
+ve
 CD19
+ve
CD24
neg
CD38
+ve 
(%)                  1.71 (.47)                 1.31 (.39)              .76 
IL10 production (MFI value)                           24.12 (15.67)             22.62 (13.98)            .68 
IL10
+ve
 CD19
+ve
CD24
int
CD38
int 
(%)                   0.91 (.32)                 0.86 (.48)               .74 
IL10 production (MFI value)                           23.71 (16.18)               26.09 (15.45)              .44 
             
        Table 2.5 IL10 expression by B cell subsets on LPS stimulation with age. 
 
2.3.10 IL10 secretion by B cells in older adults is impaired on stimulation via LPS 
 
In addition to IL10 intracellular expression, IL10 secretion by aged B cells on LPS 
stimulation was determined. Even though the IL10 levels in B cell culture supernatants 
appear low, these levels are similar to findings reported by others 
[306]
. Significantly lower 
IL10 levels were found in the supernatant of LPS stimulated B cells from old donors in 
comparison with young donor B cells, p = .04 [Figure 2.18] 
[441]
. Suggesting, that the ability 
of B cells to secrete IL10 on LPS stimulation is impaired with age. 
  
2.3.11 Age associated alteration in TLR4 expression on B cells  
On comparing TLR4 expression on the three separate B cell subsets, it was observed that the 
percentage of CD24
hi
CD38
hi
 B cells expressing TLR4 was higher compared with CD24
int
 
CD38
int
, p <.001 and CD38
-ve
 CD24
+ve 
B cells, p <.001 [Figure 2.19a] in the resting state. 
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Similarly, TLR4 expression levels (MFI) in CD24
hi
CD38
hi
 B cells was also higher compared 
with CD24
int
 CD38
int
, p = .003 and CD38
-ve
 CD24
+ve 
B cells, p = .004 [Figure 2.19b]. 
On further analysis, significant differences were found in the percentage of TLR4
+ve
 
CD24
hi
CD38
hi
 B cells, p <.01 [Figure 2.19c], but not in TLR4 expression levels (MFI) on a 
per cell basis, p = .14 [Figure 2.19d] in older adults in the resting state 
[441]
. On further 
analysis, no differences were observed in frequency of TLR4
+ve
 CD24
int
 CD38
int
 or in 
TLR4
+ve
 CD38
-ve
 CD24
+ve
 B cells or in TLR4 expression levels by these two B cell subsets 
with age (data not shown).  
2.3.12 CD80 and CD86 expression on B cell subsets with age   
The suppressive activity of B cells is not exclusively IL10 dependent 
[449, 450]
, engagement of 
CD80/CD86 with CD28 and CTLA4 expressed on T cells has been proposed as an 
additional mechanism of suppression by Bregs 
[301]
. On comparing CD80 and CD86 
expression on the three separate B cell subsets in the resting condition, it was observed that 
the percentage of  CD19
+ve
CD24
hi
 CD38
hi
 B cells expressing CD86 was higher compared 
with CD24
int
 CD38
int
 ,   p = .02  and CD38
-ve
 CD24
+ve 
B cells , p = .02  [Figure 2.20a]. 
However, CD86 expression levels (MFI) on CD19
+ve
CD24
hi
 CD38
hi
 B cells did not differ 
from CD24
int
 CD38
int
, p = .89 and CD38
-ve
 CD24
+ve 
B cells, p = .91(data not shown). No 
significant differences were observed between the percentages of CD19
+ve
CD24
hi
 CD38
hi
 B 
cells expressing CD80 in comparison with CD24
int
 CD38
int
, p = .98 and CD38
-ve
 CD24
+ve 
B 
cells, p = .87 [Figure 2.20b]. Similarly, CD86 expression levels (MFI) on CD24
hi
 CD38
hi
 B 
cells did not differ from CD24
int
 CD38
int
, p = .62 and CD38
-ve
 CD24
+ve 
B cells, p = .49 (data 
not shown).  
Further, on examining the effect of age on CD80 and CD86 expression, no significant 
differences were found between the percentage of CD19
+ve
CD24
hi
CD38
hi
 cells expressing 
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CD80 , p = .51 [Figure 2.21a] or CD86 , p = .95 [Figure 2.21c] between young and old 
donors. Similarly, no significant differences were found in cell surface expression levels 
(MFI) of CD80, p = .95 and CD86, p = .56 on CD19
+ve
CD24
hi
CD38
hi
 cells [Figure 2.21b 
and d] with age 
[441]
. 
2.3.13 CTLA4 and CD28 expression on T cells with age  
Two known ligands for B7 molecules, CD28 and CTLA4 are expressed on T lymphocytes 
[451]
. On examining the expression of CTLA4 on CD4 T cells with age, a significantly higher 
percentage of CTLA4
+ve
 CD4 T cells was found in peripheral blood of old donors , p = .006 
[Figure 2.22a], although CTLA4 expression levels (MFI) remained unaltered , p = .96 
[Figure 2.22b] with age. These findings are consistent with previous reports 
[452, 453]
.  CD28 
is constitutively expressed on the majority of T cells 
[454]
, but a significant reduction in the 
percentage of CD28
+ve
 CD4 T cells was found in our subjects with age , p <.001 [Figure 
2.22c] which is consistent with the literature 
[195, 197]
. No significant differences were found 
in CD28 expression levels (MFI) on CD4 T cells between young and aged donors, p = .61 
[Figure 2.22d] 
[441]
.    
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 Figure 2.18 IL10 secretion by B cells in old donors on LPS (T cell independent) 
stimulation.  
Representation of the mean IL10 concentration in cell culture supernatants post 48 hr  
stimulation with LPS done on B cells isolated from young (n=16) and old donors (n=15).  
Data is expressed as mean ± SEM. * p < .05. 
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Figure 2.19 TLR4 expression on B cell subsets and effect of ageing. 
a) Frequency of TLR4
+ve
CD24
hi
CD38
hi 
B cells, TLR4
+ve
CD24
int
CD38
int 
B cells and 
TLR4
+ve
CD24
-ve
CD38
+ve 
B cells in peripheral blood of young donors  (n=6)  in the resting 
state. (b) Mean TLR4 expression levels (MFI) on CD19
+ve
CD24
hi
CD38
hi
 B cells, 
CD19
+ve
CD24
int
CD38
int 
B cells and CD19
+ve
CD24
-ve
CD38
+ve 
B in PBMCs of young donors 
(n=6). Data is expressed as mean ± SEM (c) Percentage of TLR4
+ve
CD24
hi
CD38
hi 
B cells in 
peripheral of young (n=15) and old donors (n =16) in the resting state. The mean value is 
indicated by the bar. (d) Mean TLR4 expression levels (MFI) on CD19
+ve
CD24
hi
CD38
hi
 B 
cells in young (n=15) and old donors (n=16). Data is expressed as mean ± SEM.* p <.05, 
**p <.005, ***p <.001. 
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Figure 2.20 CD80 and CD86 expression on B cell subsets (resting state).  
(a) Percentage of CD86
+ve
CD24
hi
CD38
hi 
B cells, CD86
+ve
CD24
int
CD38
int 
B cells and 
CD86
+ve
CD24
-ve
CD38
+ve 
B cells in peripheral blood of young (n=6) in the resting state. (b) 
Percentage of CD80
+ve
CD24
hi
CD38
hi 
B cells, CD80
+ve
CD24
int
CD38
int 
B cells and 
CD80
+ve
CD24
-ve
CD38
+ve 
B cells in peripheral blood of young (n= 6) in the resting state. 
Data is expressed as mean ± SEM. * p <.05. 
 
 
 
 
 
 
 
 
 
 
 
 
hi
C
D
38
hi
C
D
24
 
in
t 
 C
D
38
in
t
C
D
24
 
+v
e
 C
D
24
-v
e
C
D
38
0
2
4
6
8
10
C
D
8
6
+
v
e
 B
 c
e
ll
 (
%
)
hi
C
D
38
hi
C
D
24
 
in
t 
 C
D
38
in
t
C
D
24
 
+v
e
 C
D
24
-v
e
C
D
38
0
2
4
6
8
10
C
D
8
0
+
v
e
 B
 c
e
ll
 (
%
)
a                                                               b 
* 
* n.s  
n.s  
  
95 | P a g e  
 
 
 
   
Figure 2.21 CD80 and CD86 expression on CD19
+ve
CD24
hi
CD38
hi
 B cell with age.   
 (a) Frequency of CD80
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral blood of young 
(n=20) and old donors (n=20) in the resting state .The mean value is indicated by the bar. (b) 
Mean CD80 expression levels (MFI) on CD19
+ve
CD24
hi
CD38
hi
 B cells in peripheral blood 
of young (n=20) and old donors (n=20). Data is expressed as mean ± SEM. (c) Frequency of 
CD86
+ve
CD19
+ve
CD24
hi
CD38
hi 
B cells in peripheral blood of young (n=20) and old donors 
(n=20) in the resting state .The mean value is indicated by the bar. (d) Mean CD86 
expression levels (MFI) on CD19
+ve
CD24
hi
CD38
hi
 B cells in peripheral blood of young 
(n=20) and old donors (n=20). Data is expressed as mean ± SEM. 
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Figure 2.22 CTLA4 and CD28 expression on resting CD4 Tcells with age.  
(a) Percentage of CTLA4
+ve
 CD4 T cells in peripheral blood of young (n=20) and old donors 
(n=20). The bar indicates the mean value. (b) CTLA4 expression levels (MFI) on CD4 T 
cells of young (n=20) and old donors (n=20). Data is expressed as mean ± SEM. (c) 
Percentage of CD28
+ve
 CD4 T cells in peripheral blood of young (n=20) and old donors 
(n=20). The bar indicates the mean value. (d) CD28 expression levels (MFI) on CD4 T cells 
in peripheral blood of young (n=20) and old donors (n=20). Data is expressed as mean ± 
SEM. * p <.05 and ** p <.001. 
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2.3.14 CD19
+
CD24
hi
CD38
hi
 B cells and autoimmunity  
 
As previously described, the incidence of autoimmunity increases with age (section 1.5). A 
significant fraction of older adults (approximately 25%) have detectable levels of low-
affinity autoantibodies in their blood
 [265]
, such as rheumatoid factor (RF), which are present 
in very few (only 5%) of young healthy individuals 
[455]
. On testing serum RF levels in 
healthy young and aged individuals a significant increase in serum RF levels was found in 
older adults, p<.001 [Figure 2.23a] 
[441]
. 
In this chapter, functional defects in CD19
+ve
CD24
hi
CD38
hi
 B cells with age have also been 
reported.  Additionally, a significant negative correlation was seen between serum RF 
antibody titre levels and the frequency of IL10
+ve
 CD19
+ve
CD24
hi
CD38
hi
 B cells on CD3 
stimulation (72 hr), p = .01 [Figure 2.23b].  Taken together these data suggest that age 
associated defects in IL10 production by CD19
+ve
CD24
hi
CD38
hi
 B cells, might be 
contributing towards impaired immune suppression auto-antigens production, resulting in 
elevated serum autoantibody (rheumatoid factor) levels with age 
[441]
.  
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Figure2.23. Autoantibody levels increase with age and correlate with reduced IL10 
production by CD19
+
CD24
hi
CD38
hi
 B cell in older adults.  
(a) Serum levels of rheumatoid factor (RF) in healthy young (n=10) and old donors (n=10). 
Data is expressed as mean ± SEM.* p <.05. (b) Serum RF values were plotted against 
frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cell upon CD3 stimulation in young (open 
circles) and old (closed circles) donors (n = 20).  
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2.4. Discussion 
The delicate balance between inflammation and immune suppression is dependent upon 
communication between effector and regulatory components of the immune system and 
impairment of this relationship results in autoimmunity. Advancing age is associated with 
remodelling of the immune system 
[5]
 that predisposes older adults to the development of 
autoimmune disorders ,such as rheumatoid arthritis 
[263]
. These age associated changes 
include a shift in T cell responses towards a Th2 phenotype 
[209]
, raised levels of pro-
inflammatory cytokines, termed “inflammaging” [456] and reduced Tregs immune suppressive 
activity in older adults 
[225]
. 
Over the past decade,  the paradigm of Tregs as the sole cell type involved in regulation of 
immune responses has been challenged and a role of B cells in regulating immune responses 
during autoimmunity and inflammatory disorders has been suggested 
[301, 306]
. Furthermore, 
impairment in IL10 production by B cells occurs in autoimmune diseases, such as SLE 
[301]
 
and multiple sclerosis (MS) 
[446]
. Interestingly, treatment of multiple sclerosis patients with 
mitoxantrone, an approved chemotherapy for aggressive MS, results in increased B cell IL10 
production and lower production of proinflammatory cytokines (e.g. TNFα and 
lymphotoxin) 
[457]
.  
Advancing ageing is accompanied by profound changes in B cell generation (discussed in 
section 1.4.2). In this chapter, a decline in frequency and absolute numbers of transitional 
CD19
+ve
CD24
hi
CD38
hi
 B cells and CD19
+ve
CD5
+ve
CD1d
hi
 ‘B10’ cells in peripheral blood 
with advancing age was revealed. These findings are in line with a previous report according 
to which a decline in transitional B cells was reported in aged mice 
[237]
. 
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IL10 production has been characterised as the hallmark of the suppressive function of 
transitional B cells 
[301, 319]
 and the B10 subset 
[306]
. CD40 mediated activation is essential for 
IL10 production by both transitional B cells 
[294, 301]
 and B10 cells 
[306]
 . In this chapter, a 
reduction in IL10 producing cells was reported in both subsets of Bregs post CD3 stimulation 
occurs in healthy old donors, which could not be rescued by providing an additional 
stimulus of PMA and Ionomycin. Further, to investigate the cause of impaired IL10 
production by Bregs of older adults the stability of CD40 expression with age was 
determined.  However, CD40 expression remained relatively stable with age, which is 
consistent with previous finding 
[247, 458]
.  Instead, the study revealed impairments in T cell 
helper activity with age, specifically a significant drop in the frequency of CD4 T cells 
expressing CD40L in older individuals post CD3 stimulation. These impairments in CD40L 
upregulation by CD4 T cells on stimulation have been previously seen in mice 
[205, 207]
 as 
well as humans 
[459]
. Interestingly, reduced CD40L expression on CD4 T cells with age has 
also been associated with increased levels of dual-specific phosphatase 4 (DUSP4) in CD4 T 
cells from old donors 
[460]
. T cell activation complexes are recruited to plasma membrane 
microdomains termed ‘lipid rafts’, these domains are primarily composed of cholesterol [461]. 
Altered physiochemical status of plasma membrane (higher cholesterol level) has been 
reported in the T cells of aged subjects, resulting in lower membrane and lipid raft fluidity, 
which might affect lipid raft formation 
[462]
. In addition, although not investigated here, 
impaired coalescence of lipid rafts in T cells of older adults following stimulation via CD3 
has been reported 
[463]
.  Thus, age-associated impaired ability of CD4 T cells to upregulate 
CD40L expression on CD3 activation might be a result of signal transduction defects in T 
cells of aged individuals or increased levels of DUSP4, which together contribute to reduced 
IL10 production by Bregs. 
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Defects reported in IL10 production by aged Bregs might also be due to intrinsic defects in 
these immunosuppressive B cell subsets 
[464, 465]
.  The data reported here show that age-
related intrinsic B cell defects exist, with reduced STAT3 phosphorylation post stimulation 
via CD40 pathway 
[441]
. Age-associated intrinsic defects in B cells have also been reported in 
mice. Adoptive transfer studies in severe combined immunodeficient (SCID) mice revealed 
that antibodies produced by B cells from young mice, when paired with T cells from aged 
donors, had a reduced rate of somatic mutation and VH gene usage. However, when aged B 
cells were transferred with young T cells somatic mutation still failed to accumulate 
normally 
[466]
. Another study highlighting intrinsic defects in B cells with age reported a 
decrease in transcription factor E47 expression on anti-CD40 stimulus, resulting in 
decreased class switching in aged murine B cells 
[464, 465]
.  The data in this thesis show that 
age-related intrinsic B cell defects extend to CD19
+ve
CD24
hi
CD38
hi
 B cells which might be 
a contributing factor towards the reduced ability of aged CD19
+ve
CD24
hi
CD38
hi
 B cells to 
produce IL10
[441]
. This data is also consistent with a previous report of impaired STAT3 
signalling with age
 [467]
. Additionally, CD19
+ve
CD24
hi
CD38
hi
 B cells from SLE patients 
display impaired IL10 production on CD40 activation which correlated with lower levels of 
STAT3 phosphorylation 
[301]
. Thus, impairment in downstream CD40 signalling in aged 
transitional B cells and reduced T cell helper activity might together be responsible for 
impairment in IL-10 production upon stimulation via CD40 in older subjects
[441]
.  
Microbial products are also capable of inducing IL10 production in B cells
 [308]
. For the first 
time in this chapter, an age-associated significant decline in IL10 production by both 
CD19
+ve
CD24
hi
CD38
hi
 B cells and CD19
+ve
CD5
+ve
CD1d
hi
 B cells on LPS stimulation was 
shown
[441]
. Interestingly, there have been previous reports of age-associated defects in TLR 
induced cytokine production in monocytes, macrophages and dendritic cells 
[88, 117]
, 
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including reduced IL10 production by DCs with age 
[468]
. This thesis found a reduction in 
the proportion of TLR4 expressing CD19
+ve
CD24
hi
CD38
hi
 B cells with age 
[441]
, which has 
been previously reported in monocytes and DCs 
[93, 469]
 and might be a factor contributing 
towards reduced responsiveness towards LPS. B cells also utilise RP105 to recognise and 
respond to LPS 
[470]
, and RP105 deficient mice have been shown to display impaired 
responses to LPS stimulation 
[471]
.  Interestingly, a recent study reported a reduced 
percentage of RP105 (CD180) expressing B cells in older adults 
[472]
, which might also be a 
contributor towards impaired LPS responsiveness in B cells with age. Also, reduced STAT3 
signalling in DC with age has been associated with reduced IL10 production on LPS 
stimulation 
[468]
 and could contribute to altered IL10 production on LPS stimulation by Bregs 
in older adults.  
Finally in this chapter, a link between the age-associated reduced immunosuppressive B cell 
function and increase in age-related autoimmunity is proposed, supported by data showing a 
negative correlation between IL10 production by CD19
+ve
CD24
hi
CD38
hi
 and serum RF 
levels in healthy subjects 
[441]
. Previous findings have reported an exacerbated disease 
phenotype and enhanced mortality in IL10 gene deficient lupus prone mice and 
administration of rIL-10 reduced autoantibody production, highlighting the importance of 
IL10 in down modulating autoimmunity 
[473]
. Importantly, B cell derived IL10 is known to 
play a crucial role in maintaining suppressive function of Tregs during autoimmunity 
[474, 475]
. 
Mice lacking IL10 producing B cells develop an exacerbated antigen induced arthritis, 
which is also associated with reduced numbers of Tregs and increased Th1 and Th17 cells 
[476]
. Additionally, B7 expression by B cells is also required for their regulatory function, 
mediating peak expression of IL10 and foxp3
 [477]
 . However no difference in levels of co-
stimulatory molecules (CD80 and CD86) on CD19
+ve
CD24
hi
CD38
hi
 was seen here in resting 
  
103 | P a g e  
 
state with age, suggesting that the ability to mediate contact dependent regulation of Treg 
activity is intact with age
[441]
.  
The reduced functioning of CD19
+ve
CD24
hi
CD38
hi
 and CD19
+ve
CD5
+ve
CD1d
hi
 B cells seen 
here might contribute not only to loss of Treg function with age 
[225]
, helping to promote 
autoimmunity, but also to the age-related increase in systemic inflammation.  In addition to 
effects on T cell differentiation and cytokine production, IL10 can also modulate the 
inflammatory function of monocytes. The raised level of basal monocyte cytokine output 
with age has been reported in both aged mice
 [25]
 and humans 
[456]
. Interestingly, reduced 
regulatory B cell function could be an additional factor contributing towards this age-related 
phenomenon. 
Furthermore, the success of therapeutic manipulation of B cells in autoimmune disease, 
notably the reduction in disease severity following treatment of RA patients with anti-CD20 
(Rituximab), is still poorly understood. B cell depletion has been reported to have a 
beneficial effect during autoimmune disorders 
[478, 479]
. However, the reduction in B cell 
numbers seen after anti-CD20 therapy, occurs in the absence of a reduction in autoantibody 
levels 
[480]
, due to failure to deplete long lived plasma cells. Interestingly, there have been a 
few cases of exacerbation of disease symptoms on rituximab treatment, for instance B cell 
depletion during ulcerative colitis leads to severe disease exacerbation, depletion of mucosal 
B cells was associated with suppression of local IL10 production 
[481, 482]
.  A possible cause 
for reduction in IL10 levels might be depletion of B cells with immunosuppressive 
properties. Rituximab therapy has however been associated with increased IL10 mRNA in 
macrophages, most probably via Fc ligation, providing an alternative source of the 
regulatory cytokine 
[483]
. Additionally, it has been suggested that re-population of the B cell 
compartment post rituximab treatment is accompanied by an increase in ratio of peripheral 
  
104 | P a g e  
 
transitional B cells to memory B cells 
[484, 485]
. Examination of the B cell cytokine profile 
twelve months after B cell depletion revealed that the newly developed circulating B cells 
secreted higher IL10 levels than B cells at baseline
[446]
. Together, suggesting a possible role 
of transitional B cells in mediating the beneficial effects of B cell depletion therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Interestingly, a novel B cell subset has been characterised recently by the Marrack group and 
suggested to play a role in age-related autoimmunity: the CD11c
+ 
B cell increases in 
frequency in aged female mice leading to the name “age-associated B cell (ABC)”. These 
cells are also detected in young lupus-prone mice and elderly women with autoimmune 
disease 
[287]
. Exactly how they are involved in autoimmunity is not known, but as they 
express high levels of MHC class II, they may play a role in presenting self-antigen. In mice, 
the development of ABCs is dependent upon signalling through TLR7 and importantly their 
depletion in vivo leads to a reduction in serum autoantibodies 
[287]
. Although the presence of 
ABCs was not determined here, it is interesting to postulate that their age-related increase 
could be accompanied by a decline in Bregs and represent a remodelling of the B cell pool 
towards autoimmune enhancing cells.  
In summary, the findings in this chapter demonstrate that the frequency of 
CD19
+ve
CD24
hi
CD38
hi
 and CD19
+ve
CD5
+ve
CD1d
hi
 B cells and their ability to produce IL10 
after ex-vivo maturation/stimulation declines with age and that this correlates with an age-
related increase in serum autoantibody (RF) in healthy older adults. Reduced induction of 
IL10 production was due to both compromised intrinsic B cell signalling via CD40 pathway 
and reduced expression of CD40L on CD4 T cells 
[441]
.  
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Investigating the synergistic effects of        
physical and psychological stress on                            
innate immune functioning  
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3.1 Introduction  
 
3.1.1 Background 
It is well documented that chronic stress is a global immune suppressor 
[352, 486]
 resulting in   
impairments in neutrophil bactericidal properties 
[359, 360]
,  monocyte functioning 
[487-489]  
and 
NK cell cytotoxicity 
[490-492]
. Hip fracture is a major health issue in old age 
[413]
 and has been 
previously associated with a high prevalence of depressive symptoms post-surgery 
[439]
. 
Importantly, development of depressive symptoms in hip fracture patients has health 
implications including; increased risk of infections, reduced survival 
[435]
, impaired recovery 
and a retarded ability to regain pre-fracture levels of physical functioning 
[438]
 .  A previous 
study done in our group has reported suppression  of  neutrophil superoxide production  after  
hip fracture in older adults, which was accompanied by a high incidence (37%) of post-
trauma bacterial infections 
[359]
. However, the factors that influenced recovery after hip-
fracture and whether the physical stress of the hip-fracture was the only stressor affecting 
neutrophil function remains unexplored. In addition whether other aspects of innate 
immunity are affected in this patient group was not investigated. 
The nervous, endocrine and immune system interact with one another. A hallmark of the 
neuroendocrine response to stress is activation of the HPA axis 
[362, 363]
, resulting in elevated 
cortisol output and flatter diurnal cortisol secretion slope in chronically stressed individuals 
[493, 494]
. Human ageing has also been associated with increased activation of the HPA axis 
[495, 496]
. Cortisol is known to exert an immunosuppressive effect on a range of innate 
immune cells including; neutrophils 
[411, 497]
,  monocytes 
[498]
 , dendritic cells 
[499, 500] 
and NK 
cells
[501-503]
. The previous study done in our group also reported a raised cortisol:DHEAS 
ratio in older adults after hip fracture which was not seen in young fracture patients 
[411] 
due 
possibly to the inability to increase serum DHEAS in the older patients.  Whether this ratio 
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is even further skewed in the presence of depressive symptoms and might contribute to poor 
outcome in patients with depressive symptoms is unknown and will be explored in this 
chapter. 
Ageing is accompanied by an increase in pro-inflammatory cytokines 
[17, 291]
. Similarly, an 
elevated level of pro-inflammatory cytokines has also been reported during exposure to 
chronic psychological stressors including ; caregiving 
[504, 505]
, abusive relationships 
[506]
, 
chronic work stress 
[507]
,  post-traumatic stress disorder 
[508]
 and depressive symptoms 
[509, 
510]
.  On exposure to antigen challenge, an exacerbated inflammatory response has also been 
reported in chronically stressed older individuals 
[511, 512]
. 
3.1.1 Aims  
In this chapter, we sought to test the hypothesis that psychological stress, specifically the 
presence of depressive symptoms, would act additively with the physical stress of hip 
fracture to amplify the effect of ageing upon innate immunity. 
(a) To examine the combined effects of both hip fracture and depressive symptoms on 
physical and cognitive frailty in older adults.  
(b) To test if the psychological stress of depressive symptoms could act additively with the 
physical stress of hip fracture to amplify the effect of ageing upon immunity, with specific 
reference to neutrophil, monocyte and NK cell function.  
(c) Determine the effect of emergence of depressive symptoms in hip fracture patients on 
activation of the HPA axis.  
(d) Test for correlations between depressive symptoms and inflammatory status in hip 
fracture patients. 
(e) To test the longevity of the decline in physical and cognitive function and immune status 
in hip fracture patients by repeating all tests six months post-surgery.  
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3.2 Materials and Methods  
3.2.1 Antibodies 
Those antibodies used in this chapter that were not described in chapter 2 are shown in Table 
3.1. 
 
Antibody  Dilution  Company 
Anti-human CD14 Pac blue (clone ׃ M5E2) 1/100 Biolegend 
Anti-human CD16 FITC (clone: eBio CB16) 1/25 eBiosciences 
Anti-human HLADR  PE (clone : MCA1879 ) 1/50 AbD Serotec 
Anti-human CD56 PE (clone : C5.9) 1/100 Dako 
Anti-human CD3 Pacific blue (clone : UCHT1) 1/100 Biolegend 
Anti-human CD57 FITC (clone : HCD57) 1/50 Biolegend 
Anti-human LFA1 (CD11a) FITC (clone : MHM24) 1/20 Dako 
Anti-human NKG2D PEcy7 (clone: 1D11) 1/10 eBiosciences 
Anti-human CD107a FITC (clone : eBio H4A3) 1/20 eBiosciences 
Anti-human CD69 FITC (clone: FN50) 1/10 eBiosciences 
Annexin V FITC 1/100 BD 
biosciences Anti-human  TNF α PE (clone : MAB11) 1/50 Biolegend 
Anti-human Perforin (clone : Dg9) 1/10 Biolegend 
Anti-human Granzyme (clone : GB11) 1/10 Biolegend 
 
Table 3.1.List of primary and secondary antibodies used for flow cytometry. 
 
3.2.2 Participants 
101 older hip fracture patients were recruited from five hospitals in Birmingham, UK 
including; Queen Elizabeth hospital, Russell Hall’s hospital, West Heath hospital, Good 
hope hospital and Heartlands hospital, between 2010 and 2012. Inclusion criteria were that 
participants had to be aged 60 years and over with a hip fracture sustained 4-6 weeks 
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previously but with no chronic immune-related disorders (e.g. cancer, diabetes) or taking 
any regular medications that might modify immunity (e.g.immunosuppressant). 
Additionally, patients must not have had any diagnosis of depressive symptoms by a 
physician prior to age 50 years or be taking or have previously taken anti-depressant 
medication, in order to pick up patients with depressive symptoms emerging post-hip 
fracture rather than those with a prior history of and thus propensity to depressive 
symptoms. Participants started on anti-depressant treatment, therapy, or any change that 
would mean they no longer met the inclusion criteria between week 6 and month 6 testing 
sessions were excluded.  Forty three healthy older adults were also recruited from the 
community as healthy controls via invitation letters to the Birmingham 1000 Elders cohort 
of older adults involved in current research at the University of Birmingham. These controls 
also had to meet the inclusion criteria above but not have had a hip fracture. All participants 
were Caucasian. The study was approved by South Birmingham Local Research Ethics 
Committee and all participants provided written informed consent (study ref: 09/H1203/80). 
3.2.3 Study design  
The study was a prospective case-control design with three groups of older adults: hip 
fracture patients with or without depressive symptoms and healthy older adults. Consent was 
gained whilst patients were still in hospital. All participants completed questionnaires, 
structured interviews and provided a blood sample (40 ml) 4-6 weeks and six months after 
hip fracture. Control participants completed a depressive symptoms and anxiety symptoms 
scale and basic demographic information was collected when attending the University for 
one-off blood sampling. Blood samples were taken between 08.00 and 11.00 to minimise 
any effect of diurnal variations in steroid or cytokine levels. None of the patients had an 
infection at the time of blood sampling. Interviews were performed either in the hospital or 
  
110 | P a g e  
 
in the participant’s home. Assays for phagocytosis and superoxide production and NK cell 
cytotoxicity were performed on the same day as blood sampling. PBMCs and serum were 
frozen for later analysis 
[513]
. 
3.2.4 Interview and Questionnaires 
The following interviews, questionnaires and assessments for physical and cognitive 
function were carried out by Dr Jane Upton. Standard socio-demographic and health 
behaviour information, including date of birth, sex, diet, physical activity, sleep quantity and 
occupational classifications were taken as a part of a questionnaire pack presented during the 
testing session. All medications, prescriptions and over-the-counter medications were 
recorded by the interviewer. Health behaviours were assessed using questions adapted from 
the Whitehall II study
 [514]
. 
In this thesis, we did not clinically diagnose hip fracture patients for depressive disorder, but 
instead we have examined the presence of depressive symptoms by means of structured 
interviews using standardised psychometric questionnaires. Depressive symptoms  were 
evaluated by a Geriatric Depression Scale (GDS) 
[515]
, a reliable and valid self-rating 
depressive symptoms screening scale for elderly populations. In this thesis, the term 
“depressive symptoms” was defined as a GDS score greater than or equal to 6 [401]. The 
Hospital Anxiety and Depression Scale (HADS) was also used to measure depressive 
symptoms and anxiety 
[516]
. The scale contains 14 items, with seven assessing aspects of 
depressive symptoms and seven assessing anxiety. Healthy control participants completed 
the HADS depressive symptoms sub-scale in order to check that they did not have 
significant depressive symptoms. A cut-off of >8 has previously been used to indicate 
possible depression 
[517]
. 
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3.2.5 Assessing physical frailty 
Physical frailty was assessed using a variety of tools validated in the patient group under 
study as follows:  
Activities of daily living: The Oxford Hip Score (OHS), a 12-item questionnaire to assess 
functional ability with respect to activities of daily living (ADL) and pain in patients 
undergoing hip replacement surgery 
[518]
. Each item has 5 possible responses with a score 
ranging from 0-4, with 4 being the best outcome. 
Handgrip (upper body) strength: Handgrip strength, an index of upper body strength was 
measured using a hydraulic hand dynamometer (Lafayette Instrument, UK). The participant 
was asked to perform a maximal voluntary contraction (MVC), standing with the 
dynamometer in one hand and gripping the dynamometer as hard as they could for 3 
seconds. This was repeated 3 times for each hand. A rest of 30 seconds was given between 
each trial to avoid the effects of muscle fatigue. The average of the 3 trials for each hand 
was considered to be the maximum voluntary handgrip strength. 
Timed Up and Go (TUG) Test: The timed "Up & Go" test is used for quantifying functional 
mobility 
[519]
. The TUG test measures, in seconds, the time taken by an individual to stand 
up from a standard arm chair, walk a distance of 3 metres, turn, walk back to the chair and 
sit down.  
Berg balance scale : The Berg Balance Scale (BBS) is a scale developed to measure balance 
among older people in a clinical setting and assess the performance of functional tasks 
[520]
. 
The scale involves 14 tasks that include balance activities such as sitting with arms folded, 
rising, standing, transferring between one surface and another, picking up objects from the 
floor, turning around in a full circle and standing on one leg. Each task was scored on a 5 
point ordinal scale ranging from 0 to 4 (0= unable to perform, 4= independent) and the 
aggregate score ranges from 0 to 56 
[520]
.  
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3.2.6 Assessing Cognitive function  
The Mini Metal State Examination (MMSE) is a tool that has been used to detect cognitive 
defects seen in syndromes of dementia and delirium and for measuring cognitive changes 
over time 
[521]
 and has been used in this study to assess cognitive impairments in hip fracture 
patients. MMSE is an 11 question measure that tests five areas of cognitive function: 
orientation, registration, attention and calculation, recall and language. Cognitive 
impairment assessed using MMSE is graded by a score ranging from 0 to 30.  In this thesis, 
a score of below 17 is characterised as ‘severe cognitive impairment’, a score ranging 
between 18 and 23 is an indicator of ‘mild impairment’ and scores above 24 indicate ‘no 
cognitive impairment’.  
3.2.7 Measuring neutrophil and monocyte phagocytosis 
Phagocytosis was measured in whole blood using a commercially available kit (Phagotest 
kit, Orpegen Pharma, Germany). All the reagents were provided in the kit and the 
experiments were performed according to manufacturer’s instructions. For each patient 
sample, 100 μl of peripheral whole blood was aliquoted into two FACS tubes (Becton 
Dickinson, UK). 20 μl of FITC labelled opsonised E.coli was added to both tubes, one tube 
was incubated at 37C for 10 minutes to allow phagocytosis and the control tube was kept 
on ice for 10 minutes. Following incubation, both tubes were simultaneously kept on ice and 
100 μl of quenching solution was added to each tube to stop the reaction. Samples were then 
washed twice using 2 ml of washing solution and were centrifugation at 250 x g for 5 
minutes at 4C. Post washing, red blood cells were lysed by suspending the pellet obtained 
after centrifugation in 2 ml of lysing solution for 20 minutes at room temperature. Following 
the lysis step, the cell suspension was centrifuged at 250 x g for 5 minutes at 4C and the 
pellet was washed using 3 ml of wash solution and cells were spun down at 250 x g for 5 
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minutes. After washing, cells were resuspended in 200 μl of DNA staining solution and 
analysed immediately using Cyan
TM
 ADP flow cytometer ( Dako Ltd , UK) 
[522]
.  
Data were analysed using Summit V 4.3. The side scatter vs forward scatter plot allows 
recognition of neutrophils and monocytes (characterised by their size and granularity 
relative to other blood cell populations). Separate gates were set on neutrophils and 
monocytes and their FITC fluorescence intensity was measured on a separate histogram. 
Negative controls enabled measurement of the background fluorescence.           
The phagocytic index was used as a measure of the phagocytic capabilities of neutrophils 
and monocytes. The phagocytic index was calculated as the percentage of cells that have 
ingested bacteria, multiplied by the mean fluorescent intensity (MFI), this figure was then 
divided by 100. 
                  Phagocytic index = (% of cells with ingested bacteria x MFI) 
                                                                                 100 
 
3.2.8 Measuring neutrophil and monocyte superoxide production  
Superoxide production was measured in whole blood using a commercially available kit 
(Phagoburst kit, Orpegen Pharma, Germany). The experiments were performed according to 
manufacturer’s instructions. Firstly, fluorogenic substrate dihydrorhodamine (DHR) 123 
was prepared by reconstituting the substrate disk with 1 ml of washing solution for 30 
minutes prior to the assay. For each sample, 100 μl of whole blood was added to four 
separate FACS tubes (Becton Dickinson, UK) and four treatment conditions were carried 
out: 20 μl of wash solution (negative control); 20 μl of f MLP (low control); 20 μl of PMA 
(high control) or 20 μl of opsonised E.coli (test). The tubes were incubated at 37C for 10 
minutes in a water-bath then 20 μl of fluorogenic substrate dihydrorhodamine (DHR) 123 
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was added and the samples were incubated at 37C for further 10 minutes. The reaction was 
stopped by adding 1 ml of lysis solution to cell suspension and incubated for 20 minutes at 
room temperature. Following lysis, the cells were washed using 3 ml of wash buffer and 
centrifuged at 250 x g for 5 minutes at 4C. Post washing, 200 μl of DNA staining solution 
was added to cell suspensions. Oxidation of substrate DHR123 was analysed by flow 
cytometry using a Cyan
TM
 ADP flow cytometer (Dako Ltd, UK). The superoxide production 
is indicated by the MFI of the monocyte and neutrophil population 
[522]
.  
3.2.9 Immunostaining for phenotypic analysis of monocytes 
Isolated PBMCs ( described in section 2.2.3) were resuspended in PBS (1 x 10
6
/ml) were 
transferred into polypropylene tubes (Becton Dickinson, UK) for immunostaining with a 
combination of fluorochrome conjugated antibodies including; anti-human CD14-Pacific 
blue (Biolegend, UK), anti-human CD16-FITC (eBiosciences, UK), HLADR-PE (AbD 
Serotec, UK), anti-human CD80-APC (Biolegend, UK) and anti-human CD86-APC 
(Biolegend, UK) for 20 minutes at 4C in the dark. Following incubation, cells were washed 
twice in 300 μl of PBS and centrifuged at 250 x g for 5 minutes. Cells were resuspended in 
300 μl of PBS for flow cytometric analysis using a Cyan TM ADP (Dako Ltd, UK). Gating 
strategy used to identify monocyte subsets has been shown in Figure 3.1. 
3.2.10 Monocyte stimulation - LPS  
PBMCs were resuspended in complete RPMI medium (Sigma Aldrich, UK) at a 
concentration of 1 x 10
6
/ml and 200μl aliquots were incubated in a 96 well U bottom  plate 
(Becton Dickinson, UK) with LPS isolated from Escherichia coli serotype 0111:B4 (1μg/ml;  
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Figure 3.1 Monocyte subset gating strategy. 
Representative flow cytometric plot showing the gating strategy used to identify different 
monocyte subsets on the basis of expression of CD14 and CD16. 
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Sigma-Aldrich, UK) for 4 hr at 37C in a humidified 5% CO2 atmosphere. Brefeldin A 
(1μg/ml; Sigma-Aldrich, UK) was added to one set of cells. Post incubation, cells were 
pelleted by centrifugation at 250 x g for 5 minutes. The supernatants of the cells stimulated 
in the absence of Brefeldin A were transferred into cryovials and snap frozen in liquid 
nitrogen and stored at -80C for future analysis. Cells stimulated in the presence of Brefeldin 
A were transferred into polypropylene tubes (Becton Dickinson, UK) for immunostaining 
with anti-human CD14-Pacific blue (Biolegend, UK) for 20 min in the dark at 4C. Post 
immunostaining, cells were washed using 300 μl of PBS and centrifuged at 250 x g for 5 
minutes. Pelleted cells were resuspended in 50 μl of Reagent A (Fix and Perm kit, 
Invitrogen Ltd, UK) and were incubated for 30 minutes in the dark at room temperature. 
Post fixing, cells were washed with 300 μl PBS and centrifuged at 250 x g for 5 minutes. 
The pelleted cells were resuspended in 50 μl of Reagent B (Fix and Perm kit, Invitrogen Ltd, 
UK) and anti-human TNFα-PE antibody was added (Biolegend, UK) for 30 minutes and 
cells were incubated in dark at room temperature. Finally, the cells were washed with 300 μl 
PBS and centrifuged at 250 x g for 5 minutes. Cells were resuspended in 300 μl PBS for 
flow cytometric analysis on a Cyan 
TM
 ADP (Dako Ltd, UK) and the percentage of TNFα 
expressing  monocytes as well as TNFα expression (MFI) levels were recorded.  
TNFα levels in supernatants were quantified using commercially available human TNFα 
ELISA (Abcam, UK), as per manufacturer’s instructions. Firstly, frozen supernatants were 
thawed on ice and 100 μl of cell culture supernatants were added to 96 well plate coated 
with anti-mouse TNFα. 50μl of secondary biotinylated anti-TNFα was added to wells and 
the plate was incubated at room temperature for 2hr. Post incubation, liquid was aspirated 
and the plate was washed three times with 300 μl of washing solution. Post washing, 100 μl 
of Streptavidin –horseradish peroxidase (HRP) was added to each well and incubated for 30 
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minutes at room temp. The liquid was aspirated and plate was washed again three times with 
300 μl of washing solution. 100 μl of 3, 3’, 5,5’-tetramethylbenzidine (TMB) substrate 
solution was added into each well and incubated in the dark for 12-15 minutes at room 
temperature. The enzyme substrate reaction was stopped by adding 100 μl of stop reaction 
(H2SO4) into each well. The plate was read on a spectrophotometer (BioTek® Synergy HT, 
UK) using 450 nm as the primary wavelength within 5 minutes of adding stop solution. The 
OD values for individual samples were calculated using a standard curve created by 
GraphPad Prism® software (GraphPad Software Limited, USA). 
3.2.11 Immunostaining for phenotypic analysis of NK cells 
100 μl of PBMCs (1 x 106 / ml) re-suspended in PBS were transferred into polypropylene 
tubes (Becton Dickinson, UK) for immunostaining with combinations of antibodies: anti-
human CD3-Pacific blue (Bio legend, UK) ,anti-human CD56-PE (Dako, UK) , anti-human 
CD11a-FITC (Dako, UK), anti-human CD16-FITC (eBiosciences, UK) and anti-human 
CD57-FITC (Biolegend, UK) or NKG2D-PEcy7 (eBiosciences, UK) for 20 minutes in the 
dark at 4C. Post incubation, cells were washed twice using 300μl of PBS and were 
centrifuged at 250 x g for 5 minutes at 4C. Cells were resuspended in 300 μl of PBS for 
flow cytometric analysis using Cyan 
TM
 ADP (Dako , UK). Results were expressed both as 
the percentage of cell surface marker positive NK cells and mean expression levels of cell 
surface markers (MFI).  
3.2.12 Isolation of NK cells 
NK cells were isolated from PBMCs by negative selection using MACS technology (Human 
NK cell isolation kit; Miltenyi Biotech, Germany). Freshly isolated PBMCs were counted 
and washed in 10 ml of MACS buffer (Miltenyi Biotech, Germany) and centrifuged at 300 x 
g for 10 minutes at 4C. The pellet obtained was re-suspended in 40 μl of MACS buffer (per 
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10
7
 cells; Miltenyi Biotech, Germany) and to this suspension 10 μl NK cell Biotin- antibody 
cocktail was added (per 10
7
 cells ; Miltenyi Biotech, Germany) and the cells incubated for 
10 min at 4C with occasional vortexing. Post incubation 30 μl of MACS buffer (per 107 
cells; Miltenyi Biotech, Germany) and 20 μl of NK cell microbead cocktail (per 107 cells; 
Miltenyi Biotech, Germany) was added to the cells and incubated for 15 min at 4C. Cells 
were then washed in 2ml of ice cold MACS buffer (per 10
7
 cells; Miltenyi Biotech, 
Germany) and centrifuged at 250 x g for 10 minutes at 4C. The pellet was resuspended in 
500 μl of ice cold MACS buffer. 
 For magnetic isolation of NK cells, an LS column (Miltenyi Biotech, Germany) was placed 
in the magnetic field of a Quadra MACS separator (Miltenyi Biotech, Germany). The 
column was prepared by washing with 3ml of ice cold MACS buffer (1 ml at a time). The 
PBMC suspension in MACS buffer was then applied to the column, followed by 9 ml of ice 
cold MACS buffer (1ml at a time). The elute containing purified NK cells was collected in a 
universal tube (Starsted, UK) and NK cells were pelleted by centrifugation at 300 x g for 10 
minutes at 4C. The cells were resuspended in complete RPMI 1640 (Sigma Aldrich, UK) at      
1 x 10
6 
cells/ml.  
To determine the purity of isolated NK cells, 100 μl of the isolated NK cells were taken up 
in a FACS tube (Becton Dickinson, UK) and were stained with anti-human CD3 Pacific blue 
(Biolegend, UK) and anti-human CD56 PE (Dako, UK) for 20 minutes at 4C in the dark. 
Post incubation cells were washed using 300μl of PBS and centrifuged at 250 x g for 5 
minutes. Cells were then taken up in 300 μl of PBS and purity was assessed using CyanTM 
ADP (Dako Ltd, UK). NK cells were defined as CD3
-ve
 CD56
+ve 
cells and purity obtained on 
a routine basis was > 92%. 
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3.2.13 NK cell killing assay and assessment of effector-target conjugate formation 
The MHC class I deficient NK- sensitive cell line K562 (American Type Culture Collection 
(ATCC), UK), were maintained in complete RPMI 1640 medium in 75 cm
2
 cell culture 
flasks (Starsted, UK) at 37C in a humidified 5% CO2 atmosphere and were used as the 
target population for the NK cell cytotoxicity assays. K562 cell cultures were maintained by 
replacement of RPMI medium on the day preceding the assay and K562 cells were replaced 
on a monthly basis. 
NK cell cytotoxicity against K562 cells was assessed by two-colour flow cytometry using an 
adapted version of the protocol described by Godoy-Ramirez et al 
[523]
. 100µl of isolated NK 
cells (1x 10
6
 /ml) were dispensed in to wells of a 96-well round bottomed plate (Becton 
Dickinson, UK) containing 100μl of K562 cells (1 x 105 / ml) resulting in a final effector (E) 
to target (T) cell ratio of 10:1.  Due to the limited amount of blood available from hip 
fracture patients only one E: T ratio (10:1) could be performed, though the assay was 
validated over a range of ratios initially (20:1, 10:1, 5:1 and 2.5:1). The effector-target cell 
contact was increased by centrifugation at 50 x g for 1 minute and samples were incubated at 
37C in a humidified 5% CO2 atmosphere for 2 hours. To account for spontaneous lysis of 
target cells during this period, 100µl of K562 cells were incubated in the absence of effector 
cells. Post incubation, cells were pelleted by centrifugation at 250 x g for 5 minutes, the 
supernatant was removed and cells were re-suspended in 100 μl PBS and transferred into 
FACS tubes (Becton Dickinson, UK) and stained with anti- human CD56-PE (Dako, UK) 
for 20 minutes in the dark at 4C to identify NK cells. Post incubation, cells were washed 
with 300μl of PBS and centrifuged at 250 x g for 5 minutes and the subsequent pellet was 
re-suspended in 90µl PBS. To detect cell death, 10μl of sytox blue cell stain (pre-diluted 
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1:800 in PBS; Invitrogen, UK) was added to the cells and incubated in the dark for 5 
minutes at 4C and analysed by flow cytometry using Cyan TM ADP (Dako Ltd, UK).  
Post-culture immunostaining and scatter profiles were used to distinguish between effector 
(NK cells), target cells (K562 cells) and conjugates of both cells. The NK-target conjugates 
were identified as K562 cells positive for CD56 expression [Figure 3.2]. To assess the 
percentage of lysed target cells within the sample, NK cells and K562 cells were 
distinguished from one another via staining with anti-human CD56 PE antibody. The 
percentage of dead K562 cells was determined using sytox dye and the percentage of 
specific lysis was calculated using the following equation: 
                  % Specific lysis =   (test – spontaneous)      x 100 
                                                                            2000 
In this equation, test represents the percentage of target cells lysed by NK cells and 
spontaneous represents the percentage of target cells lysed in culture in the absence of NK 
cells.  
3.2.14 Measurement of perforin and granzyme expression in NK cells 
 100 μl of PBMCs (1x 106/ ml) were transferred into FACS tubes (Becton Dickinson, UK) 
and were stained for extracellular surface markers to identify NK cells using antibodies anti-
human CD3-Pacific blue (Biolegend, UK) and anti-human CD56 PE (Dako, UK) for 20 min 
in the dark at 4C. Post incubation, cells were washed using 300 μl of PBS and centrifuged 
at 250 x g for 5 minutes. Pelleted cells were re-suspended in 50 μl of Reagent A (Fix and 
Perm kit, Invitrogen Ltd, UK) and incubated for 30 minutes in dark at room temp. Post 
fixing, the cells were washed with 300 μl PBS and centrifuged at 250 x g for 5 minutes. 
Pelleted cells were resuspended in 50 μl of Reagent B (Fix and Perm kit, Invitrogen Ltd, 
UK) and were stained with anti-human Perforin- FITC antibody (Biolegend, UK) or with  
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Figure 3.2 Flow cytometric analysis of NK cell – target conjugate formation 
Flow cytometric plot showing immunostaining of effector and target (K562) co-cultures 
with CD56-PE for identification of NK cells and K562 cells 2 hr post culture.  
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anti-human Granzyme- FITC antibody (Biolegend, UK) for 30 minutes in the dark at room 
temperature. Finally, the cells were washed with 300 μl PBS and centrifuged at 250 x g for 5 
minutes. Cells were then taken up in 300 μl of PBS and assessed using CyanTM ADP. (Dako 
Ltd, UK). The percentage of perforin
+ve
 NK cells and granzyme
 +ve
 NK as well as perforin 
(MFI) and granzyme expression levels by NK cells were recorded.  
3.2.15 Measurement of serum cortisol and DHEAS levels 
Serum cortisol and DHEAS levels were determined using a commercially available ELISA 
kit (IBL international, Germany). The ELISA was performed according to manufacturer’s 
instructions. Firstly, frozen serum was thawed on ice and 25 μl of serum was added to a 96 
well plate with wells coated with anti-cortisol or anti-DHEAS antibody. 200 μl of enzyme 
conjugate was added to each well and the plate was incubated at room temperature for 1hr. 
Post incubation, liquid was aspirated and the plate was washed three times using 300 μl of 
washing solution. Post washing, 100μl of Streptavidin – horseradish peroxidase (HRP) was 
added to each well and incubated for 15 minutes at room temperature. The enzyme substrate 
reaction was stopped by adding 100μl of stop reaction (H2SO4) in to each well. The plate 
was read on a spectrophotometer (BioTek® Synergy HT, UK) at 450 nm as the primary 
wavelength within 5 minutes of adding stop solution. The OD values for individual samples 
were calculated using a standard curve created by GraphPad Prism® software (GraphPad 
Software Limited, USA). 
3.2.16 Multiple cytokine analysis – Luminex  
A Bio-plex cytokine assay for IL1β, IL4, IL6, IL8, IL10, IL13, IL17, TNFα and GM-CSF 
(Bio-Rad Laboratories, Germany) was used for a multiple cytokine analysis using Luminex 
technology. The assay was performed according to manufacturer’s instructions. The Bio-
plex® system (Bio-Rad Laboratories, Germany) was calibrated prior to set up of the assay to 
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standardise the fluorescent signal.  The standard was reconstituted and four fold dilutions 
were performed to generate a ten-point standard curve. Coupled beads were prepared by 
dilution of stock coupled beads with assay buffer in a falcon tube (Becton Dickinson, UK) 
covered with foil. 50 μl of prepared coupled beads were added to a flat bottom 96 well black 
plate (Corning, USA), followed by two washes with 100 μl of wash solution using a 
magnetic washing plate (BioTek® Synergy HT, UK). 50 μl of standards, blanks and 
undiluted serum was added to each well and the plate was covered with sealing tape and foil 
and shaken at 1100 rpm for 30 seconds then left for 30 min on the plate shaker set at 300 
rpm. Post incubation, liquid was aspirated and plate was washed three times with 100 μl 
wash buffer. Detection antibody was diluted as per manufacturer’s instructions and 25 μl of 
diluted detection antibody was added to each well of the plate. The plate was again covered 
with sealing tape and foil and left on the plate shaker at 300 rpm for 30 minutes. The liquid 
was aspirated and plate was washed with 100 μl wash buffer three times using a magnetic 
washing plate (BioTek® Synergy HT, UK). 50 μl of streptavidin-PE was added to each well 
and the plate was covered with sealing tape and foil and incubated on the shaker set at 300 
rpm for 10 minutes. Finally, the plate was washed three times with 100 μl of wash buffer 
and 125μl of assay buffer was added to each well and the plate was covered with sealing 
tape and shaken at 1100 rpm for 30 seconds after which the plate was read on the Bio-plex® 
system (Bio-Rad Laboratories, Germany). Data acquisition and analysis was done using 
Bio-Plex Manager software version 6.0. (Bio-Rad Laboratories, Germany).  
3.2.17 Dexamethasone treatment of NK cells  
NK cells were isolated from healthy young individuals by negative selection using MACS 
technology (described in section 3.2.13). 180 μl of NK cells in complete RPMI 1640 (1 x 
10
6
 cells/ml) were treated with dexamethasone (Sigma Aldrich, UK) at 10
-5
M, 10
-7
M and 10
-
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9
M in a 96-well round bottomed plate (Becton Dickinson, UK)  for 18 hr at 37C in a 
humidified 5% CO2 atmosphere. The physiologically relevant concentration of 
dexamethasone approximates to 10
-7
M 
[501, 524]
. Post incubation, NK cells were centrifuged 
at 250 x g for 5 minute and the cells were washed twice using 300 μl of RPMI 1640. Post 
washing, the pellet of NK cells was resuspended in complete RPMI medium (1 x 10
6
  
cells/ml) for analysis of NK cell apoptosis , NK cell cytotoxicity, NK cell conjugate 
formation, and NK cell activation.  
 
3.2.18 Assessment of NK cell apoptosis  
NK cells were stained with Annexin V and sytox blue to enumerate apoptotic cells using 
flow cytometry. NK cells (1 x 10
6
cells/ml) pre-treated with dexamethasone (10
-7
M)  were 
resuspended in 100µl of Annexin V Binding buffer [0.1 M Hepes (pH 7.4), 1.4 M NaCl, 25 
mM CaCl2] and 1 μl of Annexin V- FITC (BD Biosciences, UK) was added to the cells and 
incubated for 10 minutes at 4C in the dark. NK cells were then transferred into a FACS 
tube (Starsted, UK) containing 300 μl of Annexin V Binding buffer NK cell death was also 
measured by immunostaining isolated NK cells (1 x 10
6) resuspended in 100μl of PBS with 
10μl of  sytox blue cell stain (pre-diluted 1:800 in PBS; Invitrogen, UK). The Annexin V 
positive NK cells and Sytox blue positive NK cells were detected via flow cytometry using a 
Cyan 
TM
 ADP (Dako Ltd, UK).  
 
3.2.19 Measuring NK cell activation status  
To determine NK cell activation status immunostaining for cell surface marker CD69 
expression was performed. 100µl NK cells in pre-warmed complete medium (1x 10
6
/ml) 
were dispensed into wells of a 96-well round bottomed plate (Becton Dickinson, UK) 
containing 100μl K562 cells (1 x 105/ml) or 100μl medium only (control), after which cells 
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were centrifuged at 50 x g for 1 minute and the cells were incubated at 37C in a humidified 
5% CO2 atmosphere for 2 hours. Post incubation, samples were centrifuged at 250 x g for 5 
minutes, the supernatant was removed and the pellet was re-suspended in 100μl PBS. Cells 
were immunostained with anti- human CD56 PE antibody (Dako, UK) and anti- human 
CD69-FITC antibody (eBiosciences, UK) and incubated for 20 minutes in the dark at 4C. 
Post incubation, the cells were washed using 300µl of PBS and centrifuged at 250 x g for 5 
minutes. Finally, the cell pellet was re-suspended in 300µl of PBS and cells were transferred 
to FACS tubes (Starsted, UK) and the samples were analysed by flow cytometry using a 
Cyan 
TM
 ADP (Dako Ltd, UK) and the percentage of CD69 positive NK cells was recorded.  
3.2.20 CD107a degranulation assay 
Lytic granule fusion with the NK cell membrane was assessed using a slightly modified 
version of a CD107a degranulation assay previously described by Alter and colleagues
 [525]
. 
PBMCs were suspended in per-warmed complete medium (1x10
6
/ ml) and were stimulated 
with K562 cells (1x10
6
/ml) at an E:T ratio of 1:1 in the presence of 5μl of anti-CD107a- 
FITC antibody (eBiosciences , UK)  for 1 hr at 37C in a humidified 5% CO2 atmosphere. 
6μg/ml of monensin (Sigma Aldrich, UK) was added and the samples incubated for 2 hr at 
37C in a humidified 5% CO2 atmosphere. NK cells (1x10
6
/ ml) cultured alone served as 
controls.  Post incubation, cells were pelleted by centrifugation at 250 x g for 5 minutes and 
resuspended in 100 μl PBS and stained with anti-human CD3 Pacific blue (Biolegend, UK) 
and anti-human CD56 PE (Dako, UK) for 20 minutes in the dark at 4C. Cells were washed 
using 300µl of PBS and centrifuged at 250 x g for 5 minutes and taken up in 300 μl of PBS 
and staining analysed by flow cytometry on a Cyan 
TM
 ADP (Dako Ltd, UK). CD107a 
expression on 5,000 NK cells was recorded. CD107a expressed by NK cells alone was 
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subtracted from the CD107a expression by NK cells plus K562 cells to account for 
spontaneous degranulation by NK cells. 
 
3.2.21 Statistical Analysis 
Statistical analysis was performed using IBM SPSS
 
statistics 20 software (IBM software, 
UK). Differences between the three groups of patients on demographic and health behaviors 
were tested using a chi-square test. Univariate ANOVA with least significant difference 
post-hoc tests was used to assess differences between the groups on immune variables.  
Where demographic variables differed significantly between groups, analyses were rerun 
adjusting for these variables using ANCOVA with the demographic variable as a covariate. 
Pearson’s correlations were used to examine associations between depressive symptoms 
score and immune cell function and hormone levels. Repeated measures ANOVA was used 
to assess group differences in immune variables at the week 6 and month 6 time points.  
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3.3 Results 
Hip fracture patients were classified into two groups on the basis of GDS scores: hip fracture 
patients with a GDS score of 5 or less were classified as non-depressed (HF; hip fracture 
only), those with a score of 6 or greater were categorised as depressed (HF+D; Hip fracture 
patients with depressive symptoms). 38 (37%) of the hip fracture patients  developed 
depressive symptoms as a response to stressful life event of a hip fracture 
[526]
. Recruitment 
and withdrawal data for this study in [ Figure 3.3], The consort diagram shows that 2260 hip 
fracture patients were screened in this study , but only 103 hip fracture patients were tested 
at the 6 week time point, mainly because most of the patients screened did not fulfil the 
inclusion criteria or declined to participate because they were feeling too ill or thought that 
participation in the study was time consuming or too demanding. Drop-out post consent was 
also common and mostly due to a change of mind by the patient or family member. From 
the 103 hip fracture patients tested, later two patients who were later found to violate the 
inclusion criteria were excluded from the analysis. At 6 month time point, 68 hip fracture 
patients were tested, but only 66 hip fracture patients were included in later analysis, the two 
hip fracture patients that violated the inclusion criteria were excluded from analysis. The 
main reasons of withdrawal between the 6 week and 6 month time point included: death, 
being to unwell to be tested, receiving treatment for depressive symptoms, or being non-
contactable.  
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Figure 3.3 Consort diagram showing recruitment rates.  
Assessed for eligibility 
(n= 2260 ) 
Consented (n=200) 
Participated  at  
W6 (n=103 ) 
Non-depressed (n=65 ) 
Participated at  M6 (n=46) 
 
Analysed (n= 44) 
*Excluding 2 participants who did 
not meet inclusion criteria 
Withdrew prior to M6 (n= 21) 
*Unwell/died (n=9) 
*Other reason (n= 12) 
Depressed (n=38 ) 
Participated at M6 (n=24) 
 
Analysed (n=24) 
Withdrew prior to M6 (n= 14) 
*Unwell/died (n=8) 
* Other reason (n=6) 
Withdrawal prior  to W6 (n=97 ) 
* Unwell (n=38 ) 
*Other (n=59 ) 
Excluded (n=2060 ) 
* Not meeting inclusion criteria 
(n=1541 ) 
*Declined to participate (n=249 ) 
* Other reasons (n= 270) 
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The demographic statistics for the study participants are shown in Table 3.2. The majority of 
hip fracture patients (80%) were females, which is not surprising as a higher incidence of hip 
fracture has been reported in women and women predominate in the older age group 
[527]
. 
The two groups of hip fracture patients were comparable in key variables, including age, 
BMI, type of fracture, dietary intake and health behaviours, but the healthy controls were 
younger than the hip fracture patients and had a higher BMI [Table 3.2].  
 
There were no differences in the presence of co-morbidities between the three groups, 
except that both the groups of hip fracture patients had higher incidence of  osteoporosis 
compared with healthy controls, which is not surprising as osteoporosis is a major risk factor 
for hip fracture 
[528]
 [Table 3.3].  
 
 
 
 
 
 
 
 
 
 
 
 
  
130 | P a g e  
 
Variable Healthy 
control  
Hip fracture 
patients 
(HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
Week 6      Mean (SD)  / N(%)  
N 43 63 38  
Age 74.9 (5.64) 83.8 (7.48) 84.0 (8.62) <.001 
Sex (male) 17 (40) 13 (21) 7 (18) .05 
BMI 27.3 (4.87) 23.5 (3.81) 22.7 (4.03) <.001 
Type of fracture 
(intracapsular) 
x 20 (59) 37 (63) .71 
Days between surgery and 
interview 
x 42.6 (14.06) 42.8 (12.81) .94 
Length of inpatient stay     
(days) 
x 23.35 (16.87) 25.74 (20.27) .53 
Number of infections 
during hospital stay 
x .27 (.50) .40 (.63) .28 
Patient discharged to 
rehabilitation centre 
x 10 (16%) 13 (34%) .04 
Number of readmissions x .23 (.50) .52 (.93) .06 
Occupational group 
(Manual) 
x 28 (43) 21 (58) .21 
Smokers ( one or more 
cigarettes /day) 
2 (8%) 7 (11%) 6 (19%) .60 
Alcohol consumption ( one 
or more units per week) 
13 (50%) 24 (37%) 13 (34%) .42 
Sleep ( < 8hr per night)                     24 (55.81%) 19 (30.15 %) 28 (73.36%) .75 
 
   Table 3.2 Patient demographics six weeks post-surgery . 
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Variable Healthy 
control  
Hip fracture 
patients 
(HF) 
 
Hip 
fracture 
patients 
with 
depressive 
symptoms 
(HF + D) 
p 
Week 6    Mean (SD) / N (%)  
Co-morbidities     
Osteoarthritis  3 (6.9%) 30 (47.61%) 16 (42.10%) <.001 
Hypertension 8 (18.60%) 24 (38.09%) 15 (39.47%) .06 
High Cholesterol 7 (16.27%) 11 (17.46%) 13 (34.21%) .08 
Angina 7 (16.27%) 13 (20.63%) 9 (23.68%) .70 
Other 21 (48.83) 40 (63.49%) 35 (92.10%) .12 
Diet     
Number of main meals x 1.1 (.41) 1.2 (.40) .40 
Fat content of diet  x 11.1 (4.88) 12.4 (4.24) .16 
Vegetable content of diet  x 7.9 (2.71) 8.7 (2.89) .17 
Number of caffeinated 
drinks 
x 4.9 (2.1) 4.8 (2.23) .90 
 
Table 3.3 Participant co-morbidities and health behaviours six weeks post-surgery.  
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At the 6 month follow up, data were available for 66 hip fracture patients; 17 (25.7%) of 
these participants were depressed. The dietary intake, smoking status and alcohol intake did 
not change between week 6 and month 6 [Table 3.4]. Further, the medical notes of 76 hip 
fracture patients were accessed 6 months post hip fracture to record the number of infections 
and mortality rate in these patients [Table 3.5].  
 
Variable Healthy 
control  
Hip fracture 
patients (HF) 
 
Hip 
fracture 
patients 
with 
depressive 
symptoms 
(HF + D) 
p 
Month 6      Mean (SD)  / N (%)  
Depressed  x 13 4  
Non depressed  x 11 36  
Smokers ( one or more cigarettes 
/day) 
x 3 (12.5%) 4 (9.8%) .73 
Alcohol consumption ( one or 
more units per week) 
x 9 (37.5%) 19 (46.3) .49 
Sleep ( < 8hr per night)                     x 16 (66.7%) 27 (67.5%) .95 
Number of patients put on 
antidepressants 
x X 2  
Diet     
Number of main meals x 1.1 (.28) 1.1 (.30) .85 
Fat content of diet  x 13.5 (4.87) 12.6 (4.77) .46 
Vegetable content of diet  x 7.4 (2.27) 8.2 (2.64) .23 
Number of caffeinated drinks x 5.3 (1.88) 4.6 (1.79) .12 
 
Table 3.4 Participant demographics and health behaviours 6 months post-surgery. 
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Variable Healthy 
control  
Hip fracture 
patients 
(HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
   N  (%)   
N ( 76) x 46 30  
Infections over 6 month period x 21(45.6%) 15 (50%) .21 
Number of  individuals  with 
urinary tract infections 
x 14 (30%)  11 (36.6%) .71 
Number of individuals  with chest 
infections 
x 2 (4.3%) 5 (16.6%) .15 
Number of individuals  with wound 
infections 
x 4 (8.6 %) 3 (10%) .42 
Number of individuals  with other 
infections 
x 10 (21.7%) 3 (10%) .36 
Mortality x 2 (3.17%) 5 (13.15%) .29 
 
Table 3.5 Infection and mortality data in hip fracture patients 6 months post-surgery. 
 
3.3.1 Psychosocial, frailty and cognitive measures in hip fracture patients 
 
37% of older adults that had recently suffered from the physical trauma of a hip fracture had 
depressive symptoms. Participants classified as depressed thus had significantly higher GDS 
scores, F (1, 99) = 14.76, p< .001, η2 =.66, at week 6 than those classed as non-depressed 
[Table 3.6]. At month 6, this difference in GDS scores remained significant, F (1, 64) = 
30.10, p< .001, η2 =.32 [Table 3.6] [526]. There was no detectable change in GDS  score 
between week 6 and month 6, F (1, 65) = .00, p = .95, η2 =.00. However, of those who 
provided data at both follow-ups, six of the non-depressed patients became depressed, as 
classified by the GDS at month 6, and 11 of the depressed patients were classified as non-
depressed by month 6. The main analysis by group will focus on participant’s depressive 
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symptoms classification at week 6 in order to examine the effect of emergence of depressive 
symptoms post-fracture on frailty, cognitive function and immune function. The difference 
in depressive symptoms was also confirmed by HADS depressive symptoms scale, the 
healthy controls recruited in this study were also asked to complete the HADS 
questionnaire. At week 6, significant differences were seen between the three groups, F (1, 
136) = 55.42, p< .001, η2 =.45 [Table 3.6], such that hip fracture patients with depressive 
symptoms had significantly higher HADS depressive symptoms scores than the hip fracture 
group without symptoms , p< .001 and the control group, p< .001. At month 6 , the 
difference in HADS score between hip fracture patients with and without depressive 
symptoms still remained significant , F (1,64) = 19.46, p< .001, η2 =.23 [Table 3.6]. 
Similarly, HADS anxiety scores were also significantly higher among the group with 
depressive symptoms at week 6, F (1, 98) = 22.83 p < .001, η2 =.18, and month 6, F (1, 64) = 
11.80, p = .001, η2 =.15 [Table 3.6] [526]. 
Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
Week 6      Mean (SD)    
GDS score x 2.6 (1.53) 8.2 (2.47) <.001 
HADS depressive 
symptoms 
2.4 (1.71) 3.4 (2.31) 9.1 (4.71) <.001 
HADS anxiety x 4.0 (3.71) 8.0 (4.55) <.001 
Month 6     
GDS score x 3.1 (1.99) 7.0 (3.75) <.001 
HADS depressive 
symptoms 
x 4.0 (3.71) 8.0 (4.55) <.001 
HADS anxiety x 3.5 (3.01) 7.0 (5.07) .001 
 
Table 3.6 Psychological measures in hip fracture patients and healthy controls. 
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Physical frailty was assessed in hip fracture patients using four measures. Firstly, a higher 
Oxford hip score (OHS) was reported in hip fracture patients without depressive symptoms 
compared with hip fracture patients with depressive symptoms at week 6, F (1, 72) = 65.02, 
p< .001, η2 =.45 , suggesting that hip fracture patients with depressive symptoms were less 
able to engage in activities of daily living (ADL) and the differences between OHS score of 
the two groups still remained significant at month 6, F (1, 57) = 6.22, p =.02, η2 =.09 [Table 
3.7]. The hand grip strength did not differ between hip fracture patients with and without 
depressive symptoms at week 6 or month 6, F (1, 86) = 1.32, p = .25, η2 =.01, and F (1, 57) 
= 1.34, p = .25, η2 =.02, respectively [Table 3.7]. Further, on examining the timed up and go  
(TUG) score it was observed that the hip fracture patients with depressive symptoms took 
longer to complete the TUG test at week 6, F (1, 82) = 4.16, p = .05, η2 =.04, and at month 6 
F (1, 54) = 3.90, p = .05, η2 =.06. [Table 3.7]. Finally, the hip fracture patients with 
depressive symptoms scored significantly worse on the Berg balance scale (BBS) at week 6, 
F (1, 78) = 8.35, p = .005, η2 =.09, but by month 6 there were no significant differences 
between the two groups of hip fracture patients, F (1, 46) = .83, p = .37, η2 =.16 [526].  
Cognitive function was measured in hip fracture patients using the MMSE test, no 
significant differences were detected between the two groups of hip fracture patients at week 
6, F (1, 98) = .08, p = .78, η2 =.001 or at month 6, F (1, 64) = .44, p = .51, η2 =.007 time 
point [Table 3.7]. 
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Variable Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
Week 6     Mean (SD)    
OHS 30.0 (8.04) 22.1 (9.33) <.001 
Hand grip score ( kg) 15.9 (6.69) 14.3 (6.20) .25 
TUG ( seconds) 52.4 (30.31) 69.6 (47.03) .04 
BBS 27.4 (14.16) 17.6 (14.80) .005 
MMSE score 24.7 (4.60) 24.4 (4.08) .78 
Month 6    
OHS 35.3 (8.14) 29.6 (8.97) .02 
Hand grip score ( kg) 16.3 (6.56) 14.2 (6.7) .25 
TUG ( seconds ) 34.4 (25.81) 50.8 (36.23) .05 
BBS 36.1 (12.71) 32.7 (13.4) .37 
MMSE score 25.9 (3.59) 25.3 (3.89) .51 
 
        Table 3.7. Physical frailty and cognitive measures in hip fracture patients. 
 
3.3.2 Neutrophil function in older hip fracture patients  
On comparing granulocyte count (mainly neutrophils) in peripheral blood, significant 
differences were observed between the three groups, F (2, 66) = 4.76, p = .01, η2 = .12, such 
that the healthy controls had significantly lower numbers of granulocytes than the hip 
fracture patients with, p = .01 and without depressive symptoms, p = .01 [Figure 3.4a]. As 
the demographic variables (sex, BMI and age) differed significantly between the groups, 
analyses were rerun adjusting for these variables using ANCOVA with using sex, BMI and 
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age as covariates. When all of the above analyses were repeated with adjustment for sex, age 
and BMI the results remained significant (data not shown).  
Neutrophil phagocytosis in response to opsonised E.coli did not differ significantly between 
the two groups of hip fracture patients and healthy controls, F (2,112) = 2.29, p = .11, η2 = 
.03, suggesting that the physical stress of hip fracture and psychological stress of depressive 
symptoms did not have an impact on neutrophil phagocytic ability [Figure 3.4b] 
[522]
. 
Neutrophil superoxide production in response to PMA, F (2, 87) = 5.53, p = .005, η2 = .11 
differed between the groups [Figure 3.5a], but the significant impairment was restricted to 
the hip fracture patients with depressive symptoms compared to healthy controls, p = .006 
and hip fracture patients without depressive symptoms, p = .01. Similarly, neutrophil 
superoxide production in response to opsonised E.coli also differed between the groups, F 
(2,134) = 6.53, p = .002, η2 = .08, [Figure 3.5b], such that the significant impairment was 
restricted to the hip fracture patients with new onset depressive symptoms compared to 
controls, p = .003 and compared to hip fracture patients without depressive symptoms, p = 
.001. When the above analyses were repeated with adjustment for age, sex and BMI, the 
superoxide production in response to PMA and E.coli remained significant (data not shown) 
[522]
.  
In order to check for associations with depressive symptoms scores as a continuous variable 
rather than discrete groups split at GDS = 6, regression analyses were also performed in hip 
fracture patients. It was observed that GDS score was negatively correlated with neutrophil 
superoxide production in hip fracture patients in response to PMA, β = -.26, p =.05, ΔR2 = 
.06 (data not shown) and E.coli, β = -.30, p = .002, ΔR2 = .09, [Figure 3.5c], such that hip 
fracture patients with greater depressive symptom scores had poorer neutrophil superoxide 
production 
[522]
.  
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Further, on examining neutrophil superoxide production in response to E.coli in hip fracture 
patients six weeks and six months post-surgery, a significant main effect of time was 
observed for hip fracture patients, F (1,56) = 6.83, p = .01, η2 = .10, such that superoxide 
production improved in both groups.  The significant improvement in superoxide production 
over time in both groups meant that by six months, neutrophil function did not differ 
between the groups, p = .34 [Figure 3.6].  Although the improvement in the depressed group 
was greater, there was no significant group x time interaction, F (1, 56) = 1.23, p = .27, η2 = 
.02 
[522]
.   
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Figure 3.4 Granulocyte count and neutrophil phagocytic ability in hip fracture patients. 
(a) Peripheral granulocyte count in healthy controls (n=29), hip fracture patients without 
depressive symptoms (HF; n=23), hip fracture patients with depressive symptoms (HF+D; 
n=17). Data is expressed as mean ± SEM (b) Neutrophil phagocytic ability, presented as 
phagocytic index, of healthy controls (n=35), hip fracture patients without depressive 
symptoms (HF; n = 29); hip fracture patients with depressive symptoms (HF+D; n = 23). The 
mean value is indicated by the bar.* p <.05. 
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Figure 3.5 Neutrophil superoxide production in hip fracture patients.  
(a) Neutrophil superoxide production (MFI) in response to PMA stimulus for healthy 
controls (n=29), hip fracture patients without depressive symptoms (HF; n=38), and hip 
fracture patients with depressive symptoms (HF+D; n=23). The mean value is indicated by 
the bar. (b) Neutrophil superoxide production (MFI) in response to E.coli stimulus for 
healthy controls (n=38), hip fracture patients without depressive symptoms (HF; n= 62), and 
hip fracture patients with depressive symptoms (HF+D; n=38). The mean value is indicated 
by the bar. (c) Correlation between neutrophil superoxide production in response to E.coli 
and depressive symptoms (GDS) scores in hip fracture patients (n = 55).* p <.05.  
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 Figure 3.6 Neutrophil superoxide production in hip fracture patients six weeks and six 
months post-surgery. 
Neutrophil superoxide production for hip fracture patients with depressive symptoms (n = 
24) and without depressive symptoms (n = 39) at 6 weeks and 6 months post-surgery. Data 
are mean ± SEM and * indicates p <.05. 
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3.3.3 Monocyte phenotype and function in hip fracture patients 
The differential expression of CD14 and CD16 have been used to define the three peripheral 
subsets of monocytes: classical (CD14
+ve
 CD16
-ve
) ,  intermediate (CD14
+ve
 CD16
+ve 
) and 
non-classical monocytes (CD14
+ve 
CD16
++ve
) monocytes
 [64]
. On comparing monocyte count 
in peripheral blood no significant differences were found between the three groups, F (2, 65) 
= .37, p = .69, η2 = .01 [Table 3.8]. On further evaluation of the distribution of monocyte 
subsets, no differences were seen in the percentage of ‘classical’monocytes, F (2, 67) = .23, 
p = .79, η2 = .007 [Table 3.8]; ‘intermediate’ monocytes F (2, 67) = .30, p = .73, η2 = .009 or 
‘non-classical’ monocytes F (2, 67) = .43, p = .64, η2 = .01 between the three groups [Table 
3.8]. 
Variable Healthy 
control  
Hip 
fracture 
patients 
(HF) 
 
Hip 
fracture 
patients 
with 
depressive 
symptoms 
(HF + D) 
p 
Week  6    Mean (SD)   
Monocyte count ( 10
9
/ml) . 53 (.04) .50 (.04) .55 (.05) .69 
CD14
+ve
CD16
-ve
 monocytes 
(%) 
89.32 (5.24) 89.29 (5.42) 88.31 (5.92) .79 
CD14
+ve
CD16
+ve
 monocytes 
(%) 
5.07 (2.29) 4.65 (2.94) 5.26 (2.75) .73 
CD14
+ve
CD16
++ve
 monocytes 
(%) 
5.37 (.78) 5.42 (.76) 6.38 (.90) .64 
 
   Table 3.8 The distribution of monocyte subsets in hip fracture patients.  
Similar to neutrophil phagocytosis, monocyte phagocytic ability in response to opsonised 
E.coli did not differ significantly between the three groups, F (2, 81) = 2.15, p = .12, η2 = .05 
[Figure 3.7a]. However, on examining the ability of monocytes to produce superoxide in 
response to opsonised E.coli significant differences were observed between the three groups 
F (2, 82) = 7.41, p = .001, η2 = .15, but the significant impairment in monocyte superoxide 
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generation was restricted to the hip fracture patients with depressive symptoms compared to 
healthy controls,   p = .008, and compared to hip fracture patients without depressive 
symptoms p = .002 [Figure 3.7b]. When the above analyses were repeated with adjustment 
for age, sex and BMI, the superoxide production in response E.coli still remained 
significantly different between the groups (data not shown). There was also a negative 
correlation between monocyte superoxide production and depressive symptoms (GDS score) 
in hip fracture patients, β = -.32, p = .01, ΔR2 = .10, [Figure 3.7c], such that hip fracture 
patients with a greater depressive symptom score had lower monocyte superoxide 
production. 
On evaluating the long term effect of hip fracture and depressive symptoms on monocyte 
superoxide production, the main effect of time on both groups of hip fracture patients was 
not significant  F (1, 38) = 2.31, p = .13, η2 = .05 [Figure 3.8].   Further, there was no 
significant group x time, F (1, 38) = .11, p = .73, η2 = .003, such that the two groups of hip 
fracture patients did not significantly differ in their recovery in the ability of monocytes to 
generate superoxide. 
Monocyte activation via lipopolysaccharide (LPS) is known to upregulate production and 
secretion of TNF [529].  PBMCs were stimulated with LPS for 1hr, 2hr, 4hr and 24 hr with 
LPS and TNFα production increased in a time dependent manner, being highest after 4 hrs.  
[Figure 3.9]. Upon prolonged stimulation (24 hr) with LPS a drop in TNFα production by 
monocytes was seen compared with the 4 hr time point [Figure 3.9]. Hereafter, TNFα 
production by monocytes was examined by stimulation of whole PBMCs with LPS for 4 hr. 
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On assessing TNFα cytokine production by monocytes no significant differences were 
observed in the percentage of monocytes producing TNFα between the three groups in the 
basal state, F (2, 33) = 1.24, p = .30, η2 = .07 [Figure 3.10a] or after 4hr LPS stimulations, F 
(2, 32) = .08, p = .92, η2 = .005 [Figure 3.9c]. Similarly, no significant differences were 
detected in the amount of TNFα produced by monocytes (MFI) in the basal state, F (2, 33) = 
0.60, p = .55, η2 = .03 [Figure 3.10b] or after 4hr LPS stimulation, F (2, 32) = 2.13, p = .32, 
η2 = .14 [Figure 3.9d]. Previous findings have reported that CD14+veCD16+ve monocytes 
produce higher levels of pro-inflammatory cytokines such as TNF compared with CD16
-ve 
monocytes 
[530]
, but in this thesis it was not possible to distinguish between the TNF 
production between the monocyte subsets due to loss of CD16 expression on LPS 
stimulation. 
 
In addition it was not possible to isolate monocytes from our hip fracture patients due to the 
limited volume of blood available and as a result TNFα secretion was assessed in whole 
PBMCs on LPS stimulation. TNFα production by different immune cells was measured to 
confirm that monocytes were the main producers of TNFα post LPS stimulation [Figure 
3.11a], which has also been previously reported 
[531]
. Further, no significant differences were 
observed in TNFα secretion between our three groups in the basal state F (2, 26) = .04, p = 
.95, η2 = .003 [Figure 3.11b] or on 4hr LPS stimulations F (2, 22) = .20, p = .75, η2 = .02 
[Figure 3.11c]. 
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Figure 3.7 Monocyte phagocytic ability and superoxide production in hip fracture 
patients 
(a) Monocyte phagocytic ability in healthy controls (n=18), hip fracture patients without 
depressive symptoms (HF; n =31), and hip fracture patients with depressive symptoms 
(HF+D; n = 26). The mean value is indicated by the bar. (b) Monocyte superoxide 
production in response to E.coli in healthy controls (n = 22), hip fracture patients without 
depressive symptoms (HF; n=41) and hip fracture patients with depressive symptoms 
(HF+D; n = 26). The mean value is indicated by the bar. (c) Correlation between GDS 
depressive symptoms scores and monocyte superoxide production in response to E.coli (n = 
51). * indicates p < .05, ** p < .005.  
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Figure 3.8 Monocyte superoxide production in hip fracture patients six months post-
surgery  
Monocyte superoxide production in hip fracture patients with depressive symptoms (n = 17) 
and without depressive symptoms (n= 18) at week 6 and 6 month post-surgery.  
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Figure 3.9 Time course of TNFα production by monocytes in response to LPS.  
Percentage of TNFα producing monocytes after LPS stimulation of PBMCs from healthy 
young donors (n = 3). Data is expressed as mean ± SEM. * p <.05, ** p <.005. 
 
 
 
  
 C
on
tr
ol
 1
 h
r
2 
hr
4 
hr
24
 h
r
0
20
40
60
80
100
T
N
F
+
v
e
 C
D
1
4
+
v
e
 (
%
)
 * 
** 
** 
 
 
  
148 | P a g e  
 
 
 
 
Figure 3.10 Monocyte TNFα productions in hip fracture patients.  
 
Percentage of monocytes producing TNFα in the (a) basal state, or (c) after LPS stimulation 
for 4 hr in healthy controls (n = 12); hip fracture patients without depressive symptoms (HF; 
(n = 12) and hip fracture patients with depressive symptoms (HF+D; n = 12). The mean 
value is indicated by the bar.  Amount of TNFα produced by monocytes (MFI) in (b) the 
basal state, or (d) after 4 hr LPS stimulation in healthy controls (n = 12); hip fracture 
patients without depressive symptoms (HF; n=12) and hip fracture patients with depressive 
symptoms (HF+D; n=12). Data is expressed as mean ± SEM. 
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Figure 3.11 TNFα secretion post LPS stimulation in hip fracture patients. 
 
(a) TNFα production by monocytes, T cells and B cells upon 4 hr LPS stimulation of 
PBMCs of healthy young donors (n = 3). Data is expressed as mean ± SEM. *** p <.001. 
TNFα secretion in (b) the basal condition, or (c) after 4 hr LPS stimulation in healthy 
controls (n = 10), hip fracture patients without depressive symptoms (HF; n = 10), and hip 
fracture patients without depressive symptoms (HF+D; n= 10). The solid bar represents the 
mean value. 
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To investigate possible mechanisms for the reduced monocyte superoxide generation the 
expression of relevant receptors was assessed. On measuring HLADR expression on 
monocytes, no differences were observed in the percentage of HLADR
+ve
 monocytes, F (2, 
50) = 1.58, p = .21, η2 = .06, or in the cell surface expression of HLADR, F (2, 50) = .62, p = 
.53, η2 = .02 between our groups [Table 3.9]. HLADR expression on monocyte subsets also 
showed no significant differences in the percentage of HLADR
+ve
 monocytes or the surface 
expression of HLADR in any of the subsets between the three groups [Table 3.9].  
 
Variable Healthy 
control  
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
Week  6               Mean  (SD)  
HLADR
+ve
 monocytes (%) 89.96 (5.87) 93.73 (7.46) 93.79 (8.63) .21 
HLADR expression (MFI) 79.38 (32.30) 78.24 (30.84) 68.21 (35.89) .53 
HLADR
+ve
CD14
+ve
CD16
-ve
 
(%) 
94.41 (7.64) 93.59 (8.68) 93.64 (7.86) .94 
HLADR expression (MFI) 71.36 (36.46) 64.41 (26.48) 64.32 (29.30) .75 
HLADR
+ve
CD14
+ve
CD16
+ve
 
(%) 
97.14 (2.24) 96.18 (4.73) 95.12 (5.77) .44 
HLADR expression (MFI) 174.70 (91.08) 179.60 (112.47) 
(112.47) 
(112.47) 
144.10 (87.31) .50 
HLADR
+ve
CD14
+ve
CD16
+
 
ve 
(%) 
86.55 (13.72) 86.98 (19.12) 85.32 (14.07) .95 
HLADR expression (MFI) 90.48 (42.92) 115.17 (88.04) 76.81 (56.44) .22 
 
Table 3.9 HLADR expression on monocyte subsets in hip fracture patients. 
Upon evaluation of the expression of co-stimulatory molecules CD80 and CD86 on 
monocytes of hip fracture patients the percentage of CD80
+ve
 monocytes, F (2, 41) = 1.67, p 
= .20, η2 = .07 and the CD80 expression levels on monocytes F (2, 41) = 1.86, p = .16, η2 = 
.08 were similar between the three groups [Table 3.10]. Additionally, on examining CD80 
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expression on monocyte subsets no differences were observed in the percentage of CD80
+ve
 
cells in the different subsets [Table 3.10] or between the three subject groups. Similarly 
negative data were found for CD86 cell positivity and expression on monocytes, monocyte 
subsets between the three subject groups [Table 3.10].  
Variable Healthy 
control  
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
Week  6               Mean  (SD)  
CD80
+ve
 monocytes (%) 73.98 (16.83) 79.47 (16.46) 85.00 (15.31) .20 
CD80 expression (MFI) 16.11 (5.13)  20.50 (11.56) 24.40 (14.72) .16 
CD80
+ve
CD14
+ve
CD16
-
 
ve
 (%) 71.50 (18.71) 79.94 (17.17) 83.18 (16.04) .21 
CD80 expression (MFI) 15.66 (5.36) 19.94 (10.02) 20.22 (10.48) .37 
CD80
+
CD14
+
CD16
+
 (%) 78.65 (15.71) 83.76 (16.42) 87.86 (15.56) .33 
CD80 expression (MFI) 17.35 (3.37) 24.79 (2.92) 24.93 (3.02) .18 
CD80
+ve
CD14
+ve
CD16
++
 
ve
 (%) 81.49 ( 14.88) 86.16 (14.49) 86.80 (14.98) .61 
CD80 expression (MFI) 19.84 (6.81) 28.60 (19.14) 27.35 (14.45) .28 
CD86
+ve
 monocytes (%) 96.83 (5.90) 97.60 (3.55) 96.52 (8.80) .87 
CD86 expression (MFI) 57.29 (28.83) 45.94 (16.17) 47.56 (17.57) .25 
CD86
+ve
CD14
+ve
CD16
-
 
ve
 (%) 96.50 (6.97) 97.74 (3.68) 96.51 (8.92) .81 
CD86 expression (MFI) 52.65 (28.77) 44.43 (15.33) 45.76 (18.57) .48 
CD86
+ve
CD14
+ve
CD16
+
 
ve
 (%) 99.11 (1.64) 98.82 (1.96) 97.38 (8.24) .54 
CD86 expression (MFI) 77.28 (35.52) 57.22 (19.41) 59.42 (25.46) .09 
CD86
+ve
CD14
+ve
CD16
++
 
ve
 (%) 98.59 (2.05) 96.70 (4.82) 96.14 (9.62) .49 
CD86 expression (MFI) 81.17 (32.31) 59.55 (25.32) 65.05 (26.98) .07 
 
Table 3.10 CD80 and CD86 expression on monocyte subsets in hip fracture patients. 
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3.3.4 NK cell numbers and function in hip fracture patients  
On examining NK cells in peripheral blood of hip fracture patients, there were no significant 
differences in percentages, F (2, 109) = 1.12, p = .32, η2 = .02 or absolute numbers of NK 
cells, F (2, 56) = 1.98, p = .14, η2 = .06 [Table 3.11] between the three groups.  Further, on 
examining the distribution of the two NK cell subsets – CD56dim and CD56bright no differences 
in the percentage of CD56
dim
 NK cells, F (2, 95) = .26, p = .76, η2 = .006 or in the absolute 
numbers of CD56
dim
 NK cells, F (2, 40) = .06, p = .94, η2 = .003 [Table 3.11] were seen 
between the three subject groups. Similarly, the percentage of CD56
bright
 NK cells, F (2, 95) = 
.45, p = .63, η2 = .01 and absolute numbers of CD56bright NK cells, F (2, 40) = .83, p = .44, η2 
= .04 were similar between the groups [Table 3.11]. Therefore, the CD56
dim/bright
 ratio did not 
differ between hip fracture patients with and without depressive symptoms and healthy 
controls, F (2, 95) = .42, p = .65, η2 = .009 [Table 3.11].  
Variable Healthy 
control  
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
NK cells (%) 12.74 (7.58) 14.66 (6.99) 15.32 (8.70) .32 
NK cell numbers (10
9
/ml)  .18 (.08) .17 (.09) .26 (.24) .14 
CD56
dim
 NK (%) 14.32 (6.68) 14.70 (7.57) 13.41 (7.12) .76 
CD56
dim
 numbers (10
9
/ml) .18 ( .08) .18 (.08) .19 (.15) .94 
CD56
bright
 NK (%) .67 (.44) .58 (.40) .59 (.37) .63 
CD56
bright
 numbers (10
9
/ml) .01 (.02) .006 (.003) .01 (.01) .44 
CD56 
dim/bright
 ratio 34.48 (23.44) 36.99 (29.69) 31.37 (20.17) .65 
 
     Table 3.11 NK cell subsets in hip fracture patients.  
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NK cells play an essential role in defence against viral or tumour infected cells, mainly 
mediated via granule exocytosis 
[127, 532]
. NK cell cytotoxicity towards K562 target cells was 
found to differ between the groups, F (2, 116) = 7.55, p = .001, η2 = .11 [Figure 3.12a], but 
the impairment in NK cell cytotoxicity was restricted to the hip fracture patients with 
depressive symptoms compared to healthy controls, p = .01, and hip fracture patients 
without depressive symptoms, p = .001. When the above analyses were repeated with 
adjustment for age, sex and BMI, the difference in NK cell cytotoxicity between the three 
groups still remained significant (data not shown). Further, depressive symptoms (GDS 
scores) were correlated with reduction in NK cell cytotoxic activity towards K562 cells in 
hip fracture patients, β = -.31, p = .005, ΔR2 = .09 [Figure 3.12b], such that hip fracture 
patients with a greater depressive symptom score had poorer NK cell cytotoxic activity.   
To investigate possible mechanisms for reduced NK cell function, various NK cell receptors 
were assessed as well as different stages of the cytotoxic process. CD57 is a marker for 
mature terminally differentiated NK cells 
[533]
. On examining the frequency of CD57
+ve
 NK 
cells F (2, 54) = 1.31, p = .27, η2 = .04 and CD57 expression levels on NK cells F (2, 54) = 
0.51, p = .60, η2 = .01 no differences were observed between the three groups [Table 3.12]. 
Similarly, the frequency of CD16
+ve
 NK cells, F (2, 45) = 1.08, p = .34, η2 = .04 and the 
CD16 expression levels on NK cells, F (2, 45) = .43, p = .65, η2 =.01 also did not differ 
[Table3.12].  
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Figure 3.12 NK cell cytotoxicity in hip fracture patients  
(a) NK cell cytotoxicity of healthy controls (n = 40), hip fracture patients without depressive 
symptoms (HF; n=50), and hip fracture patients with depressive symptoms (HF+D; n=28). 
The mean value is indicated by the bar. (b) Correlation between GDS depressive symptoms 
scores and NK cell cytotoxicity in hip fracture patients (n = 78).  * indicates p < .05, ** 
indicates p<.005. 
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A range of activation receptors expressed by NK cells (NKp30, NKP46, NKG2D) are 
involved in recognising ligands on tumour cells and have been associated with NK cell 
cytotoxicity
[157]
. However, this study only evaluated NKG2D expression on NK cells and 
did not record any differences in the percentage of NK cells expressing NKG2D, F (2, 42) = 
.76, p = .47, η2 = .03 or in the expression levels of NKG2D, F (2, 42) = 1.02, p = .36, η2 = 
.04 between the three groups [Table3.12]. 
 
 
Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD57
+ve 
NK cells (%) 52.17 (13.46) 49.79 (16.53) 57.59 (14.90) .27 
CD57 expression (MFI) 166.56 (81.68) 163.74 (85.49) 191.91 (117.96) .60 
CD16
+ve 
NK (%) 79.52 (13.97) 85.34 (9.81) 85.76 (13.91) .34 
CD16 expression (MFI) 201.56 (44.37) 207.02 (70.95) 225.70 (96.96) .65 
NKG2D
+ve
 NK (%) 91.53 (4.66) 93.47 (5.78) 92.70  (4.32) .47 
NKG2D expression 
(MFI) 
25.70 (4.11) 29.32 ( 5.78) 37.84 ( 40.10) .36 
 
   Table 3.12 NK cell phenotypic characterisation in hip fracture patients. 
The induction of NK cell cytotoxicity is dependent on contact between the NK cell and the 
target cell, to ensure precise targeting of the cytolytic process 
[129]
. No significant differences 
were observed in the ability of NK cells to form conjugates with K562 target cells between 
healthy controls and hip fracture patients with and without depressive symptoms  F (2, 72) = 
.41, p = .66, η2 = .01  [Figure 3.13a]. Cell conjugate formation is a dynamic process 
involving adhesion molecules. The engagement of LFA-1 (CD18/CD11b) with its ligand 
ICAM-1 on target cells is a central step in stable adhesion of NK cells to their target cells 
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and is essential for NK cell cytotoxicity 
[534]
. On examining LFA1 expression on NK cells 
no significant differences were found, F (2, 37) = .30, p = .74, η2 = .01 [Figure 3.13b] 
between the groups. Impaired NK cell cytotoxicity seen in hip fracture patients with 
depressive symptoms is therefore not a result of impaired ability of NK cells to form 
conjugates with target cells in these patients.  
Perforin and granzyme are the main constituents of cytotoxic granules that are responsible 
for inducing target cell death 
[127]
. On examining perforin expression by NK cells no 
significant differences were observed in the percentage of NK cells expressing perforin, F 
(2, 75) = .28, p = .75, η2 = .008 [Figure 3.14a] between the three groups.  However, the 
perforin expression levels on NK cells differed between the three groups, F (2, 75) = 7.99, p 
= .001, η2 = .17, but the significant reduction in perforin expression was restricted to the hip 
fracture patients with new onset depressive symptoms compared to controls, p <.001 [Figure 
3.14b]. Although perforin expression on NK cells of hip fracture patients without depressive 
symptoms was lower than healthy controls  this difference was not statistically significant , p 
= .08. When the above analyses were repeated with adjustment for age, sex and BMI, the 
results remained significant (data not shown).  
In contrast, no significant differences were observed in the percentage of NK cells 
expressing granzyme B, F (2, 56) = 0.662, p = .52, η2 = .02 [Figure 3.14c] or in the 
granzyme B expression levels in NK cells, F (2, 56) = .13, p = .87, η2 = .005 [Figure 3.14d] 
between the subject groups.  
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Figure 3.13 NK cell conjugate formation in hip fracture patients.  
 
(a) NK and target cell conjugate formation in healthy controls (n=29), hip fracture patients 
without depressive symptoms (HF; n=22), hip fracture patients with depressive symptoms 
(HF+D; n=22). The mean value is indicated by the bar. (b) LFA-1 cell surface expression on 
NK cells of healthy controls (n=15), hip fracture patients without depressive symptoms (HF; 
n=15), and hip fracture patients with depressive symptoms HF+D; n=13). Data is expressed 
as mean ± SEM. 
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Figure 3.14 Perforin and granzyme B expression in NK cells of hip fracture patients.  
 
(a) Percentage of perforin
+ve
 NK cells, or (b) the perforin expression in healthy controls 
(n=26), hip fracture patients without depressive symptoms (HF; n=26), and hip fracture 
patients with depressive symptoms (HF+D; n=26).(c) Percentage of granzyme B
+ve
 NK cells, 
or (d) Granzyme B expression in healthy controls (n=20), hip fracture patients without 
depressive symptoms (HF; n=20), and hip fracture patients with depressive symptoms 
(HF+D; n=20). *** indicates p<.001. 
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On measuring NK cell cytotoxicity in hip fracture patients with and without depressive 
symptoms at 6 weeks and 6 month post-surgery there was no significant effect of time, 
F(1,40) = 1.36, p = .25, η2 = .03 , such that the NK cell activity did not change overall with 
time [Figure 3.15a]. There was no significant group x time interaction, F (1, 40) = .36, p = 
.55, η2 = .009, such that both the groups of hip fracture patients did not differ in their 
recovery of NK cell cytotoxicity six months after surgery. The NK cell activity in hip 
fracture with depressive symptoms was reduced in comparison to hip fracture patients 
without depressive symptoms even six months post-surgery, p = .04.  
Next, the perforin expression in NK cells of hip fracture patients with and without 
depressive symptoms was evaluated  6 weeks and 6 months post-surgery , there was no 
significant effect of time, F (1, 28) = .13, p = .71, η2 = .005 [Figure 3.15b] ,such that perforin 
expression in NK cells did not improve even 6 months post-surgery in hip fracture patients .  
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Figure 3.15 NK cell cytotoxicity and NK cell perforin expression in hip fracture patients 
six weeks and six months post-surgery.  
(a) NK cell specific lysis for hip fracture patients with depressive symptoms (HF+D; n = 12) 
and without depressive symptoms (HF; n=30) at 6 weeks and 6 months post-surgery. Data 
are mean ± SEM. (b) Perforin expression in NK cells in hip fracture patients with depressive 
symptoms ( HF+D; n = 19) and without depressive symptoms (HF; n = 11)  at 6 weeks and 
6 months post injury. Data are mean ± SEM. 
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3.3.5 The HPA axis in hip fracture patients 
The two main adrenal hormones; DHEAS and cortisol are known to play role in maintaining 
immune homeostasis 
[535]
. Analysis of HPA axis hormone levels revealed significant group 
differences in serum cortisol levels, F (2,127) = 10.32, p < .001, η2 = .14, [Figure 3.16a] , 
driven by significantly higher serum cortisol levels in hip fracture patients with depressive 
symptoms compared with healthy controls, p = .006 or with hip fracture patients without 
depressive symptoms, p < .001. DHEAS levels, F (2,127) = 10.47, p < .001, η2 = .14, were 
also significantly different between the subject groups [Figure 3.16b], lower DHEAS levels 
were observed in hip fracture with depressive symptoms compared with healthy controls, p 
<.001, and the hip fracture alone group, p = .008. Also, significant differences were 
observed between DHEAS levels of hip fracture patients without depressive symptoms and 
healthy controls, p = .03 
[522]
. 
As a consequence , the overall serum cortisol:DHEAS ratio differed significantly between 
the three groups, F (2,127) = 9.36, p < .001, η2 = .12, such that only those hip fracture 
patients with depressive symptoms had a higher ratio when compared with healthy controls, 
p < .001 and with hip fracture patients without depressive symptoms , p = .006, [Figure 
3.16c]. When the above analyses were repeated with adjustment for age, sex and BMI, the 
serum cortisol:DHEAS ratio still remained significantly different between the three groups 
(data not shown) 
[522]
. An elevated serum cortisol: DHEAS ratio is a known marker for 
depressive symptoms 
[536]
 and in this study the presence of depressive symptoms, 
specifically the GDS score, in hip fracture patients correlated with the cortisol: DHEAS 
ratio, β = .28, p = .006, R2 = .07, such that hip fracture patients with higher depressive 
symptoms had an elevated cortisol: DHEAS ratio [Figure 3.16d] 
[522]
.  
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Further, on measuring serum adrenal hormone levels in hip fracture patients six months 
post- surgery there was no significant effect of time on the serum cortisol levels, F (1, 51) = 
1.90, p = .17, η2 = .03 and there remained a significant effect of group, such that serum 
cortisol levels were higher in hip fracture patients with depressive symptoms even 6 months 
post-surgery, p = .01 [Figure 3.17a]. Serum DHEAS levels in hip fracture patients six 
months after surgery showed a trend towards a decline in patients without depressive 
symptoms, but there was no significant effect of time on the serum DHEAS levels, F (1, 51) 
= 1.23, p = .27, η2 = .02 . However, the effect of group did not remain significant, such that 
serum DHEAS levels did not significantly differ between hip fracture patients with and 
without depressive symptoms 6 months post-surgery , p =.14 [Figure 3.17b]. 
Overall, the serum cortisol: DHEAS ratio did not significantly alter with time, F (1, 51) = 
.94, p = .34, η2 = .01, and there remained a significant effect of group, such that the cortisol: 
DHEAS ratio was higher in the hip fracture patients with depressive symptoms even six 
months post-surgery, p = .02 [Figure 3.17c] 
[526]
.   
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Figure 3.16 Adrenal hormone levels in hip fracture patients.  
 Serum (a) cortisol, (b) DHEAS, or (c) the cortisol: DHEAS ratio in healthy controls (n=32); 
hip fracture patients without depressive symptoms (HF; n= 62), and hip fracture patients 
with depressive symptoms (HF+D; n=38). (d) Correlation between GDS depressive 
symptoms scores and serum cortisol: DHEAS ratio in hip fracture patients (n = 90).  Data 
are mean ± SEM. * p <.05 **p <.005 and ***p <.001. 
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Figure 3.17 Adrenal hormones in hip fracture patients six months post-surgery.  
Serum (a) cortisol, (b) DHEAS or (c) the cortisol:DHEAS ratio in hip fracture patients 
without depressive symptoms (HF; n = 33) and hip fracture patients with depressive 
symptoms (HF+D; n = 20) at 6 weeks and 6 months post-surgery. Data are mean ± SEM. * p 
<.05. 
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3.3.6 In-vitro treatment of NK cells with dexamethasone  
Glucocorticoids are known to exert a suppressive effect on NK cell killing 
[501, 503]
. As 
elevated serum cortisol level in hip fracture patients with depressive symptoms was found 
here [Figure 3.15a] this might explain the reduced NK cell activity seen in the patients with 
depressive symptoms. In order to test this hypothesis, NK cells isolated from healthy young 
individuals were treated with dexamethasone for 18 hr prior to testing their cytotoxic 
potential. Overnight incubation of NK cells with dexamethasone resulted in a dose 
dependent reduction in NK cell mediated lysis of target cells [Figure 3.18]. 10
-7
M 
dexamethasone is close to the equivalent physiological serum cortisol levels observed in hip 
fracture patients with depressive symptoms and has been referred to as a physiologically 
relevant concentration in other studies 
[501, 524]
.  This data supports the hypothesis that the 
elevated cortisol levels seen in the hip fracture patients with new onset depressive symptoms 
might be one of the factors contributing towards suppressed NK cell cytotoxicity.  
To exclude the possibility that suppressed NK cell cytotoxicity reported upon treatment with 
dexamethasone was due to an increase in NK cell apoptosis, NK cells treated overnight with 
dexamethasone (10
-7
M) were immunostained with Annexin V to detect apoptosis and sytox 
green for necrosis. No significant differences were observed in the percentage of Annexin V 
positive [ p = .77; Figure 3.19a] or Sytox positive [ p = .57; Figure 3.19b] NK cells between 
untreated and 10
-7
M dexamethasone treated NK cells. Thus, dexamethasone treatment does 
not affect NK cell viability.  
The first step of NK cell mediated target cell lysis involves conjugate formation between NK 
cells and target cells 
[129]
. No significant differences  were observed in the ability of NK cells 
to form conjugates in response to treatment with a range of dexamethasone concentrations 
[Figure 3.20], which contradicts previous findings in an NK cell line 
[501]
. 
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Figure 3.18 NK cell cytotoxicity with dexamethasone treatment.  
 
NK cell cytotoxicity in cells from healthy young donors (n = 9) treated with dexamethasone 
(10
-5
M, 10
-7
M and 10
-9
M) for 18 hr. Data are mean ± SEM. * indicates p < .05, ** p < .005. 
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Figure 3.19 NK cell apoptosis and necrosis after dexamethasone treatment.  
 
Frequency of (a) Annexin V
+ve
 NK cells or (b) Sytox
+ve
  NK cells after treatment with buffer 
alone (control) or 10
-7
M dexamethasone (dex) in NK cells isolated from healthy young 
donors (n = 5). Data is expressed as mean ± SEM. 
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Figure 3.20 NK-target cell conjugate formation with dexamethasone treatment.  
 
Percentage of effector-target cell conjugates formed by NK cells from healthy young donors 
(n = 9) upon treatment with dexamethasone (10
-5
M, 10
-7
M and 10
-9
M) for 18 hr. Data are 
mean ± SEM. 
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Examination of NK cell activation after co-culture with K562 cells by staining NK cells for 
CD69 expression 
[537, 538]
 showed no significant effect of treatment with 10
-7
M 
dexamethasone, p = .72 [Figure 3.21].  
NK-target cell conjugate formation is followed by migration of cytolytic granules towards 
the immunological synapse to induce target cell death
[131]
. Cytolytic granule membranes are 
lined by highly glycosylated membrane proteins, such as lysosomal associated membrane 
protein1 (LAMP1 or CD107a). NK cell conjugation with tumour cells results in 
degranulation and CD107a appearance on the cell surface of NK cells followed by 
exocytosis of cytotoxic proteins (perforin and granzyme) 
[539]
. On measuring the percentage 
of NK cells expressing CD107a post-dexamethasone treatment, no significant differences 
were observed CD107a surface expression [Figure 3.22] in agreement with a previous report 
[501]
. 
Finally, the effect of dexamethasone on perforin and granzyme B expression by NK cells 
was examined. On measuring the frequency of perforin
+ve
 NK cells post dexamethasone 
treatment, no significant differences  were observed in response to treatment with 
dexamethasone  [Figure 3.23a], though perforin expression levels on a per cell basis were 
reduced with 10
-5
M  , p = .001 and 10
-7
M dexamethasone , p = .02 compared to untreated 
NK cells (control) [Figure 3.23b]. In contrast, no differences were found in the frequency of 
granzyme B 
+ve
 NK cells [Figure 3.23c] or granzyme B expression levels per NK cell after 
dexamethasone treatment [Figure 3.23d].  
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Figure 3.21 CD69 expression upon dexamethasone treatment of NK cells  
 
Frequency of CD69
+ve
 untreated (control) and dexamethasone treated (10
-7
M dex) NK cells 
post-stimulation with  K562 target cells for 2 hr using NK cells isolated from healthy young 
donors (n = 5). Data is expressed as mean ± SEM. 
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Figure 3.22 CD107a expressions by NK cells post dexamethasone treatment. 
 
Frequency of CD107a
+ve
 untreated (control) and dexamethasone treated NK cells (10
-5
M 
dex, 10
-7
M dex and 10
-9
M dex) post-stimulation with K562 target cells for 2 hr in NK cells 
from healthy young donors (n = 7). Data is expressed as mean ± SEM.  
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Figure 3.23 Perforin and granzyme B expression by NK cells with dexamethasone 
treatment. 
 
Percentage of (a) Perforin
+ve
  or (b) granzyme B
+ve
 and (c) perforin or (d) granzyme B 
expression levels in untreated (control) and dexamethasone treated NK cells (10
-5
M dex, 10
-
7
M dex and 10
-9
M dex) for NK cells from healthy young donors .Data is expressed as mean ± 
SEM. * p<.05 ** p < .005. 
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3.3.7 Serum cytokine levels in hip fracture patients 
 
In this chapter, serum levels of nine different cytokines were also measured in our hip 
fracture patients. Significant differences were seen in serum IL6 levels between the three 
groups, F (2, 101) = 10.25, p < .001, η2 = .16, such that a significant increase in serum IL6 
levels were detected in depressed hip fracture patients compared with healthy controls, p 
<.001 as well as non-depressed hip fracture patients , p = .002 [Table 3.13]. In addition, a 
significant association was found between GDS scores and serum IL6 levels in hip fracture 
patients, β = .29, p = .02, ΔR2 = .08, such that those with greater depressive symptoms had 
higher circulating IL6 levels (data not shown). 
Serum TNFα levels also showed significant differences between our three groups, F (2, 62) 
= 9.52, p <.001, η2 = .23, such that a significant increase was observed in serum TNFα levels 
in hip fracture patients with depressive symptoms compared with healthy controls, p <.001 
and non-depressed hip fracture patients, p = .02. [Table 3.13]. However, we did not observe 
a significant association between GDS scores and TNFα levels in hip fracture patients, β = 
.18, p = .23, ΔR2 = .01 (data not shown).  
Similarly, significant differences were also found in the serum levels of the anti-
inflammatory cytokine IL10 between our three groups, F (2, 66) = 7.25, p = .001, η2 = .18, 
such that a significant increase in serum IL10 levels was seen in hip fracture patients with 
depressive symptoms compared with healthy controls, p = .001 [Table 3.13]. No significant 
differences were observed in serum IL10 levels between hip fracture patients with and 
without depressive symptoms, p = .21. There was no association between GDS scores and 
circulating IL10 levels in hip fracture patients, β = .23, p = .21, ΔR2 = .02 (data not shown). 
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When the above analyses were repeated with adjustment for age, sex and BMI, the 
differences in IL6, TNFα and IL10 levels between the three groups still remained significant 
(data not shown). 
Finally , no significant differences were found in serum  IL8 levels, F (2, 93) = 2.57, p = .08, 
η2 = .05; IL1β levels, F (2, 58) = 2.04, p = .13, η2 = .06; IL17 levels, F (2, 63) = .36, p = .69, 
η2 = .01;  GM-CSF levels, F (2, 60) = 2.38, p = .10, η2 = .07 ;  IL4 levels, F (2, 89) = .821, p 
= .44, η2 = .01, or in serum IL13 levels F (2, 63) = 1.85, p = .16, η2 = .05 between our three 
subject groups [Table 3.13]. 
Variable Healthy 
control 
Hip fracture 
patients 
(HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
IL-6 (pg/ml) 6.25 (6.40) 7.31 (5.15) 13.79 (9.75) <.00
1 
TNFα (pg/ml) 4.28 (4.58) 9.96 (6.06) 19.25 (19.52) <.00
1 
IL-10( pg/ml) 5.27 (5.34) 10.37 (10.15) 22.41 (28.91) .001 
IL-1β ( pg/ml) 18.41 (13.77) 12.84 (7.92) 26.29 (29.62) .13 
IL-8 ( pg/ml) 25.95 (17.20) 19.09 (14.47) 18.82 (10.91) .08 
GM-CSF( pg/ml) 86.67 (79.27) 39.13 (19.48) 64.85(79.37) .10 
IL-17( pg/ml) .82 (.57) 1.48 (4.71) .79 (.41) .69 
IL-4( pg/ml) 2.37 (2.21) 1.45 (3.60) 3.37 (9.64) .44 
IL-13 ( pg/ml) 16.48 (2.67) 7.47 (4.02) 15.84 (3.77) .16 
 
Table 3.13. Serum cytokine levels in hip fracture patients.   
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3.3.8 Cortisol: DHEAS ratio and innate immune parameters  
An elevated serum cortisol: DHEAS ratio acts as a marker for depressive symptoms 
[536]
. In 
this chapter, a significant association was found between depressive symptoms (GDS 
scores) and the serum cortisol: DHEAS ratio. However, there was no association between 
serum cortisol: DHEAS ratio and neutrophil superoxide production, β = -.05, p = .39, ΔR2 = 
.003, or monocyte superoxide production, β = -.12, p = .29, ΔR2 = .01 in the hip fracture 
patients (data not shown). 
 Similarly, no significant association was found between serum cortisol: DHEAS ratio and 
NK cell cytotoxicity in the hip fracture patients, β = -.11, p = .24, ΔR2 = .01 (data not 
shown). Further, no significant association was observed between serum cortisol: DHEAS 
ratio and serum cytokines levels; including IL6 β = .10, p = .41, ΔR2 = .01 or TNFα levels β 
= .16, p = .32, ΔR2 = .02 or IL10 levels β = -.19, p = .33, ΔR2 = .03 (data not shown).  
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3.4 Discussion 
Mood disorders, especially depression, have been well studied in older patients with hip 
fracture 
[433, 434]
. About one third of our hip fracture patients had significant depressive 
symptoms post-surgery. The data shown here reveal for the first time that what we presume 
to be new onset depressive symptoms post hip fracture (participants were exluded if they 
had previous depression or treatment for it) are associated with physical frailty, innate 
immune dysregulation, a higher serum cortisol: DHEAS ratio and elevated serum levels of 
pro-inflammatory cytokines.  
Firstly, the data indicated that depressive symptoms post hip fracture were associated with 
poor physical functioning including; impaired ability to perform activities of daily living and 
reduced walking speed 
[526]
. These findings are in line with previous studies showing a 
considerable negative impact of depressive symptoms on quality of life 
[540]
 and physical 
functioning post hip fracture 
[437, 541]
.  Also, this impairment in functional ability persisted up 
to six months post fracture, suggesting that  the presence of depressive symptoms post hip 
fracture surgery is a major contribution to disability in this population. However, the 
development of depressive symptoms post fracture did not have an effect on cognitive 
impairment. These findings might be due to exclusion of individuals with dementia in our 
study which was not an exclusion criterion for the other study.  
Next, on examining the additive effect of physical and psychological distress on neutrophil 
functioning, it was found that neutrophil phagocytosis remained unaltered. These findings 
are consistent  with a previous study from our group showing that hip fracture did not have 
an effect on neutrophil phagocytic ability 
[359]
 . However, we did find that neutrophil 
superoxide production was impaired in hip fracture patients that developed depressive 
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symptoms
[522]
. In the previous study from our group ,we reported suppression in neutrophil 
superoxide production in hip fracture patients compared to healthy controls 
[359]
, however 
these patients were not screened for depressive symptoms and it is possible that only 
patients that developed depressive symptoms had supressed neutrophil function in the 
previous study as well. Our findings are supported by another study  which showed that 
depression has a suppressive effect on neutrophil superoxide production 
[542]
. Emotional 
stressors, such as bereavement in older adults have also been associated with impaired 
neutrophil superoxide generation, and again neutrophil phagocytic ability remained 
unaltered 
[360]
. Interestingly, it has also been shown that older adults with fewer stress coping 
factors, such as hobbies and close links with friends and family, have lower neutrophil 
superoxide production compared to those with greater numbers of these factors
[543]
.  
Assembly and activation of the NADPH oxidase complex involving association of cytosolic 
components p47
phox
, p67
phox
, and p40
phox
 with membrane bound gp91
phox
 and p22
phox
, 
catalyses electron transfer from NADPH to oxygen resulting in superoxide generation 
[544]
. 
A study examining the effect of academic psychological stress on neutrophil functioning 
reported that decreased superoxide production was accompanied by diminished expression 
of subunit p47
phox
 of NADPH complex 
[545]
. Although not examined in this thesis, there is a 
possibility that diminished expression of p47
phox 
on neutrophils of hip fracture patients with 
depressive symptoms might be a contributing factor towards their reduced ability of 
superoxide generation. 
On examining the effect of physical and psychological distress on monocytes ,no significant 
differences were observed in peripheral monocyte count between hip fracture patients with 
or without depressive symptoms, which is in line with previous findings of unaltered 
numbers of circulating monocytes in depressed individuals 
[487]
. Further, the presence of 
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depressive symptoms in hip fracture patients did not have an effect on the peripheral 
distribution of  monocyte subsets, which is also in line with a previous study in depressed  
patients 
[487]
. Similar to our findings in neutrophils, a suppression of superoxide production 
by monocytes was seen in hip fracture patients with depressive symptoms. However, 
another study reported an increase in superoxide generation by monocytes in depressed 
individuals, but in that study only ten individuals with major depression were assessed and 
these were all young individuals 
[487]
. Interestingly, the effect of depressive symptoms on 
monocyte function in hip fracture patients was not universal and there was no effect on 
phagocytic ability, TNFα secretion or expression of co-stimulatory and antigen presenting 
molecules. These findings are consistent with a previous study that reported intact monocyte 
cytokine production upon stimulation with bacterial components and expression of MHC-II 
molecule human leukocyte antigen DR (HLA-DR) in young patients with depressive 
symptoms 
[546]
 .  
Neutrophils and monocytes play a prime role in defence against bacterial infections, thus it 
is tempting to hypothesise that this reduction in neutrophil and monocyte bactericidal 
properties might be of clinical significance and increase susceptibility of infections in hip 
fracture patients with depressive symptoms, resulting in ill-health and increased risk of 
mortality. A high incidence of urinary tract infection (33%) and chest infections (9.2 %) 
were found in hip fracture patients over the 6 month follow up period, which is in line with 
previous reports 
[359, 547]
.  Although, hip fracture patients with and without depressive 
symptoms did not differ in the number of infections they developed during their hospital 
stay or during the six month follow up period, the study may not have had sufficient power 
to detect such changes.  Further,  excess mortality has been reported in depressed individuals 
[548]
,  especially in depressed patients post hip fracture 
[435]
 . In this study, a trend towards a 
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higher death rate in hip fracture patients with depressive symptoms was seen, but this did 
not reach statistical significance. 
Depressive symptoms post hip fracture were also associated with suppressed NK cell 
activity,  in line with numerous studies reporting a suppressive effect of severe life stressors 
such as caregiving 
[549]
 , bereavement  
[550-552]
 , occupational stress 
[491, 553] 
and depression 
[492, 554-556]
 on NK cell function. Interestingly, an association between depressive symptoms 
scores and NKCC in hip fracture patients was also seen, which has been previously reported 
in people undergoing severe life stressors, such as bereavement 
[557]
.  Even though a number 
of studies have reported an impaired NK cell activity on chronic exposure to psychological 
distress, none of these studies have attempted to explain the reason behind this impaired 
killing by NK cells. In this chapter, it was shown that the suppression in NKCC of hip 
fracture patients with depressive symptoms was not a result of altered numbers of circulating 
NK cells 
[554, 558]
 or changes in the CD56
dim
 /CD56
bright
 NK cell distribution.  Instead, a 
significant decline in perforin content on a per cell basis was detected in hip fracture patients 
with depressive symptoms. This reduction in perforin expression might result in reduced 
granzyme delivery to target cells which in turn reduces target cell killing, suggesting one 
possible mechanism contributing towards impaired NK cell activity Studies in perforin-
deficient mice have reported an increased susceptibility towards tumours 
[559]
 and inefficient 
control of viral challenges 
[560]
 in these mice due to impairments in target cell lysis by NK 
cells 
[561]
. Interestingly, another study examining the effect of psychotherapy, reported a 
reduction in depression scores and also an improvement in  NK cell activity by increasing 
NK cell perforin expression 
[562]
. 
Hyperactivity of the HPA axis resulting in elevated basal cortisol levels is one of the most 
consistent findings in depressed patients 
[563, 564]
 . In this chapter, it was shown that hip 
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fracture patients with depressive symptoms had elevated serum cortisol levels compared to 
hip fracture patients without depressive symptoms and healthy controls 
[522]
. Reduced 
feedback inhibition by glucocorticoids due to impaired functioning of the glucocorticoid 
receptor has been suggested to be responsible for the HPA axis hyperactivity in depressed 
individuals 
[565, 566]
. Although not assessed in this thesis, previous studies have shown a 
reduction in the GR expression in depressed patients 
[567, 568]
; it is possible that reduced GR 
expression on immune cells in hip fracture patients with depressive symptoms might 
contribute towards elevated cortisol levels in these patients. Additionally, a decline in 
DHEAS levels also occurred in hip fracture patients with depressive symptoms, which is 
consistent with previous findings of reduced DHEAS levels in depressed individuals 
[364, 569, 
570]
. However, there has been a contradictory report showing an increase in DHEA levels in 
depressed patients 
[571]
. Overall, an elevated serum cortisol: DHEAS ratio occurred in hip 
fracture patients with depressive symptoms 
[522]
, which is also in line with previous findings 
for patients with depression 
[536]
.  
The elevated cortisol: DHEAS ratio might be one of the mechanisms responsible for reduced 
superoxide production by innate immune cells in hip fracture patients with depressive 
symptoms. In-vitro studies have reported a suppressive effect of glucocorticoids on 
bactericidal properties, especially superoxide generation 
[498, 572] 
in neutrophils and 
monocytes 
[498, 573]
. Interestingly, a study examining the effect of dexamethasone on the 
human monocytic THP-1 cell line reported a down regulation of NADPH oxidase activity 
due to inhibition of expression of p47
phox 
genes 
[574]
. In contrast, DHEAS has been shown to 
enhance superoxide generation in in-vitro assays 
[575]
. Although it is possible that an 
elevated serum cortisol:DHEAS ratio might have a direct inhibitory effect on expression of 
p47
phox 
genes in neutrophils and monocytes, statistical analysis using the Sobel test (kindly 
performed by Dr Anna Phillips) suggested that the elevated serum cortisol:DHEAS was 
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related to depressive symptoms but did not mediate the decrease in superoxide production 
by innate immune cells 
[522]
. Further research is required to confirm this conclusion and to 
determine how depressive symptoms might mediate suppression of superoxide generation. 
 
Similarly, a suppressive effect of dexamethasone (a synthetic glucocorticoid) has been 
reported on the cytotoxic activity of an NK cell line 
[501, 524, 576]
 and peripheral blood 
leukocytes enriched for NK cells 
[503]
. In this chapter, these findings were confirmed using 
isolated NK cells from young donors. However, in future studies it might be interesting to 
examine whether a more pronounced suppressive effect of dexamethasone occurs on NK 
cell activity in healthy older adults. In-vitro incubation of NK cells with dexamethasone 
resulted in a reduction in perforin content per NK cell, which is in line with previous 
findings 
[524]
, suggesting that reduced perforin expression on NK cells on exposure to 
glucocorticoids might contribute towards reduced NK cell cytotoxicity seen in stressed 
adults. Mifepristone (a glucocorticoid antagonist) is capable of augmenting NK cell 
cytotoxicity via ERK-mediated increase in perforin expression, which can be blocked by 
cortisol 
[577]
. Taken together with our data, it is reasonable to propose that prolonged NK cell 
exposure to cortisol, as occurred in hip fracture patients with depressive symptoms, reduces 
their expression of perforin and compromises NKCC. Although not explored in this thesis, 
glucocorticoids are capable of inducing epigenetic modifications and regulate gene 
transcription of immune responsive genes 
[578]
. Glucocorticoids induce reduced acetylation 
at histone 4 lysine 8 (H4-K8), resulting in reduced promoter accessibility which has a 
suppressive effect on gene transcription on NK cell activity regulating genes, such as 
perforin, resulting in reduced NK cell functional activity 
[501]
. Further, in-vitro studies have 
also shown that DHEA increases NK cell cytotoxicity 
[579]
 , raising the possibility that 
elevated cortisol: DHEAS might be one of the mechanisms responsible for reduced NK cell 
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cytotoxicity in hip fracture patients with depressive symptoms. However, once again Sobel 
analysis suggested that the elevated serum cortisol: DHEAS was related to depressive 
symptoms, but did not mediate the decrease in NK cell activity in hip fracture patients with 
depressive symptoms.  
 
In addition to the HPA axis, depression has also been associated with sympathetic nervous 
system activation, resulting in release of neuropeptides such as norepinephrine 
[580-582]
. 
Norepinephrine (noradrenalin) mediates its effects via adrenergic receptors, which are 
expressed in high levels on NK cells and has a suppressive effect on NK cell activity 
[554, 583, 
584]
 by reducing levels of perforin and granzyme B 
[585]
. Future research could investigate 
this possibility.  
 
Depression has been characterised by some as an inflammatory disorder accompanied by 
elevated levels of pro-inflammatory cytokines, including IL6, TNFα and IL1β [509, 586, 587]. In 
this chapter, elevated levels of TNFα and IL6 were seen in hip fracture patients with 
depressive symptoms compared with patients without depressive symptoms and healthy 
controls 
[522]
. This is consistent with the findings of a previous study in which older hip 
fracture patients with high levels of pro-inflammatory cytokines such as IL6 also had higher 
GDS scores 
[588]
. Epidemiological studies have also reported an association between IL6 and 
depressive symptoms in older people 
[589, 590]
. Further, studies in animal models have shown 
that administration of pro-inflammatory cytokines is known to induce ‘sickness behaviour’ 
resulting in behavioural changes including ; sleep disturbance, loss of appetite, memory 
impairment and loss of interest in social activities that overlap with many of the symptoms 
of depression in humans 
[591, 592]
. This ‘sickness behaviour can be reversed on withdrawal of 
cytokines 
[593]
. A few studies conducted in older adults have suggested that inflammation 
might play a potential causal role in the development of depressive symptoms 
[594, 595]
. 
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Interestingly, IL6 knockout mice are resistant to development of stress-associated 
depression-like behaviour 
[596]
, suggesting that elevated levels of pro-inflammatory 
cytokines in certain hip fracture patients might increase the risk of development of 
depressive symptoms.  
As discussed previously, depressive symptoms is associated with HPA axis hyperactivity, 
resulting in elevated cortisol levels. Interestingly, there is evidence to suggest that pro-
inflammatory cytokines (IL6, TNFα, and IL1β) have neuromodulatory properties and can 
result in activation of the HPA axis 
[597-599]
. Glucocorticoid resistance has been suggested as 
a potential mechanism relevant to HPA axis activation induced by pro-inflammatory 
cytokines 
[510, 600]
. In the present study, depressive symptom scores significantly correlated 
with IL6 levels, but there was no association between serum cortisol levels and IL6.  
Anti-inflammatory cytokines, such as IL10 are responsible for reducing production of pro-
inflammatory cytokines and dampening immune responses 
[312]
. In this thesis, in addition to 
an elevation in levels of pro-inflammatory cytokines, an elevated serum IL10 was seen in 
hip fracture patients with depressive symptoms 
[522]
. A similar elevation of IL10 levels has 
been previously reported in depressed individuals 
[601, 602]
 and in animal models of 
depressive behaviour 
[603] 
which might be a counter regulatory mechanism to reduce 
inflammatory responses and restore homeostasis 
[601]
.  
Chronic stress induced adverse health consequences and immune dysregulation may persist 
even after chronic stress has abated 
[357, 604, 605]
. This lasting, detrimental effect of stress 
might reflect a premature ageing of the immune system associated with chronic stress 
[606]
.  
Interestingly, studies done on long term follow up have reported that the mortality 
disadvantage in hip fracture patients  can persist for up to five years after the fracture 
[607, 
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608]
. Recovery after hip fracture is a long process and only one-third hip fracture patients 
return to their pre-fracture functional status one year post-surgery 
[422]
. In this chapter, it was 
observed that neutrophil superoxide generation in hip fracture patients with depressive 
symptoms had improved after 6 months, but monocyte superoxide generation and NK cell 
cytotoxicity remained impaired in the depressed hip fracture patients 6 months post-surgery.  
Additionally, perforin expression on NK cells in hip fracture patients with depressive 
symptoms did not improve even 6 months post-surgery and might contribute towards 
suppressed NK cell function in these patients 6 month post-surgery. Elevated serum cortisol: 
DHEAS ratio was also observed in the hip fracture patients with depressive symptoms at the 
six month time point. 
In summary, this chapter shows for the first time that depressive symptoms in hip fracture 
patients is characterised by suppression of neutrophil and monocyte superoxide generation, 
reduced NK cell cytotoxicity, elevated pro-inflammatory cytokine levels and an increased 
serum cortisol:DHEAS ratio. These effects were not seen in patients with hip fracture alone. 
Further, this suppressed monocyte and NK cell functioning observed in hip fracture patients 
with depressive symptoms persisted six months after surgery and did not improve with time. 
Taken together the data suggest that development of depressive symptoms after a hip 
fracture is the main driver of immune dysregulation in these patients post-surgery.  
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                            Chapter 4 
 
The synergistic effects of                       
physical and psychological distress on                 
adaptive immune functioning 
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4.1 Introduction 
 
4.1.1 Background 
Ageing is accompanied by a range of alterations in the adaptive immune system resulting in 
reduced adaptive function such as vaccination responses (reviewed in chapter 1). Similarly, 
chronic stress has also been associated with remodelling of the immune system and reduced 
immunity similar to that seen in ageing including; reduced levels of lymphocytes 
[609, 610]
, 
altered ratio of helper to suppressor T cells 
[611]
, accumulation of senescent T cells 
[612, 613]
, 
reduced telomere length and greater telomerase activity 
[614-616]
, impairment in proliferation 
responses to mitogens 
[494, 617]
 and a shift in CD4 helper response from a Th1 to Th2 
phenotype 
[618, 619]
. Although  data regarding the effect of chronic stress on Th17 cells is 
limited a recent study reported an increase in inflammatory Th17 cells in mice with 
depression like behaviour 
[620]
. Further, the decrement in functioning of the thymus that 
occurs with normal ageing has also been reported to occur during periods of psychological 
stress 
[621, 622]
.  
Exposure to chronic stress is accompanied by HPA axis hyperactivity 
[363, 623]
. In the 
previous chapter, it was reported that an elevated serum cortisol: DHEAS ratio occurs in hip 
fracture patients with depressive symptoms. Importantly, a range of immune modulating 
effects of cortisol on T lymphocytes have been previously reported including; increased T 
cell apoptosis 
[624]
, reduced telomerase activity 
[625]
, a
 
shift towards Th2 lineage commitment 
[624, 626]
 and dysregulated cytokine production 
[627, 628]
. The literature regarding the effect of 
chronic stress on B cells is limited. A few studies have reported that circulating numbers of 
B cells remain unaltered on exposure to chronic stress 
[629]
. Moreover, no study has 
examined the effect of glucocorticoids on B cell function or phenotype.  
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Regulatory immune cells play an essential role in maintaining immune homeostasis. An age 
associated increase in Treg frequency and a decline in suppressive capacity of regulatory T 
cells have been previously discussed (reviewed in chapter 1). Additionally, chronic stressors 
have been associated with numerical and functional alterations in CD4
+ve
CD25
+ve
Foxp3
+ve
 
Tregs 
[630, 631]
. Further, a novel subset of CD19
+ve
CD24
hi
CD38
hi
 B cells with 
immunosuppressive properties has been recently identified in humans 
[301]
. In this thesis, it 
was shown for the first time that the frequency of CD19
+ve
CD24
hi
CD38
hi
 B cells and their 
ability to produce IL10 post-stimulation declines with age (described in chapter 2) and that 
this correlated with an age-related increase in serum autoantibody (RF) in healthy older 
adults 
[441]
. However, the effect of chronic stress on this novel subset of immunoregulatory B 
cells remains unexplored.  
4.1.2 Aims  
In the previous chapter the effects of development of depressive symptoms post hip fracture 
on phenotype and functional capacity of innate immune cells was determined. Additionally, 
HPA axis abnormalities and elevated pro-inflammatory cytokine levels were reported in hip 
fracture patients with depressive symptoms.  In this chapter, the aim was to examine if the 
psychological distress of depressive symptoms could act additively with the physical stress 
of hip fracture to amplify the effect of ageing upon adaptive immunity and determine 
possible mediators of the additive effects.  
(a) To examine the effect of physical and psychological distress on total peripheral T cell 
count, CD4:CD8 ratio, naïve: memory T cell ratio and frequency of senescent and activated 
T cells.  
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(b) Determine if emergence of depressive symptoms in hip fracture patients exerts an effect 
on frequency of regulatory immune cells, especially CD4
+ve
CD25
+ve
 Foxp3
+ve
 (Tregs) and 
CD19
+ve
CD24
hi
CD38
hi
 (Bregs) and their IL10 production capacity.  
(c) Test for role of cortisol: DHEAS ratio and the balance of pro- and anti-inflammatory 
cytokines as potential mediators of any additive effects observed. 
(d) To test the longevity of alterations in immune status in hip fracture patients by repeating 
tests in which differences were observed at the six month time point.  
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4.2. Materials and Methods  
4.2.1 Solutions and Antibodies 
Freezing Medium:  10% DMSO in HiFCS 
Antibody  Dilution  Company 
Anti-human CD3 PEcy7 (clone ׃ UCHT1) 1/100 eBiosciences 
Anti-human CD3 APCcy7 (clone ׃ HIT3a) 1/100 Biolegend 
Anti-human CD4 Alexa fluor 450 (clone ׃ RPA-T4 ) 1/100 eBiosciences 
Anti-human CD8 PE (clone ׃ UCHT4) 1/100 Immunotools 
Anti-human CCR7 FITC (clone ׃ 150503 ) 1/20 R and D systems 
Anti-human CD45RA APC (clone ׃ HI-100 ) 1/500 Biolegend 
Anti-human CD25 APC (clone ׃ BC-96 ) 1/20 Biolegend 
Anti-human CD28 APC (clone ׃ CD28.2 ) 1/200 BD biosciences 
Anti-human CD57 FITC (clone ׃ HCD57 ) 1/50 eBiosciences 
Anti-human  foxp3 PE 1/10 Biolegend 
 
Table 4.1 List of primary antibodies used for flow cytometry. 
4.2.2 Flow cytometric staining of T cells  
Frozen PBMCs were thawed and washed in RPMI (described in section 2.2.4) and the 
pelleted cells were re-suspended in PBS (1 x 10
6
 cells/ml) and 100 μl of cells in PBS were 
incubated for 20 minutes in the dark at 4C with combinations of antibodies including; anti-
human CD3-PEcy7 (eBiosciences, UK), anti-human CD4 Alexa fluor 450 (eBiosciences, 
UK), anti-human CD8 PE (Immunotools, UK), anti-human CCR7 FITC (R and D systems, 
UK) and anti-human CD45RA APC (Biolegend, UK). Post incubation, cells were washed 
twice with 300 μl of PBS and centrifuged at 250 x g for 5 minutes. Post washing, pelleted 
cells were resuspended in 300 μl of PBS for flow cytometric analysis using a Cyan TM ADP 
(Dako Ltd, UK). T cells can be classified into four distinct subsets on the basis of expression 
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of cell surface markers, CCR7 and CD45RA; naïve (CD45RA
+ve
 CCR7
+ve
), central memory 
(CD45RA
-ve
 CCR7 
+ve
), effector memory (CD45RA
-ve
 CCR7
-ve
) and effector memory RA 
(CD45RA
-ve
 CCR7
–ve
) [Figure 4.1] 
[183, 184]
.  
100 μl of isolated PBMCs resuspended in PBS (1 x 106/ml) in FACS tubes (Becton 
Dickinson, UK) were immunostained with a combination of fluorochrome conjugated 
antibodies including; anti-human CD3-PEcy7 (eBiosciences, UK), anti-human CD4 Alexa 
fluor 450  (eBiosciences, UK), anti-human CD8-PE (Immunotools, UK), anti-human CD28 
APC (BD Biosciences, UK), anti-human CD57 FITC (eBiosciences, UK) ,anti-human 
NKG2D PEcy7 (eBiosciences , UK) , anti-human CD69 FITC (eBiosciences, UK), anti-
human CD25 APC (Biolegend, UK) and anti-human HLADR PE (eBiosciences, UK) for 20 
minutes in dark at 4C. Post incubation, cells were washed twice with 300 μl of PBS and 
centrifuged at 250 x g for 5 minutes. Post washing, pelleted cells were resuspended in 300 μl 
of PBS for flow cytometric analysis using a Cyan 
TM
 ADP (Dako Ltd, UK).  Results have 
been expressed both as the percentage of T cells that were CD28
+ve
, CD28
-ve
, CD57
+ve
 and 
NKG2D
+ve
 to identify senescent T cells. Additionally, the percentage of T cells that were 
CD69
+ve
, CD25
+ve
 and HLADR
+ve
 were identified as activated T cells. 
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Figure 4.1 Identification of T cell subsets by immunostaining using flow cytometry.  
PBMCs from a young individual were stained with anti-CD3, CD4, CD8, CD45RA and 
CCR7 antibodies. T cells (CD3
+
) were gated (a) to identify CD4 and CD8 T cells (b). (c) 
Schematic representation of T cells subsets identified on basis of CD45RA and CCR7 
expression. 
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4.2.3 Foxp3 staining of Regulatory T cells 
To detect regulatory T cells, 100 μl of isolated PBMCs resuspended in PBS (1 x 106/ml) 
were transferred into FACS tubes (Becton Dickinson, UK) and cells were stained with anti-
human CD3-PEcy7 (eBiosciences, UK), anti-human CD4 Alexa fluor 450 (eBiosciences, 
UK) and anti-human CD25 APC (Biolegend, UK) antibodies as described above (section 
4.2.2) for 20 minutes in dark at 4C. Post incubation, cells were washed with 300 μl PBS 
and centrifuged at 250 x g for 5 minutes. Post washing, the cells were re-suspended in 1 ml 
of foxp3 Fix Perm Working solution prepared by doing a 1:3 dilution of the foxp3 fix perm 
concentrate (eBiosciences , UK) with foxp3 diluent (eBiosciences , UK) and then left for 30 
minutes in dark at room temp. Post incubation, cells were washed with 2 ml of 1x foxp3 
permeabilization buffer (eBiosciences, UK) prepared by doing a 1:10 dilution with 
deionized water and centrifuged at 250 x g for 5 minutes. Post centrifugation, 100 μl of 1 x 
permeabilization buffer and anti-human foxp3 PE antibody (eBiosciences, UK) was added to 
the cells and left for incubation for 30 minutes in dark at room temp. Finally, the cells were 
washed with 2 ml of 1 x permeabilization buffer and were centrifuged at 250 x g for 5 
minutes. Pelleted cells were resuspended in 300 μl of PBS for flow cytometric analysis on 
Cyan 
TM
 ADP (Dako Ltd , UK) and the percentage of CD3
+ve
 CD4
+ve
 CD25
+ve
 Foxp3
+ve
 T 
cells were recorded [Figure 4.2]. 
4.2.4 Stimulation of PBMCs to induce IL10 production  
Human cell cultures were performed in complete RPMI1640 (Sigma Aldrich, UK) 
containing 10% HiFCS (Biosera, UK) supplemented with glutamine/penicillin/streptomycin 
(Life Technologies, UK). PBMCs were stimulated for 4 hr with PMA (50 ng/ml; Sigma 
Aldrich, UK) and Ionomycin (500ng/ml; Sigma Aldrich, UK) in presence of Brefeldin A 
(10μg/ml; Sigma Aldrich, UK). Post stimulation, cells were transferred into FACS tubes 
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(Becton Dickinson, UK) and centrifuged at 250 x g for 5 minutes and washed twice with 
300 μl PBS. Pelleted cells were re-suspended in 100 μl PBS and stained using anti-human 
CD3 APCcy7 (eBiosciences, UK) and anti-human CD4 Alexa fluor 450 (eBiosciences, UK) 
for 20 min in the dark at 4C. Post immunostaining, cells were washed with 300 μl PBS and 
centrifuged at 250 x g for 5 minutes. The cells were re-suspended in 50 μl Reagent A (Fix 
and Perm kit, Invitrogen, UK) and incubated for 30 minutes in the dark at room temperature. 
Post incubation, cells were washed with 300 μl PBS and centrifuged at 250 x g for 5 
minutes. The pelleted cells were re-suspended in 50 μl Reagent B (Fix and Perm kit, 
Invitrogen, UK) and anti-human IL10 Alexa fluor 647 (eBiosciences , UK) was added and 
samples were incubated in the dark at room temperature for 30 minutes. Post incubation, the 
cells were washed with 300 μl PBS and centrifuged at 250 x g for 5 minutes and 
resuspended in 300 μl PBS for flow cytometric analysis on a Cyan TM ADP (Dako Ltd , 
UK). The percentage of IL10
+ve
 CD4 T cells and the IL10 expression levels (MFI) was 
recorded.  
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Figure 4.2 Gating strategy used to identify Regulatory T cells  
PBMCs were stained for surface expression of CD3, CD4 and CD25, after which cells were 
fixed, followed by intracellular staining for Foxp3. (a) Firstly lymphocytes were gated on 
the basis of forward and side light scatter properties; (b) after gating on lymphocytes 
CD3
+ve
CD4
+ve
 T cells and (c) CD25
+ve
 Foxp3
+ve
 CD4 T cells were gated, indicating the 
frequency of regulatory T cells in CD4 T cells. 
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4.3 Results 
4.3.1 T cell subsets in hip fracture patients  
Firstly, significant differences were observed in the percentages of CD3
+ve
 T cells in the 
PBMC pool between our three subject groups, F (2, 90) = 3.58, p = .03, η2 = .07, [Figure 
4.3a], which was driven by a significant decline in the percentage of T cells in hip fracture 
patients with depressive symptoms compared with healthy controls, p = .03, but not with hip 
fracture patients without depressive symptoms, p = .75. Further, on examining the absolute 
numbers of T cells significant differences were seen between our three subject groups, F (2, 
50) = 6.91, p =.002, η2 = .21 [Figure 4.3b], driven by a significant decline in T cell numbers 
in hip fracture patients with depressive symptoms compared with hip fracture patients 
without depressive symptoms, p = .03 and a further drop was observed on comparison with 
healthy controls, p = .003. When the above analyses were repeated with adjustment for age, 
sex and BMI, the results still remained significant (data not shown).  
 
On further analysis, no significant association was observed between GDS scores and 
frequency of peripheral T cells, β = -.15, p = .24, ΔR2 = .02 or absolute T cell numbers, β = -
.15, p = .40, ΔR2 = .02 in hip fracture patients (data not shown).  
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Figure 4.3 Frequency of peripheral T lymphocytes in hip fracture patients.   
(a) Percentage CD3
+ve
 T cells in healthy controls (n=36), hip fracture patients without 
depressive symptoms (HF; n=31) and hip fracture patients with depressive symptoms 
(HF+D; n=26). The solid bar represents the mean value. (b) Absolute numbers of T cells in 
healthy controls (n=20), hip fracture patients without depressive symptoms (HF; n=18) and 
hip fracture patients with depressive symptoms (HF+D; n=15). Data are mean ± SEM.  * p 
<.05, ** p <.005. 
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Next , on comparing peripheral T cell frequency in hip fracture patients six weeks and six 
months post-surgery, there was no significant effect of time , F (1, 28) = .69, p = .41, η2 = 
.02 [Figure 4.4] and no significant group x time interaction, F (1, 28) = .10, p = .75, η2 = 
.004. Both groups of hip fracture patients did not differ in the T cell frequency six months 
after surgery, p = .77. These findings are not surprising; as there was no significant 
difference in T cell frequency at the 6 week time point between the two groups of hip 
fracture patients. The absolute T cell numbers in hip fracture patients at 6 month time point 
was not measured as the whole blood count data at 6 month time point for hip fracture 
patients was not collected. 
T lymphocytes are composed of two main subsets, CD4 T cells (helper T cells) and CD8 T 
cells (cytotoxic T cells). No differences were found in the percentage of CD4
+ve
 T cells 
between our three groups, F (2, 85) = 2.40, p = .09, η2 = .05 [Table 4.2]. However, a 
significant difference occurred in absolute number of CD4
+ve
 T cells, F (2, 51) = 5.87, p = 
.005, η2 = .19, [Table 4.2], driven by a significant decline in absolute numbers of CD4 T 
cells in hip fracture patients with depressive symptoms compared with healthy controls, p = 
.005. No significant differences were observed in the percentage of CD8 T cells, F (2, 85) = 
1.52, p = .22, η2 = .03 [Table 4.2] or in absolute number of CD8 T cells between the three 
groups, F (2, 51) = .27, p = .27, η2 = .04 [Table 4.2]. Thus, no significant differences 
occurred in the CD4:CD8 ratio between the three groups, F (2, 85) = 2.16, p = .12, η2 = .04 
[Table 4.2]. 
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Figure 4.4 Frequency of circulating T cells in hip fracture patients six weeks and six 
months post-surgery.  
Frequency of T cells in hip fracture patients without depressive symptoms (HF; n=12) and 
hip fracture patients with depressive symptoms (HF+D; n=18) at 6 weeks and 6 months 
post-surgery. Data are mean ± SEM. 
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Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD4
+ve
 T cells (%) 65.55 (10.57) 70.90 (10.92) 70.62 (11.15) .09 
Absolute numbers (10
6
/ml) .84 (.26) .65 (.28) .55 (.22) .005 
CD8
+ve
 T cells (%) 28.31 (10.01) 24.89 (10.26) 23.83 (11.53) .22 
Absolute numbers (10
6
/ml) .32 (.22) .25 (.16) .21 (.18) .27 
CD4:CD8 ratio 2.80 (1.76) 3.84 (3.24) 4.02 (2.68) .12 
 
Table 4.2 The distribution of CD4 and CD8 T cells in hip fracture patients. 
 
As previously discussed, CD4 and CD8 T cells can be divided into different subsets, on the 
basis of expression of CD45RA and the chemokine receptor CCR7, namely naïve, central 
memory (CM), effector memory (EM) and terminally differentiated effector memory cells 
(EMRA)
[183]
. On examining the percentage, F (2, 85) = .13, p = .87, η2 = .003, and absolute 
numbers of naïve CD4 T cells, F (2, 51) = 2.07, p = .13, η2 = .07 no significant differences 
were found in these cells in peripheral blood of our three subject groups [Table 4.3]. For 
memory CD4 T cell subsets, no significant differences occurred in percentages, F (2,86) = 
.90, p = .40, η2 = .02, or absolute numbers F (2, 51) = 1.37, p = .26, η2 = .05,  of central 
memory CD4 T cells or in the percentage, F (2, 86) = .20, p = .81, η2 = .005, or in absolute 
numbers, F (2, 51) = .77, p = .46, η2 = .03, of effector memory CD4 T cells between our 
three groups [Table 4.3]. Finally, no significant differences were seen in the percentage, F 
(2, 86) = .23, p = .79, η2 = .005, or in absolute numbers of EMRA CD4 T cells, F (2, 51) = 
1.83, p = .16, η2 = .06, between our three groups [Table 4.3]. 
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 Finally, the naïve: memory ratio in CD4 T cells also did not significantly differ between hip 
fracture patients with and without depressive symptoms and healthy controls, F (2, 89) = 
.21, p = .80, η2 = .005 [Table 4.3].   
 
Next, the distribution of naïve and memory cell subsets amongst CD8 T cells was examined. 
No differences were observed in the percentage, F (2, 85) = .05, p = .94, η2 = .001, or 
absolute numbers of naïve CD8 T cells F (2, 51) = 1.77, p = .18, η2 = .06, between the three 
groups [Table 4.3]. On examining memory CD8 T cell subsets, no significant differences 
were observed in: percentages , F (2,85) = 1.34, p = .26, η2 = .03, or absolute numbers F (2, 
51) = .80, p = .45, η2 = .03 of central memory CD8 T cells;  percentage  F (2, 85) = 2.77, p = 
.07, η2 = .06, or absolute numbers of effector memory CD8 T cells F (2, 51) = 1.21, p = .30, 
η2 = .04; or the percentage F (2, 85) = .55, p = .57, η2 = .01, or absolute numbers of EMRA 
CD8 T cells, F (2, 51) = .50, p = .60, η2 = .01, between the subject groups [Table 4.3]. 
 Similarly, the naïve: memory ratio in CD8 T cells did not significantly differ between hip 
fracture patients with and without depressive symptoms and healthy controls, F (2, 86) = 
.12, p = .89, η2 = .003, [Table 4.3].  
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Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD4 T cells     
Naïve CD4 T cells (%) 38.92 (19.65) 36.87 (20.55) 36.55 (18.11) .87 
Absolute numbers (10
6
/ml) .35 (.27) .22 (.22) .21 (.15) .13 
CM CD4 T cells (%) 3.49 (6.99) 3.49 (3.37) 5.38 (6.98) .40 
Absolute numbers (10
6
/ml) .01 (.01) .03 (.02) .02 (.02) .26 
EM CD4 T cells (%) 19.38 (10.62) 20.33 (10.93) 21.39 (15.31) .81 
Absolute numbers (10
6
/ml) .14 (.07) .14 (.11) .10 (.08) .46 
EMRA CD4 T cells (%) 38.40 (17.15) 40.10 (17.36) 36.96 (16.42) .79 
Absolute numbers (10
6
/ml) .31 (.14) .26 (.17) .22 (.10) .16 
Total memory CD4 T cells 
(%) 
61.07 (19.64) 63.16 (20.54) 63.44 (18.04) .87 
Absolute numbers (10
6
/ml) .46 (.14) .39 (.21) .34 (.15) .12 
Naïve:memeory ratio .82 (.87) .87 (.84) .73 (.63) .80 
CD8 T cells     
Naïve CD8 T cells (%) 16.98 (16.12) 15.73 (13.11) 16.61 (13.89) .94 
Absolute numbers (10
6
/ml) .05 (.07) .02 (.04) .02 (.01) .18 
CM CD8 T cells (%) 26.55 (14.61) 33.17 (20.09) 32.03 (16.01) .26 
Absolute numbers (10
6
/ml) .06 (.06) .10 (.11) .09 (.09) .45 
EM CD8 T cells (%) 41.04 (13.27) 33.40 (16.16) 33.56 (14.44) .07 
Absolute numbers (10
6
/ml) .13 (.09) .09 (.10) .09 (.08) .30 
EMRA CD8 T cells (%) 14.44 (11.09) 17.02 (13.50) 17.63 (13.64) .57 
Absolute numbers (10
6
/ml) .04 (.04) .04 (.09) .02 (.02) .60 
Total memory CD8 T cells 
(%) 
83.01 (16.12) 83.99 (12.89) 82.43 (14.65) .92 
Absolute numbers (10
6
/ml) .27 (.20) .21 (.16) .19 (.19) .39 
Naïve:memeory ratio .26 (.41) .23 (.26) .28 (.45) .89 
Table 4.3 Naive and memory T lymphocytes in hip fracture patients. 
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4.3.2 Accumulation of senescent T cells in hip fracture patients  
CD28 is a co-stimulatory molecule involved in T cell activation, proliferation, cytokine 
production and survival 
[192]
. Ageing has been associated with an increase in CD28
-ve
 cells 
which have reduced function and have been considered as senescent.  On examining the 
frequency of circulating CD28
-ve
T cells, there were significant differences, F (2, 56) = 8.16, 
p = .001, η2 = .22 between our three groups of subjects, driven by a significant increase in 
the percentage of CD28
-ve
 T cells in hip fracture patients with depressive symptoms 
compared with healthy controls, p = .001 and hip fracture patients without depressive 
symptoms, p = .02 [Table 4.4].  The frequency of CD28
-ve 
CD4T cells also significantly 
differed between groups, F (2, 56) = 6.11, p = .004, η2 = .17 [ Table 4.4], but was limited to 
an increase in frequency of CD28
-ve
 CD4 T cells in hip fracture patients with depressive 
symptoms compared with healthy controls, p = .001 and hip fracture patients without 
depressive symptoms, p = .02. Similarly, the frequency of CD28
-ve 
CD8T cells was also 
significantly different, F (2, 56) = 6.69, p = .002, η2= .19 between our three groups [Table 
4.4], and a significant increase in the frequency of CD28
-ve
 CD8 T cells occurred only in hip 
fracture patients with depressive symptoms compared with healthy controls, p = .003 and 
hip fracture patients without depressive symptoms, p = .02. When the above analyses were 
repeated with adjustment for age, sex and BMI, the results still remained significant. As a 
consequence of the above, significant differences were seen in CD28
+ve
 T cells [Table 4.4]. 
However, CD28 expression levels (MFI) on T cells did not significantly differ between our 
subjects groups (data not shown). 
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Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD28
-ve
 T cells (%) 17.75 (7.47) 20.50 (6.14) 29.14 (12.98) .001 
CD28
+ve
 T cells (%) 82.24 (7.47) 78.20 (8.18) 70.85 (12.98) .002 
CD28
-ve
 CD4 T cells (%) 6.41 (5.34) 8.20 (4.48) 13.96 (10.31) .004 
CD28
+ve
 CD4 T cells (%) 93.58 (5.33) 91.19 (5.66) 85.50 (11.35) .006 
CD28
-ve
 CD8 T cells (%) 36.32 (16.25) 38.82 (11.43) 52.29 (15.48) .002 
CD28
+ve
 CD8 T cells (%) 63.36 (16.14) 59.62 (14.54) 47.67 (15.49) .006 
 
Table 4.4 CD28
 
expression on T lymphocytes in hip fracture patients. 
The expression of CD57 on T cells has also been identified as a marker for cell senescence 
[632]
. Significant differences in CD57
+ve
 T cells, F (2, 56) = 4.05, p = .02, η2 = .12 were 
observed between our three groups [Table 4.5], driven by an increase in the percentage of 
CD57
+ve
 T cells in hip fracture patients with depressive symptoms compared with healthy 
controls, p = .02 but not in comparison with hip fracture patients without depressive 
symptoms, p = .68. Further, on examining frequency of CD57
+ve 
CD4 T cells significant 
differences, F (2, 56) = 6.82, p = .002, η2 = .19 were found between our three groups [Table 
4.5], due to accumulation of CD57
+ve
 CD4 T cells in hip fracture patients with depressive 
symptoms compared with healthy controls, p = .002 only and but not in comparison with hip 
fracture patients without depressive symptoms, p = .10. Similarly, frequency of CD57
+ve 
CD8 T cells was also significantly different, F (2, 56) = 5.36, p = .007, η2 = .16 between our 
three groups [Table 4.5], due to an increase in CD57
+ve
 CD8 T cells in hip fracture patients 
with depressive symptoms compared with healthy controls, p = .005 only and not in 
comparison with hip fracture patients without depressive symptoms, p = .33.  
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When the above analyses were repeated with adjustment for age, sex and BMI, the results 
remained significant. However, no significant differences were reported in CD57 expression 
levels (MFI value) on T lymphocytes between our three groups (data not shown).  
Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD57
+ve
 T cells (%) 12.56 (9.04) 17.57 (7.31) 21.89 (14.23) .02 
CD57
+ve
 CD4 T cells (%) 4.29 (3.36) 6.86 (4.26) 11.24 (9.25) .002 
CD57
+ve
 CD8 T cells (%) 25.31 (17.89) 33.37 (13.43) 42.55 (18.60) .007 
 
Table 4.5 CD57
 
expression on T lymphocytes in hip fracture patients. 
Finally, on examining frequency of CD28
-ve
 CD57
+ve
 T cells, significant differences were 
seen F (2, 56) = 5.25, p = .008, η2 = .15 between our three groups [Figure 4.5a], driven by 
accumulation of CD28
-ve
CD57
+ve
 T cells in hip fracture patients with depressive symptoms 
compared with healthy controls, p = .008 only and not in comparison with hip fracture 
patients without depressive symptoms, p = .33. Similarly, on examining frequency of CD28
-
ve
CD57
+ve CD4 T cells significant differences, F (2, 56) = 6.28, p = .003, η2 = .18 occurred 
[Figure 4.5b], due to increased frequency of CD28
-ve
 CD57
+ve
 CD4 T cells in hip fracture 
patients with depressive symptoms compared with healthy controls, p = .002, but not on 
comparison with hip fracture patients without depressive symptoms, p = .13. The frequency 
of CD28
-ve 
CD57
+ve
 CD8 T cells were also significantly different, F (2, 56) = 4.12, p = .02, 
η2 = .12 between our three groups [Figure 4.5c], due to a significant increase in frequency of 
CD28
-ve
 CD57
+ve
 CD8 T cells in hip fracture patients with depressive symptoms compared 
with healthy controls, p = .02 but not in comparison with hip fracture patients without 
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depressive symptoms, p = .49. When the above analyses were repeated with adjustment for 
age, sex and BMI, the results still remained significant (data not shown).On further analysis, 
no significant association was found between GDS scores and frequency of peripheral 
CD28
-ve
 T cells, β = .23, p = .16, ΔR2 = .05; peripheral CD57+ve T cells, β = .09, p = .59, 
ΔR2 = .009 or CD28-ve CD57+ve T cells in hip fracture patients, β = .11, p = .51, ΔR2 = .01 ( 
data not shown).  
NKG2D is a known NK cell receptor that is also expressed on T cells and acts as a marker 
of senescence 
[202]
. On examining NKG2D expression on T cells, no significant differences  
were observed in the frequency of NKG2D
+ve
 T cells, F (2, 28) = .13, p = .87, η2 = .009, or 
the frequency of NKG2D
+ve
 CD4 T cells F (2, 28) = .07, p = .93, η2 = .005, or NKG2D+ve 
CD8 T cells  F (2, 28) = .30, p = .73, η2 = .02 [Table 4.6], between the three groups. Further, 
no significant differences were reported in NKG2D expression levels (MFI) on T 
lymphocytes between our three groups (data not shown).  
 
Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
NKG2D
+ve
 T cells (%) 9.28 (5.25) 10.03 (4.38) 10.50 (5.57) .87 
NKG2D
+ve
 CD4 T cells (%) 5.50 (4.05) 5.55 (2.30) 5.11 (2.96) .93 
NKG2D
+ve
 CD8 T cells (%) 16.15 (7.16) 13.56 (5.63) 15.12 (7.59) .73 
 
Table 4.6 NKG2D
 
expression on T lymphocytes in hip fracture patients. 
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Figure 4.5 CD28
-ve
 CD57
+ve
 T lymphocytes in hip fracture patients.   
Percentage of  (a) CD28
-ve
CD57
+ve 
T cells, (b) CD28
-ve
CD57
+ve 
CD4T cells, or (c) CD28
-
ve
CD57
+ve 
CD8 T cells in healthy controls (n=23), hip fracture patients without depressive 
symptoms (HF; n=19) and hip fracture patients without depressive symptoms (HF + D; 
n=17). The solid bar represents the mean value. * p <.05. 
 
 
 
 
a                                                               
b                                                              c 
    
     
   n.s 
n.s 
n.s n.s 
n.s 
n.s
  
* 
* 
*   
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4.3.3 Activated T cells in hip fracture patients  
CD69 (early), CD25 (middle) and HLA-DR (late) are markers for T cell activation 
[633, 634]
. 
In an attempt to examine activation status of circulating T cells in hip fracture patients the 
expression of these activation markers on T lymphocytes was compared. The percentage of 
CD69
+ve
 T cells, showed significant differences, F (2, 53) = 4.65, p = .01, η2 = .15, driven by 
a significant increase in the percentage of CD69
+ve
 T cells in hip fracture patients with 
depressive symptoms compared with healthy controls, p = .01 only and not in comparison 
with hip fracture patients without depressive symptoms, p = .12 (data not shown). When the 
above analyses were repeated with adjustment for age, sex and BMI, the results still 
remained significant (data not shown). Next, on comparing the frequency of CD69
+ve
 CD4 T 
cells F (2, 53) = 2.59, p = .08, η2 = .08 [Figure 4.6a] no significant differences were observed 
between our three groups. However, significant differences occurred in the percentage of 
CD69
+ve
 CD8 T cells, F (2, 53) = 3.50, p = .03, η2 = .11, driven by a significant increase in 
percentage of CD69
+ve
 CD8 T cells in hip fracture patients with depressive symptoms 
compared with healthy controls, p = .04 but not in comparison with hip fracture patients 
without depressive symptoms, p = .17 [Figure 4.6b]. Suggesting, an accumulation of 
activated CD69
+ve
 CD8 T cells in the hip fracture patients with depressive symptoms. 
 No significant association was found between GDS scores and frequency of peripheral 
CD69
+ve
 T cells, β = .24, p = .14, ΔR2 = .05 (data not shown). Finally, no significant 
differences were reported in CD69 expression levels (MFI value) on T lymphocytes between 
our three groups (data not shown).  
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Figure 4.6. CD69 expression on CD4 and CD8 T lymphocytes in hip fracture patients 
Frequency of (a) CD69
+ve 
CD4 T cells  or (b) CD69
+ve 
CD8 T cells in healthy controls 
(n=19), hip fracture patients without depressive symptoms (HF; n=19) and hip fracture 
patients with depressive symptoms (HF+D; n=19). The solid bar represents the mean value. 
* p <.05. 
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Next, on examining peripheral distribution of CD25
+ve
 T cells no significant differences 
were found, F (2, 40) = 1.41, p = .25, η2 = .06 between our three groups [Table 4.8]. 
Similarly, no differences were reported between distribution of CD25
+ve
 T cells in the CD4 
T cell subset F (2, 40) = .63, p = .53, η2 = .03, or the CD25+ve T cells in CD8 T cell subset F 
(2, 40) = .57, p = .56, η2 = .02 [Table 4.8], between the three groups. However, no 
significant differences were reported in CD25 expression levels (MFI value) on T 
lymphocytes between our three groups (data not shown).  
 
Variable Healthy 
control 
Hip fracture 
patients (HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
CD25
+ve
 T cells (%) 3.48 (1.73) 3.98 (1.08) 4.37 (1.35) .25 
CD25
+ve
 CD4 T cells (%) 5.85 (1.73) 6.14 (1.60) 6.28 (1.32) .76 
CD25
+ve
 CD8 T cells (%) 4.42 (2.05) 5.02 (1.31) 4.66 (.96) .56 
 
Table 4.8. CD25 expression on T lymphocytes in hip fracture patients. 
 
 
 
 
 
 
 
 
  
210 | P a g e  
 
Finally, on examining peripheral distribution of HLADR
+ve
 T cells, significant differences 
were observed, F (2, 48) = 3.43, p = .04, η2 = .13 between our three groups (data not shown), 
driven by an increase in percentage of HLADR
+ve
 T cells in hip fracture patients with 
depressive symptoms compared with healthy controls, p = .03 but not on comparison with 
hip fracture patients without depressive symptoms, p = .55. When the above analyses were 
repeated with adjustment for age, sex and BMI, the results still remained significant (data 
not shown). Further, on comparing frequencies of HLADR
+ve
 CD4 T cells between our three 
groups, F (2, 48) = 1.76, p = .18, η2 = .06 [Figure 4.7a] no significant differences were 
found. In contrast, significant differences occurred in HLADR
+ve
 CD8 T cells, F (2, 48) = 
7.72, p = .001, η2 = .24, driven by an increase in percentage of HLADR+ve CD8 T cells in 
hip fracture patients with depressive symptoms compared with healthy controls, p = .001 but 
not in comparison with hip fracture patients without depressive symptoms, p = .06 [Figure 
4.7b]. Suggesting, an accumulation of activated HLADR
+ve
 T cells only in the CD8 T cell 
subset of hip fracture patients with depressive symptoms. No significant association was 
reported between GDS scores and frequency of peripheral HLADR
+ve
 T cells, β = .26, p = 
.12, ΔR2 = .07. Also, no significant differences were reported in HLADR expression levels 
(MFI value) on T lymphocytes between our subject groups (data not shown). 
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Figure 4.7. HLADR expression on CD4 and CD8 T lymphocytes in hip fracture 
patients. 
Percentage of (a) HLADR
+ve 
CD4 T cells or (b) HLADR
+ve 
CD8 T cells in healthy controls 
(n=17), hip fracture patients without depressive symptoms (HF; n=18) and hip fracture 
patients with depressive symptoms (HF+D; n=16). The solid bar represents the mean value. 
* p <.05. 
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4.3.5 Regulatory T cells in hip fracture patients  
Tregs have been identified as a subpopulation of T cells expressing CD4, CD25 and the 
transcription factor foxp3 
[277, 635]
 that plays an essential role in Treg cell differentiation and 
development
[636]
. On examining circulating frequency of Tregs , no significant differences 
were observed between hip fracture patients with and without depressive symptoms and 
healthy older adults, F (2, 57) = 1.24, p = .29, η2 = .04 [Figure 4.8a]. Similarly, no 
significant differences were found between absolute numbers of regulatory T cells, F (2, 31) 
= .98, p = .38, η2 = 06 [Figure 4.8b] between our three subject groups.  
4.3.6 IL10 production by CD4 T cells in hip fracture patients  
Next, on examining IL10 production by CD4 T cells on stimulation with PMA and 
Ionomycin (4hr) significant differences were seen in the percentage of IL10 producing CD4 
T cells between our three groups, F (2, 50) = 4.93, p =.01, η2 = .16 [Figure 4.9a], driven by a 
significant increase in percentage of IL10
+ve
 CD4 T cells in hip fracture patients with 
depressive symptoms compared with healthy controls, p = .02 and hip fracture patients 
without depressive symptoms, p = .04.  However, no significant differences were observed 
in the amount of IL10 produced (MFI value) by CD4 T cells between our groups, F (2, 42) = 
.46, p =.63, η2 = .02 [Figure 4.9b]. Interestingly, there was a significant association between 
GDS scores and frequency of peripheral IL10
+ve 
CD4 T cells in hip fracture patients, β = .34, 
p = .04, ΔR2 = .11, such that hip fracture patients with greater depressive symptoms (GDS 
score) had higher frequency of IL10
+ve 
CD4 T cells [Figure 4.9c].  
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Further, on comparing frequency of IL10
+ve 
CD4 T cells in hip fracture patients six weeks 
and six months post-surgery, there was a significant effect of time , F (1, 19) = .09, p = .04, 
η2 = .01 , [Figure 4.10] but no significant group x time interaction, F (1, 19) = 2.62, p = .17, 
η2 = .32. Overall, the two groups of hip fracture patients did not differ in IL10 production by 
CD4 T cells on stimulation with PMA and Ionomycin (4hr)  six months after surgery, p = 
.76. 
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Figure 4.8 CD4
+ve 
CD25
+ve
 Foxp3
+ve
 regulatory T lymphocyte in hip fracture patients  
 
(a) Percentage of CD4
+ve 
CD25
+ve
 Foxp3
+ve
 T cells in healthy controls (n=20), hip fracture 
patients without depressive symptoms (HF; n=20) and hip fracture patients with depressive 
symptoms (HF+D; n=20). The solid bar represents the mean value. (b) Absolute number of 
CD4
+ve 
CD25
+ve
 Foxp3
+ve
 regulatory T cells in healthy controls (n=12), hip fracture patients 
without depressive symptoms (HF; n=13) and hip fracture patients with depressive 
symptoms (HF+D; n= 10). Data are mean ± SEM.   
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Figure 4.10 IL10 production by CD4 T lymphocytes in hip fracture patients. 
(a) Percentage IL10
+ve 
CD4 T cells and (b) mean IL10 production (MFI value) by CD4 T 
cells in healthy controls (n=17), hip fracture patients without depressive symptoms (HF; 
n=20) or hip fracture patients with depressive symptoms (HF+D; n=20). The solid bar 
represents the mean value in (a) and data are mean ± SEM in (b). (c) Correlation between 
GDS depressive symptoms scores and IL10 production by CD4 T cells in hip fracture 
patients (n = 36).  * p <.05. 
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Figure 4.10 Frequency of IL10 producing CD4 T cells in hip fracture patients six 
months post-surgery.  
Frequency of IL10
+ve
 CD4 T cells in hip fracture patients without depressive symptoms (n = 
9) and hip fracture patients with depressive symptoms (n = 10) at 6 weeks and 6 months 
post-surgery. Data are mean ± SEM. 
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4.3.7 B cells in hip fracture patients  
On examining B cells in peripheral blood of hip fracture patients , no  significant differences 
were observed in B cell frequency, F (2,67) = .16, p = .15, η2 = .04, [Figure 4.11a] or  
absolute numbers of B cells, F (2,69) = .30, p = .73, η2 = .01 [Figure 4.11b] between the 
three groups.   
When peripheral frequency of regulatory B cells were assessed significant differences were 
found in the percentages of CD19
+ve
CD24
hi
CD38
hi
 B cells, F (2, 61) = 11.16, p <.001, η2 = 
.26 between our three groups [Figure 4.12a], due to a decline in this subset of B cells in hip 
fracture patients with depressive symptoms compared with healthy controls, p< .001 as well 
as hip fracture patients without depressive symptoms, p = .001. When all of the above 
analyses were repeated with adjustment for age, sex and BMI, the results still remained 
significant (data not shown). Similarly, significant differences were seen in absolute 
numbers of peripheral CD19
+ve
CD24
hi
CD38
hi
 B cells, F (2, 38) = 4.85, p = .01, η2 =.20 
[Figure 4.12b] between our three groups, driven by a significant decline in absolute numbers 
in hip fracture patients with depressive symptoms compared with healthy controls, p = .04 as 
well as hip fracture patients without depressive symptoms, p = .02. 
 
Interestingly, a significant association was observed between GDS scores and frequency of 
peripheral CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients, β = -.38, p = .01, ΔR2 = 
.15, such that hip fracture patients with greater depressive symptoms (GDS score) had lower 
frequency of CD19
+ve
CD24
hi
CD38
hi
 B cells [Figure 4.12c].  
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Figure 4.11 B lymphocytes in hip fracture patients.   
(a) Percentage and (b) absolute numbers of CD19
+ve
 B cells in peripheral blood of healthy 
controls (n = 26), hip fracture patients without depressive symptoms (HF; n = 19) and hip 
fracture patients with depressive symptoms (HF+D; n= 25). The solid bar represents the 
mean value in (a) and data are mean ± SEM in (b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
on
tr
ol H
F
H
F+
D
0
5
10
15
20
B
 c
e
ll
s
 (
%
)
C
on
tr
ol H
F
H
F+
D
0.00
0.05
0.10
0.15
A
b
s
o
lu
te
 n
u
m
b
e
rs
 (
 1
0
6
/ 
m
l)
a                                                            b 
    
n.s 
    
    n.s 
  
219 | P a g e  
 
 
 
 
 
Figure 4.12 Frequency of CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients. 
(a) Percentage and (b) absolute numbers of CD19
+ve
CD24
hi
CD38
hi
 cells in healthy controls 
(n = 21), hip fracture patients without depressive symptoms (HF; n=15) and hip fracture 
patients with depressive symptoms (HF+D; n=22). The solid bar represents the mean value 
in (a) and the data are mean ± SEM in (b). (c) Correlation between percentage of 
CD19
+ve
CD24
hi
CD38
hi
 and GDS scores in hip fracture patients (n = 36). * p <.05, ** p 
<.005 and *** p <.001.  
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Further, on examining frequency of  CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients 
six weeks and six months post-surgery, there was a significant effect of time on hip fracture 
patients, F (1,25) = 13.63, p = .001, η2 = .35, but no effect of group x time interaction F (1, 
25) = 2.72, p = .11, η2 = .09. However, the effect of group remained significant between hip 
fracture patients with and without depressive symptoms, p = .002 [Figure 4.14].  
 
Next, the frequency of IL10 producing CD19
+ve
CD24
hi
CD38
hi
 B cells post CD3 stimulation 
(72 hr) was determined. The data revealed significant differences between our groups, F (2, 
55) = 4.88, p = .01, η2 = .15, but the reduction in IL10 induction was restricted to hip 
fracture patients with depressive symptoms compared with healthy controls, p =.04 and hip 
fracture patients without depressive symptoms, p = .01 [Figure 4.15a]. When all of the 
above analyses were repeated with adjustment for age, sex and BMI, the results still 
remained significant (data not shown). Further, mean IL10 production (MFI) by 
CD19
+ve
CD24
hi
CD38
hi
 B cells post stimulation did not differ between the subject groups, F 
(2, 55) = .85, p = .43, η2 = .03 [Figure 4.15b].  
There was a significant association between GDS scores and the frequency of IL10 
producing CD19
+ve
CD24
hi
CD38
hi
 B cells post stimulation in hip fracture patients, β = -.34, p 
= .03, ΔR2 = .34, such that hip fracture patients with greater depressive symptoms (GDS 
score) had a lower frequency of CD19
+ve
CD24
hi
CD38
hi
 B cells [Figure 4.15c]. 
The percentage of IL10 producing cells in the CD24
int
CD38
int B cell subset F (2, 55) = .04, p 
= .95, η2 = .002 and their IL10 expression levels F (2, 55) = 2.90, p = .07, η2 = .09 did not 
differ between our three groups [Table 4.9]. Also, the percentage of IL10 producing CD24
-
ve
CD38
+veB cells F (2, 55) = 1.59, p = .21, η2 = .05 and their IL10 expression levels F (2, 55) 
= 2.47, p =.09, η2 = .08 did not differ significantly [Table 4.9]. 
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Figure 4.13 CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients 6 months post-
surgery. 
Percentage of peripheral CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients without 
depressive symptoms (n = 10) and hip fracture patients with depressive symptoms (n = 17) 6 
weeks and 6 months post-surgery. Data are mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
* 
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Figure 4.14 IL10 production by CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients.  
(a) Frequency of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 cells in healthy controls (n=18), hip fracture 
patients without depressive symptoms (HF; n=21) or hip fracture patients with depressive 
symptoms (HF+D; n=19). The solid bar represents the mean value. (b) IL10 production by 
CD19
+ve
CD24
hi
CD38
hi
 cells in healthy controls (n=18), hip fracture patients without 
depressive symptoms (HF; n=21) or hip fracture patients with depressive symptoms (HF+D; 
n=19). Data are mean ± SEM.  (c) Correlation between percentage of 
IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cells post CD3 stimulation (72hr) and GDS scores in hip 
fracture patients (n = 40). * p <.05. 
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Variable Healthy 
control 
Hip fracture 
patients 
(HF) 
 
Hip fracture 
patients with 
depressive 
symptoms 
(HF + D) 
p 
              Mean  (SD)  
IL10
+ve
 CD24
int
 CD38
int
 
B cells (%) 
.84 (.52) .84 (.83) .82 (.50) .95 
IL10 expression (MFI) 21.18 (6.81) 27.26 (13.10) 20.28 (8.37) .21 
IL10
+ve
 CD24
+ve
 CD38
-ve
 
B cells (%) 
1.36 (1.13) 1.93 (1.33) 2.33 (2.29) .21 
IL10 expression (MFI) 24.90 (6.57) 25.63 (7.65) 20.57 (8.57) .09 
 
Table 4.9 IL10 producing B cell subsets in hip fracture patients. 
 
Further, on examining the frequency of  IL10
+ve
CD24
hi
CD38
hi
 B cells in hip fracture 
patients six weeks and six months post-surgery post CD3 stimulation, there was no 
significant effect of time on hip fracture patients, F (1,21) = 2.50, p = .12, η2 = .10. Further, 
no significant effect of group x time interaction F (1, 21) = 2.72, p = .11, η2 = .09 was 
observed and the effect of group did not remain significant between hip fracture patients 
with and without depressive symptoms, p = .36, six month post-surgery [Figure 4.15]. 
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Figure 4.15 IL10 production by CD19
+ve
CD24
hi
CD38
hi
 B cells in hip fracture patients 6 
months post-surgery. 
Percentage of IL10
+ve
CD19
+ve
CD24
hi
CD38
hi
 B cells post CD3 stimulation in hip fracture 
patients without depressive symptoms (n = 9) and hip fracture patients with depressive 
symptoms (n = 14) 6 weeks and 6 months post-surgery. Data are mean ± SEM and * 
indicates p <.05. 
 
 
 
 
 
 
 
 
 
  
 
 
 
* 
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4.3.8 Cortisol:DHEAS ratio and adaptive immune parameters  
An elevated serum cortisol:DHEAS ratio acts as a marker for depressive symptoms 
[536]
 and 
in this study GDS scores were also significantly associated with the cortisol:DHEAS ratio 
(described in chapter 3) 
[522]
. However, there was no association between serum cortisol: 
DHEAS ratio and T cell frequency in hip fracture patients, β = -.09, p = .38, ΔR2 = .009 or 
absolute T cell numbers β = -.21, p = .24, ΔR2 = .04. Similarly, no association was observed 
between serum cortisol levels and frequency of circulating T cells β = -.17, p = .18, ΔR2 = 
.03 or absolute T cell numbers β = -.20, p = .27, ΔR2 = .04 in the hip fracture patients (data 
not shown). 
There was also no association between serum cortisol: DHEAS ratio and the frequency of 
senescent CD28
-ve
 CD57
+ve
 T cells, β = .16, p = .35, ΔR2 = .02, CD69+ve T cells, β = .12, p = 
.47, ΔR2 = .01 (data not shown) or HLADR+ve T cells in hip fracture patients, β = .04, p = 
.81, ΔR2 = .002. Further, no significant association was found between the serum cortisol: 
DHEAS ratio and IL10 producing CD4 T cells in hip fracture patients, β = .24, p = .10, ΔR2 
= .24, CD24
hi
CD38
hi 
B cell frequency in the resting state, β = -.15, p = .09, ΔR2 = .08 or in 
IL10 producing CD24
hi
CD38
hi
 B cells post CD3 stimulation in hip fracture patients, β = -
.15, p = .35, ΔR2 = .02. 
4.3.9 Proinflammatory cytokines and T cells  
On examining associations between pro-inflammatory cytokines  and circulating T cells we 
have reported a significant association between circulating TNFα levels and frequency of 
circulating T cells, β = -.34, p = .04, ΔR2 = .12 in whole sample, such that patients with 
elevated serum levels of TNFα had fewer circulating T cells [Figure 4.16]. Similarly, a 
significant association between circulating TNFα levels and absolute numbers of circulating 
T cells, β = -.52, p = .03, ΔR2 = .27 was observed in whole sample, such that patients with 
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elevated serum levels of TNFα had fewer circulating absolute numbers of T cells (data not 
shown).  
However, no significant associations was reported between serum IL6 levels and frequency 
of circulating T cells, β = .04, p = .71, ΔR2 = .002 in whole sample (data not shown).  
 A significant association was found between circulating IL6 levels and the frequency of 
senescent CD28
-ve
 CD57
+ve
 T cells, β = .37, p = .01, ΔR2 = .13, such that patients with 
higher serum levels of IL6 had a higher frequency of circulating CD28
-ve
 CD57
+ve
 T cells 
[Figure 4.17a]. A similarly association was observed between serum TNFα levels and the 
frequency of circulating activated CD28
-ve
 CD57
+ve
 T cells, β = .44, p = .01, ΔR2 = .19 
[Figure 4.17b], but not for serum IL1β levels, β = .26, p = .13, ΔR2 = .06 (data not shown). 
Elevated pro-inflammatory cytokines , such as IL6 have been proposed as an underlying 
cause of immune activation in patients with depressive symptoms
[637]
.  On examining 
associations  between IL6 levels and T cell activation status a significant association was 
found between serum IL6 and frequency of circulating activated HLADR
+ve
 T cells, β = .38, 
p = .01, ΔR2 = .15, such that patients with higher serum levels of IL6 had a higher frequency 
of circulating HLADR
+ve
 T cells [Figure 4.17c]. 
However, there was no association between serum IL6 levels and frequency of circulating 
activated CD69
+ve
 T cells, β = .16, p = .30, ΔR2 = .02. There was also no association 
between serum TNFα and IL1β levels and activated T cells (HLADR+ve, CD69 +ve, CD25+ve; 
data not shown). 
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Figure 4.16 Association between circulating TNFα levels and peripheral T cells. 
Representation of correlation between serum TNFα levels and circulating T cells in hip 
fracture patients (n = 35). 
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Figure 4.17 Association between circulating pro-inflammatory cytokines and senescent 
and activated T cells. 
Representation of correlation between (a) serum IL6 levels and circulating CD28
-ve
 CD57
+ve
 
T cells (n = 44) (b) serum TNFα levels and circulating CD28-ve CD57+ve T cells (n = 29) (c) 
serum IL6 levels and circulating HLADR
+ve
 T cells (n = 36). 
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4.4 Discussion 
In the previous chapter, the immunosuppressive effects of depressive symptoms in hip 
fracture patients on innate immune cells were described. In this chapter, it was reported for 
the first time that the development of depressive symptoms in hip fracture patients was 
accompanied by a decline in total circulating T cells and an accumulation of senescent and 
activated T cells. Further on examining the effect of depressive symptoms on regulatory 
immune cells, the data show no effect on the frequency of Tregs, but an increase in IL10 
production in CD4 T cells. Interestingly, both numerical defects and impaired IL10 
production was observed in Bregs in hip fracture patients with depressive symptoms. For the 
majority of the observations, as with innate immunity, compromised function was restricted 
to those patients who developed depressive symptoms and was not seen hip fracture alone. 
The reduced T cell frequency and absolute numbers in hip fracture patients with depressive 
symptoms compared with healthy controls is in agreement with previous reports of reduced 
circulating T cells in depressed individuals 
[486, 638, 639]
. Although the exact mechanism 
responsible has not been explored in this thesis, a few possibilities can be proposed. Firstly, 
T cells in depressed individuals have been shown to undergo accelerated apoptosis, 
especially CD4 T cells 
[640, 641]
 . Further, glucocorticoids are known inducers of T cell 
apoptosis 
[624, 642]
 and the hip fracture patients with depressive symptoms had higher serum 
cortisol levels 
[522]
. However, there was no association between circulating T cells and serum 
cortisol levels, suggesting that additional mechanisms may be involved. TNFα is also known 
to induce T cell apoptosis 
[643, 644]
 and elevated serum TNFα was seen here in hip fracture 
patients with depressive symptoms (described in chapter 3). Interestingly, we have reported 
an association between circulating TNFα levels and peripheral T cells in this study. Unlike T 
cells,  neither the frequency nor absolute B cell numbers were affected in hip fracture 
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patients with depressive symptoms, similar findings have been reported in studies of 
depressed individuals 
[645, 646]
.  
The proportion of CD4 and CD8 T cells and the CD4:CD8 ratio did not differ between hip 
fracture patients with and without depressive symptoms and healthy controls. Our findings 
are in line with a few previous reports showing that the CD4:CD8 ratio was unaltered in 
depressed individuals 
[413, 647]
. However, there are also reports showing an increase in the 
CD4:CD8 T cell ratio in depressed individuals 
[637, 646]
. It is possible that these inconsistent 
findings might be a result of differences in the severity and chronicity of depression in 
different studies, in particular it has been suggested that the increase in the CD4:CD8 ratio is 
related to severity of depression 
[648]
. Furthermore, hip fracture alone or in synergy with 
depressive symptoms did not have an effect on naïve: memory ratio of T cells. These 
findings contradict a previous study reporting an increase in memory T cells in depressed 
patients 
[648, 649]
. This discrepancy might be due to the differences in cell surface markers 
used to identify memory T cells; Maes et al identified memory T cells as CD45RA
-ve
 T cells, 
whereas in this study both CD45RA and CCR7 were used to identify T cell subsets. 
Ageing is accompanied by an accumulation of CD28
-ve
 T cells (described in chapter1). On 
examining the additional effect of chronic distress on CD28 expression, a significant 
increase in the percentage of CD28
-ve
 T cells was seen, especially in CD8 T cells in hip 
fracture patients with depressive symptoms. Moreover, an increase in CD57
+ve
 T cells, again 
most marked in CD8 T cells, was also observed in hip fracture patients with depressive 
symptoms, which is in line with  previous studies in depressed individuals
[648]
.  Interestingly, 
poor mental health associated with reduced job satisfaction has also been characterised by an 
increase in CD57
+ve
 CD8 T cells 
[612]
. The lack of CD28 expression or gain of CD57 
expression has been identified as markers for replicative senescence 
[632]
. The majority of the 
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CD57
+ve
 T cells are also CD28
-ve [650]
, therefore it is not surprising that an accumulation of 
CD28
-ve
CD57
+ve
 T cells was seen in hip fracture patients with depressive symptoms and this 
has also been reported in depressed individuals 
[651]
. CD28
-ve
 CD57
+ve
 T cells are 
characterised by critically shortened telomeres and impaired ability to undergo cell-cycle 
division and an expansion of this subset has been reported during immune activation 
[200]
. 
The accumulation of these expanded T cells might reduce T cell repertoire in hip fracture 
patients with depressive symptoms and reduce their immune response towards novel 
pathogens and vaccines 
[652, 653]
.  
TNFα is known to induce down regulation of CD28 expression on T cells [654] . Ageing and 
inflammatory diseases have been associated with elevated levels of pro-inflammatory 
cytokines 
[290, 655]
 and accumulation of CD28
-ve
 T cells 
[192, 656]
. In the previous chapter, 
elevated serum levels of IL6 and TNFα in hip fracture patients with depressive symptoms 
were described. Interestingly, there was a correlation between circulating CD28
-ve
 CD57
+ve
 
T cells and serum IL6 and TNFα levels. Thus, it is tempting to suggest that the pro-
inflammatory environment in hip fracture patients with depressive symptoms might be 
contributing towards accumulation of CD28
-ve
 CD57
+ve
 T cells.  
Cytomegalovirus (CMV) is a β herpes virus that is highly prevalent in over 65 year olds [14, 
657] 
and is a source of continuous antigenic stimulation 
[188]
. CMV seropositivity has been 
associated with senescence in the T cell compartment and accumulation of late differentiated 
CD28
-ve
 CD57
+ve
 T cells 
[658, 659]
. As individuals with higher antibody titres against CMV 
exhibit higher symptoms of depression, it is possible that rather than CMV infection itself 
the magnitude of CMV-specific immune responses is associated with depressive symptoms 
[651, 660]
. Although, CMV seropositivity has not been tested in our hip fracture patients, it is 
  
232 | P a g e  
 
possible that there might be an association between CMV titres in our hip fracture patients 
and accumulation of CD28
-ve
 CD57
+ve
 T cells in hip fracture patients.  
Furthermore, chronic viral infections (such as CMV) often result in terminal differentiation 
of pathogen specific CD8 T cells into exhausted T cells, which have upregulated expression 
of inhibitory surface receptor PD-1 
[661]
. T cell exhaustion is characterised by a loss of 
effector T cell function , including cytokine production , proliferation capacity and ex vivo 
killing 
[662, 663]
. Limited studies examining PD-1 with age have reported an increase in PD-1 
expression on T cells of aged mice 
[453, 663]
. However, no study has so far has examined the 
effect of exposure to prolonged stress on exhausted T cells and future studies could test the 
possibility that in addition to an accumulation of senescent T cells there would be an 
increase in exhausted  PD-1
+ve
 T cells in hip fracture patients with depressive symptoms. 
In addition to being an inflammatory disorder, depression is also characterised by activation 
of cell-mediated immunity 
[664]
. Although this study failed to report signs of monocyte 
activation in hip fracture patients with depressive symptoms (discussed in chapter 3), an 
increase in T cells expressing the activation markers CD69 and HLADR was seen in hip 
fracture patients with depressive symptoms. These findings are consistent with previous 
reports of increased activated HLADR
+ve
 T cells in depressed individuals 
[486, 649, 665]
. In 
contrast , the frequency of cells expressing CD25 did not differ between hip fracture patients 
and healthy controls, but these findings do not agree with a previous report showing an 
increase in CD25
+ve
 activated T cells in depressed patients 
[665]
.  
It has been previously hypothesised that cytokines such as IL6 and IL1β are the underlying 
cause of immune activation reported in depressive individuals 
[637]
. Interestingly, in this 
chapter we have reported an association between serum IL6 levels and HLADR
+ve
 T cells, 
  
233 | P a g e  
 
suggesting that the pro-inflammatory environment in hip fracture patients with depressive 
symptoms might be contributing towards accumulation of activated T cells. Although 
unexplored in this thesis, soluble interleukin-2-receptor (s IL2R) which has  been identified 
as an additional marker of T cell activation has been reported to be increased in depressed 
individuals 
[666, 667]
.  
Regulatory cells are known to suppress unwanted immune responses. Therefore, it is 
tempting to hypothesise that a deficiency in regulatory immune cells might contribute 
towards the inflammatory state that was seen here in hip fracture patients with depressive 
symptoms. In this chapter,  surprisingly no significant differences were observed in the 
frequency of circulating CD4
+ve
CD25
+ve
Foxp3
+ve
 Tregs in hip fracture patients with 
depressive symptoms, which  contradicts the findings of two previous studies showing a 
decline in Tregs in mice with depression-like behaviour 
[668]
 and humans with major 
depression 
[669]
. In the second chapter of this thesis, an age associated numerical deficit in 
Bregs with age was described. In this chapter, a further reduction in both frequency and 
absolute numbers of circulating CD19
+ve
CD24
hi
CD38
hi
 B cells was seen in hip fracture 
patients with depressive symptoms.  
Both Tregs and Bregs are known to mediate a suppressive effect on effector T cell responses 
via IL10 production 
[301, 670]
 . Although IL10 production by CD4
+ve
 CD25
+ve
 T cells was not 
considered here, it has been previously reported that CD4
+ve
 CD25
-ve
 T cells secrete very 
little IL10 but are known to produce IFNγ, but CD4+ve CD25+ve T cells on the other hand 
predominantly produce IL10 and produce only low levels of IFNγ and IL4 [671] . The data in 
this chapter showed a marked increase in IL10 production by CD4 T cells of hip fracture 
patients with depressive symptoms compared to healthy controls. Interestingly, a significant 
positive  association was also found between GDS scores and IL10 production by CD4 T 
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cells in our hip fracture patients .Although this is the first study to examine the effect of 
depressive symptoms on IL10 production by CD4
+ve
 T cells , a few studies examining the 
effect of  chronic stress such as caregiving have reported increased IL10 production 
[614, 619]
. 
Interestingly, cortisol has been shown to enhance IL10 production by CD4 T cells 
[672, 673]
, 
though in this chapter no association was found between frequency of IL10
+ve
 CD4 T cells 
and serum cortisol levels.  
In the case of the functional capacity of Bregs, a significant decline in IL10 producing 
CD19
+ve
CD24
hi
CD38
hi
 B cells upon CD3 stimulation was observed in hip fracture patients 
with depressive symptoms. Again to the best of our knowledge this is the first study to 
examine the effect of psychological distress on IL10 production by B cells. These data are 
surprising when considered with the increased IL10 production by CD4 T cells in hip 
fracture patients with depressive symptoms.  Although the effect of glucocorticoids on Bregs 
remains unexplored, it is possible that elevated cortisol levels observed in hip fracture 
patients with depressive symptoms had an opposite effect on IL10 production by B cells and 
T cells.  
As mentioned in the introduction to this thesis, ageing is accompanied by extensive 
remodelling of the immune system, including decline in thymic output, accumulation of 
senescent CD28
null
 T cells and increase circulating levels of pro-inflammatory cytokines 
(IL6, TNFα). Similar phenotypic and functional signs of premature immunesenescence have 
been shown in RA patients including; elevated levels of serum proinflammatory cytokines 
(IL6, TNFα) [674, 675], increased proportion of autoreactive CD28-ve CD4 T cells [676-678] and 
reduced circulating number and impairment in IL10 production by CD19
+ve
CD24
hi
CD38
hi 
B 
cells
 [301, 302]
. Chronic psychological distress has been associated with exacerbation of 
autoimmune disorders 
[679, 680]
 . A higher incidence of autoantibodies has been shown in 
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psychiatric disorders 
[681]
, including depression 
[667]
. The results of this chapter suggest the 
possibility that exposure to psychological distress challenges results in a further decrement 
in immunity, enhancing immunesenescence, as evidenced by even higher circulating levels 
of pro-inflammatory cytokines, increased senescent T cells and a further decline in 
circulating CD19
+ve
CD24
hi
CD38
hi 
B cell and their ability to produce IL10. Taken together 
these factors may contribute to the poorer prognosis in hip fracture patients with depressive 
symptoms, making them more susceptible to infection and inflammation related frailty and 
pathology. 
In summary, in this chapter the data show that development of depressive symptoms in older 
hip fracture patients is characterised by a reduction in circulating T cells, accumulation of 
CD28
-ve
CD57
+ve
 senescent T cells and HLADR
+ve
 and CD69
+ve
 T cells and also numerical 
and functional defects in Bregs. Moreover, the suppressive effect of depressive symptoms on 
the frequency of Bregs in hip fracture patients persisted up to 6 months post-surgery. 
 
 
 
 
 
 
 
  
236 | P a g e  
 
 
 
 
 
           
                                     Chapter 5 
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Organisms are challenged with a number of physiological and psychological stressors during 
their lifetime and the ability to handle stressors has a profound effect on health 
[353]
.  Over 
the years a number of models of chronic stress including life stressors such as marital stress, 
bereavement, caregiving, feelings of loneliness and social disruption have been reported to 
have a detrimental effect on immune function 
[357, 682]
, which might have clinical 
consequences such as increased risk of infections 
[683, 684]
 and impaired vaccine responses 
[358]
. 
The worldwide prevalence and disability caused as a result of depression has made it a 
major public health issue 
[685]
. Depression was rated as the fourth leading cause of disease 
burden in 2000 
[686]
. The term depression is sometimes used to refer to depressive illness, 
and sometime to the presence of depressive symptoms. In much of the research into these 
psychiatric symptoms in physical health conditions, depressive symptom indices are used, 
and so the term depression often refers to the presence of depressive symptoms rather than a 
psychiatrically-diagnosed condition. A high incidence of depression (that is depressive 
symptoms) occurs in individuals suffering from chronic diseases 
[687, 688]
 and the 
development of depressive symptoms has been identified as a potential risk factor for 
decrements in health and increased morbidity and mortality in these patients 
[689, 690]
. 
Previous studies have reported a high prevalence of depressive symptoms in hip fracture 
patients post-surgery 
[435, 439]
. In addition to being a psychiatric disorder, depressive 
symptoms has also been recognised as an immune disorder 
[691]
. In this thesis, for the first 
time the interactive effects of physical trauma (hip fracture), psychological distress 
(depressive symptoms) and ageing on the immune system have been examined. The key 
finding was that new onset depressive symptoms post hip fracture can further suppress age 
associated impairments in both innate and adaptive immune responses, including a recently 
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identified subset of B cells with immune regulatory properties. Interestingly by 6 weeks after 
the hip fracture, immunity was not reduced in the patients who only had a fracture, 
suggesting that either the physical stressor was less potent or was transient.  Hopefully, these 
data will result in a fresh analysis of the need to ameliorate depressive symptoms in this 
vulnerable patient group. 
 
5.1 Summary of main findings  
 
In the first study of this thesis (chapter 2) the effect of age on B cells with immune 
suppressive properties, namely transitional B cells and B10 cells, was examined. There was 
a decline in both peripheral frequency and absolute numbers of CD19
+ve
CD24
hi
CD38
hi
 and 
CD19
+ve
CD5
+ve
CD1d
hi
 B cells with age. Impairments in IL10 production were also observed 
in both these subsets of Bregs post-stimulation via CD40 or TLR pathway in healthy older 
donors. On investigating the mechanisms involved in suppressed IL10 production by Breg 
cells, age-related effects on both T cells and B cells were observed, specifically CD40 ligand 
expression was lower in CD4 T cells from older donors following CD3 stimulation and 
signalling through CD40 was also impaired in regulatory B cells from older adults as 
evidenced by reduced phosphorylation and activation of STAT3. Also, impairments in IL10 
secretion by isolated B cells on stimulation via CD40 and TLR pathway were observed. 
Finally, there was a negative correlation between IL10 production by CD19
+ve
CD24
hi
CD38
hi
 
B cell and serum autoantibody (rheumatoid factor) levels in healthy individuals. It was 
therefore proposed that an age-related decline in CD19
+ve
CD24
hi
CD38
hi
 B cell number and 
function may contribute towards the increased autoimmunity and reduced immune tolerance 
seen with advancing age.   
  
239 | P a g e  
 
In the second major study in this thesis (chapter 3 and chapter 4) the potential synergistic 
effects of physical distress (hip fracture) and psychological distress (depressive symptoms) 
on immunesenescence was investigated. The data revealed a suppressive effect of depressive 
symptoms on neutrophil, monocytes and NK cell functioning in older hip fracture patients, 
but not of the hip fracture alone. Additionally, the suppression in monocyte and NK cell 
functioning in hip fracture patients with depressive symptoms remained up to six months 
post-surgery. 
Further, the data also showed that the development of depressive symptoms was associated 
with HPA axis activation, resulting in elevated serum cortisol levels in hip fracture patients 
with depressive symptoms. Additionally, a reduction in serum DHEAS levels was also 
observed in these patients, resulting in an overall elevated serum cortisol: DHEAS ratio in 
hip fracture patients with depressive symptoms that remained elevated six months post-
surgery. Cortisol is known to have immune suppressive properties and DHEAS is an 
immune enhancer. Thus, this elevated serum cortisol: DHEAS ratio in hip fracture patients 
with depressive symptoms might be one of the factors contributing towards the immune 
suppression seen in these patients.  
Ageing is accompanied by an increase in circulating levels of pro-inflammatory cytokines 
(section 1.2) .In this thesis it was reported that the additional effect of psychological distress 
on the aged immune system resulted in a further increase in levels of pro-inflammatory 
cytokines, including IL6 and TNFα in hip fracture patients with depressive symptoms. Also, 
an increase in serum IL10 levels was observed in hip fracture patients with depressive 
symptoms. 
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Further, on examining the effect of physical and psychological distress on adaptive immune 
cells, there was a decline in circulating T cells in hip fracture patients with depressive 
symptoms, but no change in the CD4:CD8 ratio and naïve:memeory T cells ratio. 
Additionally, CD28
-ve
 CD57
+ve
 senescent T cells were reported to be raised in hip fracture 
patients with depressive symptoms and there was an accumulation of activated CD69
+ve
 and 
HLADR
+ve
 T cells in hip fracture patients with depressive symptoms. 
Finally, on examining the effect of chronic distress on regulatory immune cells, although 
there were no differences in circulating levels of Tregs, a dramatic reduction in Bregs was 
observed in hip fracture patients with depressive symptoms that remained for six months 
post-surgery. IL10 production by T cells post-stimulation was increased but IL10 production 
was reduced in Breg cells in hip fracture patients with depressive symptoms. 
5.2 Expected outcome and future direction  
In this thesis, it was suggested that numerical and functional defects in Breg cells with 
advancing age might be a novel contributing factor towards increased risk of autoimmunity 
in older adults. Although unexplored in this thesis , there have been previous reports of a 
decline in the frequency of circulating immunosuppressive CD19
+ve
CD24
hi
CD38
hi 
B cells in 
RA patients 
[302]
. Thus, in the future development of therapeutic agents to improve Breg cell 
numbers and/or function in older adults could reduce incidence of autoimmune disorders.  In 
one such approach, isolation of CD19
+ve
CD24
hi
CD38
hi 
B cells from older RA patients 
followed by in-vitro expansion and re-infusion of these B cells into older adults might be 
useful in suppressing autoimmunity. Additionally, it might also be possible to identify older 
adults at higher risk of developing autoimmune disorders by examining the functioning of 
their Breg cells.  
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The data in this thesis raise a variety of research questions that can be addressed in future 
studies. Although we have reported numerical and functional defects in 
CD19
+ve
CD24
hi
CD38
hi 
B cells with age, the immunosuppressive effect of IL10 on young 
and aged immune cells still remains unexplored. In future studies, it might be interesting to 
examine the effects of IL10 on production of pro-inflammatory cytokines (IFNγ) in young 
and old CD4
+ve
 T cells. Additionally, the effect of IL10 on suppression of pro-inflammatory 
cytokine production (TNFα, IL6) and antigen presentation (surface expression of MHC class 
II and co stimulatory molecule) by young and aged monocytes could also be examined. This 
will provide novel insight into the effect of age on anti-inflammatory responses to IL10. It is 
possible that in addition to impaired IL10 production and secretion with age the response to 
IL10 is also defective in older adults.  
 
This thesis also reported that depressive symptoms post hip fracture in older adults results in 
poorer functional outcome, increased immune dysregulation and altered adrenal hormone 
balance. These findings can have several clinical implications and help improve patient care.  
Firstly, the findings highlight the importance of screening for the presence of depressive 
symptoms in hip fracture post-surgery. It is also possible that other major surgery may 
produce the same outcome regarding depressive symptoms and the data may therefore have 
more far reaching importance. Secondly, this study provides an evidence base for the use of 
interventions to reduce depressive symptoms as a way of reducing immune dysregulation 
and improving outcome in hip fracture patients. Thus, we suggest that stress management 
and psychological support can help improve the immune outcome post hip fracture in older 
adults. 
The treatment of depressive symptoms in hip fracture patients with antidepressants might 
improve their psychological well-being and might also has a beneficial effect on their 
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immune cell functioning. Firstly, antidepressants are capable of restoring HPA axis activity 
and glucocorticoid levels, by normalisation of GR mediated feedback inhibition of the HPA 
axis 
[565, 692]
. Additionally, two independent clinical studies have reported an additional 
improvement in NK cell activity on treatment with anti-depressants 
[566, 693, 694]
 . 
Interestingly, antidepressants have a suppressive effect on production of pro-inflammatory 
cytokines by activated monocytes and Tcells 
[695, 696]
. In-vivo studies have also reported that 
treatment with selective anti-depressants, including selective serotonin reuptake inhibitors 
(SSRI) can normalise initially increased serum IL6 levels in depressed individuals
[697, 698]
.  
Therefore, it is not surprising that anti-inflammatory medication has been suggested as an 
alternative treatment option for depressive symptoms 
[699, 700]
 and might be an additional 
therapeutic strategy to treat depressive symptoms post hip fracture. However, caution is 
required as an association has been shown between the rate of falls and use of antidepressant 
drugs in older adults 
[701]
. The use of antidepressants can also have negative effects on the 
microarchitecture of bone and increase the future risk of another hip fracture
 [702-704]
.  
 
In contrast a range of beneficial effects of DHEA supplementation has been reported in older 
adults including ; improvement in arterial stiffness 
[705]
, improved physical performance 
[706] 
and exercise capacity 
[707]
 as well as reduced rates of infections 
[708]
. Additionally, a few 
clinical studies have also reported that DHEA supplementation has a beneficial effect on 
psychological well-being of individuals, including reduction of depressive symptoms and 
anxiety 
[709, 710]
 and DHEA also has a mood enhancing effect 
[711]
. Further, anti-
glucocorticoid effects of DHEA have also been reported 
[364]
. Interestingly, studies in animal 
models showed that treatment with DHEA ameliorated the trauma induced increase in 
circulating levels of corticosteroids 
[712]
. Further,  DHEA supplementation is also known to 
modify immune function in vivo 
[395]
, including improvement in the age-associated 
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dysregulation in IL6 production 
[407]
. Immune enhancing effects of DHEAS have been 
reported in in vitro studies of neutrophil superoxide generation 
[575]
, NK cell cytotoxicity 
[579, 
713]
 and T cell proliferation and cytokine production 
[712]
. Moreover, a previous study by our 
group has shown that cortisol mediated suppression of neutrophil superoxide generation in 
vitro that could be prevented by coincubation with DHEAS 
[411]
.   
The findings in this thesis provide a rationale for the use of DHEA supplementation as an 
intervention to reset cortisol: DHEAS ratio and improve psychological and physical 
outcome and thereby indirectly reduce immune dysregulation in hip fracture patients with 
depressive symptoms. DHEA supplementation might be therapeutically useful in preventing 
development of depressive symptoms and would avoid the side effects on bone density and 
falls incidence associated with the use of antidepressants. In future, intervention trials for 
determining an effective dosage and regime for a beneficial effect of DHEAS 
supplementation on emotional distress, physical frailty and immune dysregulation in hip 
fracture patients are required. 
In addition to pharmacological interventions, counselling, psychological support, broadening 
social involvements 
[714]
 and maintaining healthful practices (proper diet, exercise) may also 
help to combat the deleterious effects of psychological distress or prevent its onset and 
thereby preserve immune functioning. For instance, a study has suggested a protective effect 
of good social support (marriage, frequent contact with friends and family) on cancer-related 
stress and immunity, facilitating recovery in cancer patients 
[715]
. Beneficial effects of 
physical activity have been reported on depression 
[716, 717]
, with moderate exercise 
associated with increased DHEAS levels 
[718]
, reduced serum cortisol levels 
[719]
, reduced 
serum circulating IL6 and TNFα levels [719, 720] and reduced frequency of antigen 
experienced and senescent T cells 
[721]
 during chronic stress. Physical activity interventions 
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might therefore help restore cortisol and DHEAS balance and prevent immune dysregulation 
in hip fracture patients with depressive symptoms. Interestingly, music therapy has also been 
shown to a reduce stress related cortisol/DHEAS imbalance and has been shown to have a 
beneficial effect on immune parameters, such as NK cell activity 
[722]
, and might be an 
alternative stress coping strategy.  
Although emotional well-being is not usually the focus of orthopaedic care, the data from 
this thesis suggest that early detection and treatment of psychological distress reducing 
would help improve the quality of life in older hip fracture patients, improve their degree of 
recovery of physical functioning, reduce loss of immunity and thus reduce costs of 
hospitalisation and social care. 
5.3 Study limitations 
A numerical and functional deficit in Breg cells was seen with advancing age. However, it 
was not possible to isolate CD19
+ve
CD24
hi
CD38
hi 
B cells from peripheral blood of our 
participants to determine if they showed reduced ability to suppress T cell responses, the 
ultimate test of regulatory function. This was mainly due to the extremely low circulating 
numbers of these cells in peripheral blood and the large volumes of blood that would be 
required. As a result, to look for age associated impairments in regulatory function IL10 
secretion was assessed by ELISA on cultures of B cells rather than cultures on 
CD19
+ve
CD24
hi
CD38
hi 
B cells. In future studies it would be worth doing co-culture assays of 
CD19
+ve
CD24
hi
CD38
hi 
B cells and CD4 T cells to examine the ability of cells from young 
and old donors to suppress CD4 T cell proliferation and cytokine production (TNFα, IFNγ).  
The next two chapters reported the findings from the hip fracture study. One of the biggest 
limitations of this study was that it was not possible to recruit a healthy older population 
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with depressive symptoms alone to compare our findings reported in hip fracture patients 
with depressive symptoms. This was because any individuals that we might be able to 
identify from general practitioner records would already be undergoing anti-depressant 
treatment, which was one of our exclusion criteria. However we do know from other work in 
the group that psychological distress alone, specifically bereavement, in older adults also 
results in reduced neutrophil superoxide generation 
[360]
. This aspect of innate immunity may 
therefore be particularly susceptible to the negative effects of stress. What would also have 
been interesting would have been to assess immune function closer to the time of injury, 
such as a few days after, to determine if the physical stress did have an effect but that this 
was transient. At that time it may have been possible to detect additive effects of physical 
and psychological stress. 
Secondly, our exclusion of previously depressed patients or those with cognitive 
impairment, or immune-related comorbidities means that the findings may not be 
generalised to the wider hip fracture population. However, this had to be done to exclude the 
possible effects of various comorbidities on immune function of hip fracture patients, to 
exclusively examine the effect of depressive symptoms on immunity. It is also difficult 
sometimes to distinguish cognitive impairment from depression, and so including people 
with cognitive impairment could confound the investigation into the specific effect of 
depressive symptoms. Also a person with a previous history of depression may have other 
factors driving the depressive symptoms that would have made attempts to identify 
causative agents much more difficult. However, if anything you would expect the immune 
dysregulation to be even worse in depressed hip fracture patients in the presence of 
additional co morbidities.  
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Also, we were only able to measure the serum cortisol and DHEAS levels in hip fracture 
patients at one time during the day, though this was kept constant.  Ideally, a diurnal 
assessment would be undertaken to give a more a fuller picture of changes in hormone 
secretion.  However, in this frail patient group, it was not practical or ethical to increase the 
number of blood samples taken. 
Finally, there were a relatively high number of withdrawals in the study as many patients felt 
too unwell to participate, but this is common in studies of hip fracture in older patients. 
Thus, the sample of hip fracture patients included that have been tested at the six month time 
point are likely to be in relatively better health compared to those who withdrew. 
 
5.4 Conclusions 
It is well established that ageing and exposure to chronic stressors, both physical and 
psychological, result in immune dysregulation. Moreover, the effects of chronic stress and 
age can be interactive and intensify health threats in older adults. In this thesis, it has been 
demonstrated for the first time that development of depressive symptoms in hip fracture 
patients results in immune dysregulation and elevated pro-inflammatory cytokine levels, 
whereas the hip fracture alone had minimal impact at the time points assessed. 
Adrenocortical hormone imbalance was also demonstrated in hip fracture patients 
depressive symptoms and might be contributing indirectly to the immunosuppression seen in 
these patients. Additionally, an age associated numerical and functional defect in a novel 
subset of CD24
hi
CD38
hi
B cells with immunosuppressive properties was demonstrated and 
this defect worsened in the presence of chronic psychological distress in older adults. 
Overall, the data supports the original hypothesis of a relationship between psychological 
distress and immune related health, but did not confirm synergy between psychological and 
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physical stress in the older adults studied. The findings are relevant to healthcare 
professionals and highlight the importance of routine screening for depressive symptoms 
and providing appropriate interventions to improve recovery post hip fracture. Furthermore, 
it is proposed that correcting the elevated cortisol: DHEAS levels in hip fracture patients by 
DHEA supplementation could help improve psychological well-being reduce physical frailty 
and restore immune function in this patient group. 
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